No retraction, correction or concern found when last checked on Oct 23, 2026.

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

Thian-Sze Wong, Guangzhi Li, Shiliang Li and 7 more

Signal Transduction and Targeted Therapy · 2023 · Review · CC BY

Abstract

Neuropsychiatric disorders are multifactorial disorders with diverse aetiological factors. Identifying treatment targets is challenging because the diseases are resulting from heterogeneous biological, genetic, and environmental factors. Nevertheless, the increasing understanding of G protein-coupled receptor (GPCR) opens a new possibility in drug discovery. Harnessing our knowledge of molecular mechanisms and structural information of GPCRs will be advantageous for developing effective drugs. This review provides an overview of the role of GPCRs in various neurodegenerative and psychiatric diseases. Besides, we highlight the emerging opportunities of novel GPCR targets and address recent progress in GPCR drug development.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The nervous system employs membrane receptors to detect extracellular stimuli and transmit signals across the cell membrane. As the largest membrane protein family, G protein-coupled receptors (GPCRs) allow the nervous system to respond accurately to external stimuli and internal states. GPCRs are structurally similar transmembrane proteins containing seven transmembrane (TM) α-helices linked by three extracellular loops and three intracellular loops. The unique ligand binding pockets formed by the 7TM regions allow the receptor to engage with various stimuli, including neurotransmitters, nucleotides, amines, peptides, cytokines, and hormones in the extracellular environment (Fig. 1). Through expressing GPCRs with different ligand-recognizing abilities, the nervous system could filter and select particular signals to respond. Furthermore, the intrinsic ligand selectivity of neuronal GPCRs allows crosstalk and proper integration between signal transduction pathways. GPCRs drive signal transduction via two major modulators: heterotrimeric G protein and arrestins. Characterizing the physiological functions of GPCRs in the nervous system and pathological mechanisms in disease models could accelerate GPCR-targeted drug development.

2The progressive dysfunction of neural tissues in the central and peripheral nervous systems is the hallmark feature of neurodegenerative diseases. Neurodegenerative diseases are increasing in the elderly population. It is estimated that neurodegenerative diseases affect over 50 million people across the globe. Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and Multiple sclerosis are representative examples. Currently, there is no effective cure. The pathogenesis and underlying mechanisms of neurodegenerative diseases remain poorly understood. At present, symptom control is the primary treatment objective. It is estimated that neurodegenerative diseases will become the second most common cause of death.

3Alzheimer’s disease and dementias are in the top-ten ranking leading cause of death globally. Deposition of the insoluble and phosphorylated β-amyloid peptide (derived from amyloid precursor protein) in the brain parenchyma of Alzheimer’s disease patients affects functions/regeneration of various forms of neurons. The resulting widespread neuron damage affects synaptic communication leading to cognitive deficits, regional brain shrinkage, and brain atrophy; Huntington’s disease could appear in childhood or adolescence. Aberrant expansion of DNA segment containing CAG trinucleotide repeats in the huntingtin gene is a hallmark feature. Large CAG repeat is associated with early symptoms manifestation. Symptoms include poor coordination, chorea (involuntary dance-like movements), slow movement, seizures, and slurred speech; Parkinson’s disease affects motion control. Rigidity, tremor, and slow movement (bradykinesia) are frequently observed. Risk factors include genetic polymorphism, chronic inflammation, and metabolic disorders. Multiple sclerosis is a relapsing-remitting disease caused by an autoimmune attack in the central nervous system. Damage of myelin sheath in multiple areas by immune cells causes cognitive impairment, fatigue, muscle weakness, tremor, and vision problems.

4Brain disorders are frequently associated with mental/psychiatric illnesses. Mental illness is burdening the healthcare system with enormous unmet medical needs., Serious mental illness is closely linked to reduced life expectancy due to a higher risk of cardiovascular morbidity and mortality. Common mental illnesses include anxiety, depression, bipolar disorder, attention deficit hyperactivity disorder, and schizophrenia. Both children and adolescents are vulnerable to mental illnesses. Mental health condition is interlinked with physical health. The generation of suicide ideation/attempts and self-destructive thoughts are closely related to psychiatric diseases. Patients with degenerative diseases could also present emotional symptoms adding complexity to disease diagnosis and management. Recent studies reveal that hospitalized patients with COVID-19 and survivors display different levels of neuropsychiatric complications and the underlying mechanisms remain to be explored.

5GPCRs are one of the most intensively exploited targets for drug development. Approximately 35% of the FDA-listed drugs act through GPCRs., With our increasing understanding of the neuronal relay functions of GPCRs in the nervous system, many GPCRs are perceived as promising druggable targets for neurodegenerative and psychiatric diseases. This review summarizes the multifaceted role of GPCRs in chronic neurodegenerative conditions exemplified by Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and Multiple sclerosis. The emerging role of GPCRs on psychiatric illnesses, including Schizophrenia, Bipolar disorder, Depression, Attention deficit hyperactivity disorder, and Tourette’s disorder, are discussed. We also highlight the emerging opportunities for the previously unexplored GPCRs and provides examples of pharmaceutical development of GPCR-targeted therapeutics.

G protein-coupled receptors signaling

6Synaptic transmission can be classified into two types: fast and slow synaptic transmission. In fast synapses, GPCRs such as glutamate and GABA (γ-aminobutyric acid) receptors generate membrane depolarizing signals in less than 1/1000 s. In slow synapses, biogenic amines, peptides, and amino acid receptors generate signals in hundreds of milliseconds to minutes. GPCRs are structurally similar membrane proteins (Fig. 1). They elicit different intracellular signal pathways by interacting with heterotrimeric G proteins (α, β, and γ). GPCRs can be stabilized by an array of neurotransmitters and neurological modulators, including ions, hormones (peptide or non-peptide), vitamins, metabolites (ATP, fatty acids, etc.), natural products, and pharmacological ligands. A plethora of GPCR signaling events are involved in developing neuropsychiatric disorders. Understanding the downstream signaling events of disease-associated GPCR is essential for designing efficacious therapy.

7Human GPCR can be classified into five distinct subtypes: rhodopsin (class A), secretin (class B1), adhesion (class B2), glutamate (class C), and frizzled (class F). To date, over 750 ligand-bound or apo-GPCR structures (including 96 CNS-related GPCRs) have been reported (Table 1). For details: https://gpcrdb.org. The transmembrane helical core exhibits high similarity. The helical core forms the orthosteric binding pocket for cognate ligands. GPCR can be divided into three different functional regions: (1) extracellular region including N-terminus, extracellular loops (ECLs), and extracellular ends of the transmembrane helices are involved in ligand recognition and selectivity; (2) intracellular region consisting of C-terminus, intracellular loops (ICLs) and intracellular ends of the transmembrane helices provide docking cavity for G proteins/ arrestins and interacts with different regulatory proteins such as GPCR kinases; (3) helical core in-between extracellular and intracellular region deliver and covert ligand signals via unique conformational change (Fig. 1b).,

8Activated receptors generate second messengers via the G protein. In heterotrimeric form, the G protein is inactive. After binding to the intracellular cavity formed by GPCR, the GDP-binding pocket on the Gα subunit of heterotrimeric G proteins is opened, facilitating subsequent exchange for GTP. GTP is physiologically more abundant as compared to GDP. The nucleotide exchange is a rate-limiting step in the G protein activation process. GTP binding prevents Gα protein from forming heteromer with Gβγ subunit. The free Gα and Gβγ subunits modulate different downstream effector pathways. By hydrolyzing GTP to GDP, the active GTP-bound Gα subunit returns to an inactive state and forms a complex with the Gβγ subunit again. G proteins are classified based on their Gα subunit. There are four different Gα protein families: Gαi/o, Gαs, Gαq/11, and Gα12/13. Each family regulates a specific set of downstream responses. Individual GPCR could mediate different functions in different cellular contexts via preferential G protein coupling (Figs. 1 and 2).

Gα proteins: Gαs and Gαi/o

9Gαs (stimulatory regulator of adenylyl cyclase G protein activates adenylyl cyclase) promotes the generation of 3’-5’-cyclic adenosine monophosphate (cAMP) from ATP by adenylate cyclase. cAMP is essential for protein kinase A (PKA)-mediated signal transduction; In contrast, Gαi/o suppresses adenylyl cyclase activity, which prevents cAMP accumulation and reduces PKA activity. cAMP is a crucial regulator of the phosphoinositide 3-kinase/AKT murine thymoma viral oncogene homolog (PI3K/AKT) signaling pathway. It has been shown that PI3K/AKT is associated with the inflammatory response in multiple neurodegenerative diseases.– cAMP is also linked to calcium dynamics in neuronal cells and neurodegenerative diseases. Details can be found in the comprehensive review by Sobolczyk and Boczek.

Gα protein: Gαq/11

10Gαq activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-biphosphate into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates protein kinase C, which phosphorylates various downstream signaling proteins. IP3 stimulates calcium efflux from the endoplasmic reticulum through specific IP3 receptors. Calcium signaling is essential for the release of neurotransmitters., For instance, dysregulation of the dopamine D1 receptor-mediated PLC/IP3/Ca2+ pathway in the anterior cortex of the brain is associated with mental illness in rats., PLC/IP3/Ca2+ pathway regulates the electrical response of the neuron. Impaired Ca2+ homeostasis by Aβ exposure is one of the underlying causes of amyloid toxicity in Alzheimer’s disease. In psychiatric disorders, Ca2+ signaling regulates neuronal connectivity, synaptic plasticity, and glial functions.

Gα protein: Gα12/13

11Gα12/13 binding can stimulate Rho family GTPases. Rho GTPases activate the cytosolic Rho protein by promoting GDP/GTP exchange. Activated Rho is released from inhibitory protein, migrates to the plasma membrane, and modulates multiple downstream effectors. One of which is ROCK1/2 (Rho kinase). The Rho-ROCK pathway is essential in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. ROCK activity is closely associated with neuronal cell loss, impaired synaptic functions, and cytoskeleton modulation in central nervous system disorders. Rho/ROCK signaling modulates the activity of transcription regulators such as AP-1, MRTF-A, YAP, NF-κB, and serum response factor., Rho family GTPases are essential for axon guidance, cell polarity, and synapse formation. It has been shown that Rho GTPase regulates neuronal cell survival by inhibiting AKT signaling.

GPCR kinases (GRKs)

12Activated GPCR is subjected to desensitization to protect the cell from sustained stimulation. After peak response, ligand-bound receptor activity will return to basal level. Receptor phosphorylation by a family of GPCR kinases (GRKs), including GRK1/7, GRK2/3, and GRK4/5/6, is an essential first step to switch off sustained signaling., GRKs are second messenger-independent kinases (e.g., in contrast to PKA, which is dependent on cAMP levels). Serine/threonine residues on the GPCR carboxyl-terminal tail are common phosphorylation sites targeted by GRKs. GRKs translocate from cytoplasm to plasma membrane and initiate receptor phosphorylation by binding to Gβγ., GRK could also interfere with G protein binding through direct interaction. GRK level is affected by inflammatory responses in neonatal and adult neurons. GRK dysfunction is associated with cognitive impairment and tau hyperphosphorylation in Alzheimer-like pathology. Colocalization of GRK with amyloid plaques is observed in brain tissues of Alzheimer’s disease patients. Patients of Parkinson’s disease with dementia have increased GRK3/5 transcripts. GRK might promote the formation of pathological Lewy bodies in sporadic Parkinson’s disease, but the mechanism is yet to be defined. In psychiatric disorders, upregulating brain GRKs are observed in schizophrenia and major depression.,

Arrestins in GPCR desensitization

13Active GPCR is ready for the arrestins (signal terminators) binding after GRK phosphorylation. Arrestins can be classified into visual arrestins (arrestin 1 and arrestin 4) and non-visual arrestins (β-arrestin 1/2 or arrestin 2/3). Visual arrestins express exclusively in retina photoreceptors. They regulate light-activated rhodopsin signaling., β-arrestin 1/2 are ubiquitously expressed cytoplasmic proteins (Fig. 3a, b). β-arrestins and G proteins compete for the receptors. They bind to the same inter-helical cavity on the intracellular region (Fig. 3c). β-arrestin reduce G protein singling by hindering interaction between receptor and heterotrimeric G proteins. Further, β-arrestins facilitate receptor recycling by promoting internalization and cellular trafficking., The C-edge of arrestin protein with proximity to the membrane surface functions membrane anchor to stabilize the arrestin-active receptor complex (Fig. 3a). Recent studies illustrate the association of β-arrestin in multiple physiological functions and neuropsychiatric disorders., Phosphorylation of PI3K/AKT is remarkably reduced in the β-arrestin 2-deficient adult neural stem cells, indicating the crucial role of β-arrestin 2-PI3K/Akt pathway in adult hippocampal neurogenesis.,

Biased signaling of GPCRs

14G protein-biased signaling is regarded as the canonical signaling pathway employed by GPCRs.

15β-arrestin can modulate GPCR signal transduction in G protein-independent mechanism. β-arrestin can use the receptor as a structural component to generate an intracellular signaling complex consisting of agonist-occupied receptor and nonreceptor tyrosine kinases (c-Src). β-arrestin can maintain ERK signaling by acting as a scaffold for ERK mitogen-activated protein kinase. Other downstream effectors of β-arrestins include phosphatases and transcription factors. β-arrestins can act as a scaffold protein for specific downstream effectors., In the mouse model, β-arrestin 2 exerts anti-inflammatory functions by inhibiting nuclear factor kappa-B. Maintaining the arrestin-dependent signaling of M1 muscarinic acetylcholine receptor can prevent the insoluble misfolded proteins accumulation in Alzheimer’s disease model which thereby slowing down neurodegenerative disease progression.

16β-arrestin is important for astrocyte-mediated pro-inflammatory cytokine production. In mouse Parkinson’s disease models, β-arrestin 2-biased ligands suppress glia-derived inflammation and prevent neuron loss. IL-1β produced by the inflammation site is suppressed by β-arrestin 2. As compared to agonists which facilitate G protein and β-arrestin signaling at the same time, a β-arrestin-biased agonist for δ-opioid receptor can effectively control anxiety-like behaviour by activating ERK1/2 in the limbic structures of the brain. Hence, identifying therapeutic modulators that could preferentially stabilize GPCR structure for G proteins or β-arrestins is important for developing effective treatments for neurodegenerative and psychiatric diseases.

β-site APP cleaving protein 1 (BACE1)

17The proteolytic activity of BACE1 promotes the generation of β-amyloid (Aβ) peptides from amyloid precursor protein in Alzheimer’s disease. BACE1 expression can be activated by muscarinic acetylcholine receptor M1/M3 via PKC and MAP kinase signaling cascades. BACE1 activity is modulated by other GPCRs, such as the A2A and delta-opioid receptors. It has been shown that selective activation of the M2 receptor will suppress BACE1 expression via PKA-mediated signaling events.

cAMP-response element binding protein (CREB)

18GWAS analysis indicates that genes involved in the cAMP/PKA/CREB pathway are genetically associated with schizophrenia and bipolar disorder. CREB is a transcription factor activated by phosphorylation after GPCR activation. The binding of CREB to a specific cAMP response element (CRE) in the transcription regulatory region enhances particular gene transcription. For instance, neurotransmitter-activated dopamine D1 receptor on dopaminergic neurons can elicit transcription brain derived growth factor (BDNF) and other neurotrophins. In patients with bipolar disorder and schizophrenia, CREB expression is remarkably reduced in the dorsolateral prefrontal cortex and cingulate gyrus. While CREB protects neuronal cells in neurogenerative diseases, constitutively active CREB can reduce hippocampal neuron numbers and trigger sporadic epileptic seizures., It has been shown that the CREB modulator could enhance synaptic plasticity, which is beneficial for schizophrenia treatment.

DARPP-32 and PP1

19DARPP-32 (dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32,000) regulates neuronal excitability levels by prolonged depolarizations and voltage oscillations. DARPP-32 is the downstream target of Gi-coupling receptors such as the D2 dopamine receptor. DARPP-32 functions as a protein phosphatase-1 (PP1) inhibitor, a eukaryotic serine/threonine protein, upon phosphorylation at Thr-34 by PKA. PP1 is a phosphatase with multiple physiological functions. PP1 controls clock component PER2 accumulation in neurons, influencing circadian rhythm by light-mediated clock resetting. PP1 is an inducer of long-term synaptic depression in the hippocampus. Dysregulation of glutamate and dopamine signaling is common in neurodegenerative and neuropsychiatric disorders. Quantitative modeling results suggested that DARPP-32 could integrate dopamine and glutamate signals in striatal neurons. PP1 signaling reduces GABA(A) receptors in neostriatal medium spiny neurons depending on PKA and DARPP.

Structural insights

20Class A GPCR is the most heavily investigated GPCR family for drug development. Ligand binding to the unique pocket stabilizes GPCR in a particular conformation. Comparative analysis reveals that the outward bending/rotation of intracellular TM6 is a universal structure feature of receptor activation throughout the GPCR superfamily (Fig. 4a). Hydrophobic packing interactions between the transmembrane helices help to maintain the active conformation of TM6. Apart from TM6, rearrangements of other transmembrane helices, including TM3/5/7, open the intracellular milieu to facilitate recruitment of G protein. Class A GPCR has a consensus binding interface for G protein coupling. The receptors employ unique structure motifs as microswitches to transmit external stimuli (Fig. 4b). D3.49R3.50Y3.51 motif (Ballesteros–Weinstein number) at the intracellular region of TM3 forms the classic “ionic lock” with E6.30 on TM6 to constrain the receptor in the ground state., Disruption of the ionic lock is an activation feature of class A GPCRs. Side chains of Y7.53 (NPxxY motif) on TM7 and W6.48 (CWxP motif) on TM6 are subjected to orientation rearrangement during receptor activation., The P5.50I3.40F6.44 motif, formed by a group of hydrophobic residues on TM3/5/6, is also a crucial switch for receptor activation. Polar interactions and aromatic stacking interactions between the conserved aromatic residues are frequently observed in the ligand binding region of activated class A GPCRs.

Acetylcholine receptors (muscarinic)

21Acetylcholine is a neurotransmitter employed by cholinergic neurons in the brain and spinal cord. Muscarinic acetylcholine receptors in the central and peripheral nervous systems have five distinct subtypes. M1, M3, and M5 receptors are excitatory M1-like receptors. In contrast, M2-like receptors (M2 and M4 receptors) inhibit adenylyl cyclase activity. All the subtypes are detected in the brain. M2 and M3 receptors are also found in peripheral tissues.

22Reduced acetylcholine signaling due to the loss of cholinergic neurons is common in Alzheimer’s disease. Amyloid-β proteins could interrupt the interaction between the M1 receptor and G protein. M1 receptor-knockout mice show Alzheimer’s disease-like pathology with age-dependent cognitive decline. M1 receptor function is impaired by the binding of tau protein, a microtubule-associated protein in the extracellular matrix, which is toxic in secreted form;, Autoantibodies to recombinant human M1 receptors are detected in patients with schizophrenic disorders, mood disorders, and other psychiatric disorders.,

23The M1 receptor is a promising target for schizophrenia treatment. Allosteric modulation of M1 receptor activity could improve cognitive performance with antipsychotic activity. However, substantial loss of cortical M1 receptor might affect the efficacy of positive allosteric modulator.

24M2 receptor reduction is noted in the frontal cortex of Alzheimer’s disease patients. Suppressing M2 receptor expression with siRNA alters the expression of β-site APP cleaving protein. This transmembrane aspartic endopeptidase is involved in beta-amyloid formation.

25M2 receptor is suspected to be related to the major depressive disorder and bipolar disorder development. M2-encoding gene is genetically associated with the cholinergic dysfunction seen in mood disorders.

26M3 receptor level is remarkably reduced in the post-mortem frontal cortex tissues of patients with bipolar disorder. However, conflicting results are observed in another study cohort. Genetic variants of the M3 receptor-encoding gene are associated with abnormal neural connectivity in schizophrenia and cannabis-induced hallucinations.,

27Acetylcholine elevation is observed in Parkinson’s disease.– Targeting the M4 receptor with various antagonists showed promising treatment results for Parkinson’s disease., M4 receptor is abundantly expressed in striatal neurons, which regulates the balance between acetylcholine and dopamine responses. M4 receptor promotes the development of the dopamine hypersensitivity phenotype of schizophrenia. It has been shown that the M5 receptor can potentiate drug addiction by reinforcing rewarded behavior.

Adenosine receptor

28Adenosine (A1A, A2A, A2B, A3A) receptors are synaptic modulators that transmit inhibitory signals from adenosine to excitatory synapses. Adenosine is also known as a “retaliatory metabolite” as it is produced exponentially from tissue under stress. Astrocytes release adenosine to modulate synaptic transmission during hypoxia. A1A and A2A receptors exhibit widespread expression in the brain. A1A and A3A receptors are Gi-coupling receptors. In contrast, A2A and A2B receptors prefer Gs for downstream signaling.

29Although dopamine-replacement therapy is the mainstay treatment for Parkinson’s disease, it remains challenging to manage dyskinesia during replacement treatments. Animal study reveals that activating the A2A receptor will reduce the agonistic effects of dopaminergic D2 receptor-targeting drugs. As the A2A receptor is colocalized with D2 dopaminergic receptors, it is suggested that interactions between A2A and D2 receptors might be involved in the pathophysiology of Parkinson’s disease.

30Epidemiological data support that caffeine (a naturally occurring methylxanthine) consumption might reduce the risk of depression or depressive symptoms., The psychoactive function of caffeine is mediated via the non-selective antagonistic action on A1/A2A receptors. How A1/A2A receptors regulate depression-like behaviour remains unclear. It should be noted that caffeine at high doses might function other than adenosine receptor antagonists causing insomnia and anxiety.,

31Activated A2A receptor suppresses nitric oxide (NO) production by inhibiting NO synthetase. NO signaling is associated with various neurodegenerative diseases, including Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer’s disease. NO is a mediator of neuroinflammation, which triggers the microglial to release pro-inflammatory factors. NO induces protein S-nitrosylation (covalent addition of a NO group to a cysteine thiol/sulfhydryl), imposing endoplasmic reticulum stress in neurons., As A2A receptor activation affects synaptic plasticity and introduces memory deficits, antagonizing the A2A receptor might be helpful to control age-related cognitive impairments in Alzheimer’s disease.

Adrenergic receptor

32Brain adrenergic receptors on neurons and glia are activated by the monoamine neurotransmitter norepinephrine (produced primarily in the locus coeruleus of the brain stem) and epinephrine. Norepinephrine is produced from dopamine and converted into epinephrine. Norepinephrine and epinephrine released at synaptic junctions in the autonomic nervous system control classical fight-or-flight response. Norepinephrine controls response to environmental changes by regulating neuronal excitability. Epinephrine and norepinephrine also affect intelligence. Human has 2 adrenergic receptor subtypes: α-adrenergic (α1, α2A, α2B, α2C) receptors and β-adrenergic (β1, β2, β3) receptors. All the subtypes can be detected in the brain tissues.

33Adrenergic receptor protects the central nervous system from uncontrolled inflammatory responses. In the neonatal Lewis rats model, norepinephrine protects neuronal damage from inflammation.– Blocking β-adrenergic receptors signaling with beta-blockers (β-adrenergic antagonists) could exacerbate neuroinflammation in a mouse model of Alzheimer’s disease.

34Patients of Alzheimer’s disease and Parkinson’s disease show profound cell loss in locus coeruleus. Amyloid Aβ affects norepinephrine production and alters adrenergic receptor signaling in Alzheimer’s disease; Low norepinephrine level is linked to mood disorders such as anxiety, depression, and attention deficit hyperactivity disorder. α2-adrenergic receptors are established targets for antidepressant therapy. Depressed suicide victims showed high α2A-adrenergic receptor in the prefrontal cortex. Presynaptic α2-adrenergic receptor is an auto-receptor with the highest affinity to norepinephrine. Activated α2-adrenergic receptor inhibits norepinephrine synthesis and release. Thus, antagonizing presynaptic α2-adrenergic receptors could benefit depression treatment by enhancing norepinephrine release.

Cannabinoid receptor

35Cannabinoid signaling is involved in nociception, neurotransmission, and neuroprotection. It is also engaged in learning, memory, motor, food intake, anxiety, pain perception, and fear memories. Cannabinoid receptor type 1 (CB-1) is the primary subtype in the central nervous system. In comparison, the CB-2 receptor is mainly found in immune tissues. Cannabinoid receptors in the presynaptic nerve terminals can be activated by endogenous lipid endocannabinoids 2-arachidonoylglycerol (2-AG) and N-arachidonoyl-ethanolamine (AEA; anandamide). 2-AG is a full agonist for cannabinoid receptors, while AEA is a weak partial agonist. Cannabinoid receptors can also be activated by phytocannabinoids such as Δ9-tetrahydrocannabinol and non-euphoric cannabidiol (CBD) extracted from cannabis.,

36The CB-1 receptor is the dominant subtype in the brain., CB-1 receptor can be found in different neuronal types (e.g., GABAergic, glutamatergic, and serotonergic neurons) and controls cholinergic transmission., Exogenous administration of endocannabinoids protects neurons from β-amyloid (Aβ) neurodegeneration and apoptosis. Targeting cannabinoid receptors can improve spasticity (increase in muscle stiffness) and central neuropathic pain in patients with multiple sclerosis. Substantial reduction of CB-1 receptor in lateral globus pallidus and substantia nigra pars reticulata is associated with neurodegeneration in Huntington’s disease., Genetic polymorphisms on the CB-1 receptor are a risk factor for schizophrenia. CBD treatment is effective for neuroinflammatory-derived conditions such as epilepsy and anxiety.

37The pathological functions of the CB-2 receptor in inflammatory conditions (e.g., Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stress response, and depression) are under active investigation., Inflammation is a driving factor of depression and could counter the effects of antidepressant therapies. CB-2 receptor-overexpressing mice showed a significant reduction in depressive-related behaviors. In contrast, pro-inflammatory chemokines and cytokines are markedly reduced in the brain of CB-2 receptor-deficient mice. CB-2 receptor can suppress microglial activation and prevent pro-inflammatory mediators release., In bipolar disorder, a neuropsychiatric disorder presenting with mood fluctuation, selective activation of the CB-2 receptor can stabilize mood and reduce mood swings.

Other receptors for endogenous cannabinoids: GPR12, GPR18, and GPR55

38GPR12 is phylogenetically related to the cannabinoid (CB-1 and CB-2) receptors. GPR12 is a constitutively active receptor. Apart from cannabidiol, lysophospholipid sphingosine 1-phosphate and phingosyl-phosphorylcholine are potential endogenous ligands for GPR12., GPR12 expressed mainly in the central nervous system (frontal cortex, piriform cortex, thalamus, hypothalamus, hippocampus, amygdala, and olfactory bulb). In mice, GPR12 expresses in the area controlling emotion and metabolism. GPR12 promotes neurite outgrowth by activating ERK1/2 signaling. Other functions include pain control, neurite outgrowth, and regeneration. SNP microarray-based genome-wide association study reveals a close association between GPR12 and antipsychotic response in schizophrenia treatment.

39GPR18 and GPR55 also act as receptors for endogenous cannabinoids 2-AG and AEA., GPR18 and GPR55 exhibit high structural similarity. GPR18 regulates polymorphonuclear cell infiltration and protects organs from acute immune responses. It has been shown that GPR18 could interact with the CB-2 receptor in activated microglia of Alzheimer’s disease model; GPR55 expresses predominantly in the brain. The receptor can be activated by endocannabinoids, phytocannabinoids, synthetic cannabinoid ligands, and lysophosphatidylinositol. GPR55 antagonist exhibits anti-inflammatory functions by modulating GPR55-expressing immune cells such as monocytes and microglia. Given the high expression of GPR55 in the striatum, GPR55 signaling is suspected to be involved in motor impairment in Parkinson’s disease.

Dopamine receptor

40Dopamine is a catecholamine neurotransmitter in the brain. Dopamine/ dopamine receptors are crucial for motor function, cognition, learning, and memory. There are two receptor subtypes: D1-like (D1 and D5) and D2-like (D2, D3, and D4). D1 and D2 receptors are the most abundantly expressed dopamine receptor subtypes in the brain.

41D1 and D2 receptors are significantly reduced in asymptomatic Huntington’s disease patients. In the early stage of Huntington’s disease, dopamine signaling is associated with the development of dance-like movements (chorea). Clinical studies show that dopamine receptor blockers or depleting agents control motor dysregulation, especially chorea. In the late stage, however, a remarkable reduction in dopamine/ dopamine metabolite level is observed. The D1 receptor is remarkably reduced in patients presenting mild to moderate functional impairment. It is noted that targeting the dopaminergic signaling cascade might lead to rapid cognitive decline in Huntington’s disease patients.

42Disturbances in the dopaminergic system are frequently observed in other neurodegeneration disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Reduced dopamine receptors are correlated with the progression of Alzheimer’s disease; Loss of dopaminergic neurons is a hallmark feature of Parkinson’s disease. Activating D2-like receptors (D2/3 receptors) or increasing circulating dopamine are effective treatment strategies for symptomatic Parkinson’s disease; Dopamine dysregulation contributes to the demyelinating process (resulting from autoimmune attack) in multiple sclerosis. Dopamine can modulate pro-inflammatory cytokines secretion in T helper Th17 cells in uncontrolled neuroinflammatory responses.,

43The development of β-arrestin-biased modulators might improve treatment outcomes and avoid side effects. Dopamine receptor agonist exhibits mild to serious side effects. This is partly caused by the activation of both G proteins and the β-arrestin signaling cascade., Many antipsychotics could interfere with dopamine-dependent β-arrestin 2 recruitment. Selective activating the D2 receptor-β-arrestin pathway with biased agonist is beneficial to correct dopamine signaling in schizophrenia.

Histamine receptor

44Histamine is an inflammatory biogenic amine synthesized from L-histidine. Histamine stimulates peripheral immune cells to release pro-inflammatory cytokines. In the central nervous system, histamine signaling in the tuberomammillary nucleus (TMN) controls sleep-wake, circadian and feeding rhythms. Elevated histamine increases blood-brain barrier permeability, allowing peripheral immune cells to enter and act on brain parenchyma.

45Four different histamine (H1–H4) receptors are reported. H1 and H2 receptors are expressed in the brain, central nervous system, and peripheral tissues. H1 receptor activation promotes neuron differentiation. In contrast, H2 receptor activation induces neural stem cell proliferation. H3 receptor is localized in the brain. H3 receptor is an important therapeutic target for cognitive disorders. The neurological function of the H4 receptor remains unclear. H4 receptor can be detected in the non-neuronal cells of the brain. H4 receptor activation is involved in the inflammatory responses regulated by mast cells, eosinophils, and T cells. Histamine acts on H1 and H3 receptors to control normal sleep/wake behavior.

46Alterations in histamine signaling are found in both neurodegenerative and psychiatric disorders. Due to structural similarity, H1 and H4 receptors are suggested to have cross-functional impacts on disease development. Positron emission tomography results show that reduced H1 or H4 receptor is present in a subgroup of Alzheimer’s disease, schizophrenic and depressed patients.– The role of histamine signaling in Alzheimer’s disease remains controversial due to the conflicting results on histamine levels. H1 receptor upregulation is associated with myelin damage mediated by focal lymphocytes in multiple sclerosis. Targeting the H3 receptor with selective antagonists could stimulate the release of crucial neurotransmitters, including acetylcholine, dopamine, norepinephrine, and histamine. H4 receptor is involved in M1-activated microglia cells (primary inflammatory cells in the brain) driven neuroinflammation. Attenuating H4 receptor signaling is beneficial in controlling inflammation propagation in Parkinson’s disease.

Melanin-concentrating hormone receptor

47Melanin-concentrating hormone (MCH) is the pro-melanin expressed by the central nervous system. MCH is well documented for its function in controlling motivated behaviours, including feeding and drinking. Later studies suggest that MCH promotes non-REM sleep and modulates energy homeostasis., MCH receptor 1 is a stress modulator regulating fear and anxiety processes. MCH receptor 1-signaling is responsive to physiological- or neurochemical-controlling stress and affective states in genetically knockout models. MCH is associated with behavioural disorders and depressive symptoms observed in Huntington’s disease patients. Animals without MCH receptor expression exhibit schizophrenia-like phenotypes.

Melatonin receptor

48Melatonin (MT) or N-acetyl-5-methoxytryptamine is a neuroendocrine hormone produced by the pineal gland. MT is a regulator of the circadian rhythm (sleep-wake cycle). Melatonin is converted from tryptophan/ serotonin in the pinealocytes. Melatonin also functions as an antioxidant to protect tissues from free radical damage. The antioxidant activity of melatonin is essential in tissue (such as the brain) with high reactive oxygen species (ROS) resulting from oxygen consumption. Peripheral tissues, such as the gut and skin, could also secrete melatonin. Melatonin secretion is suppressed by daylight through the retino‐hypothalamic tract and reaches a peak at night. Rhythmic nocturnal secretion (secreted in the dark) allows melatonin to distributes throughout the body via circulation.

49Circadian rhythm dysregulation is a common symptom presented by patients with neurodegenerative disease due to functional impairment of the retina-suprachiasmatic nucleus (SCN)-pineal axis. In Alzheimer’s disease, melatonin and MT1 receptor level in SCN and cortex diminishes remarkably., Pathological α-synuclein aggregation (a stepwise aggregation of presynaptic neuronal protein observed during Parkinson’s disease development) is reduced in animal models subjected to melatonin treatment., In multiple sclerosis and amyotrophic lateral sclerosis, melatonin demonstrates anti-apoptotic functions and offers neural protection from oxidative damage.,

50Dysregulation in MT1/2 receptor signaling contributes to the pathological development of anxiety, sleep disorders (insomnia), and depression.– In a post-mortem study on depressed patients, hypothalamic MT1 expression increased in the hypothalamic suprachiasmatic nucleus and is correlated with disease duration. Melatonin treatment can alleviate symptoms of psychiatric disorders with few side effects (even at high dosages). Exogenous melatonin may also be administered to control anxiety. Melatonin is an effective medication for sleep disturbances in depression. However, no solid empirical evidence supports melatonin or melatonin receptor agonists as the cure for depression. The use of melatonin to normalize the disrupted circadian cycle might not be sufficient to alleviate depression.

Sphingosine 1-phosphate (S1P) receptor

51S1P is an active lysophospholipid. S1P exerts its biological functions through S1P receptor 1-5. S1P/S1P receptor controls angiogenesis, chemotaxis, and egress of lymphocytes (from bone marrow, thymus, and lymphoid tissues). S1P receptor-expressing immune cells in lymphoid tissues are attracted by the high S1P level in the bloodstream. S1P receptors on immune cells are inactivated in peripheral blood by receptor internalization. S1PR1 can be found in B, T, and dendritic cells. During inflammation, S1PR1 on immune cells is upregulated. S1PR1 enhances inflammation by activating neuroglia/microglia (immune cells orchestrating inflammatory response in the central nervous system). S1PR1 might contribute to the development of multiple sclerosis by promoting chronic and acute inflammation., Unlike S1PR1, S1PR5 is mainly detected in natural killer and dendritic cells. S1PR5 expression on natural killer cells is critical for its egress from lymph nodes and bone marrow. Hence, targeting S1P receptors might protect the brain from immune attacks by limiting lymphocytes from passing through the blood-brain barrier in multiple sclerosis.

Opioid receptor

52The opioid receptor family is composed of delta (δ)-opioid receptor (DOR), kappa (κ)-opioid receptor (KOR), mu (μ)-opioid receptor (MOR), and nociceptin receptor. Opioid receptor recognizes a variety of endogenous neuropeptides, including enkephalins, endorphins, and dynorphins. The endogenous opioids are one of the neuromodulators produced by the body to attenuate stressful states. Opioid receptor in the central and peripheral nervous system regulates stress and pain responses. locus coeruleus (LC) in the brain is the stress-integrating site. The opioid receptor can sensitize neurons in LC to corticotropin-releasing factor (CRF), a potent psychological mediator regulating stress-induced behaviors. Chronic or persistent acute stress can alter LC functions. Hyperactive LC is associated with psychiatric disorders. Dysregulation of the opioid receptors affects emotion processing in patients with major depressive disorders. Opioid receptor levels are related to neurocognitive deficits. Elevated opioid receptors level might elicit symptoms of schizophrenia resulting in treatment resistance.

53δ-opioid receptor and mu-opioid receptor exhibit opposite functions in the pathogenesis of Alzheimer’s disease. δ-opioid receptor agonist reduces expression of β-site APP cleaving enzyme 1 (BACE1), which cleaves amyloid precursor protein to initiate Aβ peptide production in PC12 cells (harbouring mimicked injury of Alzheimer’s disease)., On the contrary, knocking down δ-opioid receptor increases BACE1 expression, leading to high production of Aβ42, the essential pathogenic Aβ peptides in Alzheimer’s disease with 42 amino acids. For the μ-opioid receptor, it is noted that agonist-induced receptor activation enhances BACE1 and Aβ42 expression. Hence, targeting δ-opioid/μ-opioid receptor signaling might benefit Alzheimer’s disease treatment; Parkinson’s disease patients have reduced brain kappa-opioid receptor levels. Activating κ-opioid receptor ameliorates Parkinsonian behaviours and restores locomotor in marmoset with Parkinsonism. In addition, κ-opioid receptor agonists can alleviate dyskinesia behaviour derived from L-DOPA in Parkinson’s disease rats.

Serotonin receptor

54Dysregulation of serotonin (5-hydroxytryptamine, 5-HT) receptors is observed in nearly all neurodegenerative and psychiatric disorders., 5-HT receptors 1 and 2 are the most intensively studied drug targets. The receptors have various effects with multiple subtypes and alternative splice variants. 5-HT1 and 5-HT2 receptors have different expression patterns in the brain with similar or opposite functions. 5-HT1 receptor has 5 subtypes: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F receptors. 5-HT1A receptor can be found in both serotonin neurons and non-serotonin neurons. 5-HT1A receptor is associated with anxiety and mental traits in transgenic mice. Partial agonists targeting the 5-HT1A receptor are suggested to be useful in controlling alcohol abuse. Anterior cingulate cortex (ACC) is a brain region regulating emotion regulation, pain perception, and cognitive control. Patients with bipolar disorder, major depressive disorder, and schizophrenia have higher 5-HT1B receptor expression in the outer ACC layers compared to the inner ACC layers; 5-HT2 receptor has 3 subtypes: 5-HT2A, 5-HT2B, and 5-HT2C receptors. 5-HT2 receptors are implicated in various neuropsychiatric phenotypes, including schizophrenia, attention deficit hyperactivity disorder, affective disorders, eating disorders, anxiety disorders, obsessive-compulsive disorder, suicide, and Alzheimer’s disease.

Structural insights

55Class C GPCRs are distinguished from other classes of GPCRs by two unique features. First, the orthosteric ligand binding pocket is located in the large extracellular venus flytrap domain (VFT). VFT is connected to the transmembrane helix via the cysteine-rich domain (CRD) (Fig. 4c). Among class C GPCRs, only the GABAB receptor lacks CRD; Second, class C GPCR forms hetero- or homo-dimers at physiological conditions.– VFT domain forms an asymmetric dimer interface to facilitate dimer formation. Ligand engagement at either subunit is sufficient to activate the receptor.,, The surface interface between dimers is the potential binding site for the therapeutic modulator. The conformation rearrangement between ICL2 and ICL3, and C-terminus contributes to receptor activation.–

γ-aminobutyric acid B receptor

56γ-aminobutyric acid B (GABAB) is an inhibitory neurotransmitter. GABAB receptor is a heterodimer consisting of two subunits, GABAB1 and GABAB2. GABAB1 expression is reduced in the brain of Alzheimer’s disease patients. The GABAB1 protein level is negatively associated with the neurofibrillary tangle. Results from a genome-wide association study (GWAS) show that GABAB1 SNPs are a risk factor for schizophrenia. GABAB2 SNPs are correlated with the development of Huntington’s disease. Activating GABAB receptor can ameliorate motor impairment and reduces inflammation/ oxidative damage in Parkinson’s disease models.

Metabotropic glutamate receptors

57The excitatory neurotransmitter glutamate mediates neuronal excitability via metabotropic glutamate receptors (mGluRs). Functional mGluR is a homodimeric receptor consisting of 8 members (mGluR1-8). Dysregulation of mGluR signaling pathways is observed in both neurodegenerative and psychiatric disorders.

58Group I mGluR composes of mGluR1 and mGluR5. mGluR1 localizes in the hippocampus, hypothalamus, periaqueductal gray, and amygdala, which are associated with anxiety. mGluR5 activity is linked to the cognitive symptoms of Alzheimer’s disease.– Deleting mGluR5 improved spatial learning impairment and decreased Aβ oligomers in Alzheimer’s disease models. Interaction between mGluR5 and cellular prion protein could also play a part in the pathogenesis of Alzheimer’s disease., Activating mGluR5 promotes striatal neuron survival in Huntington’s disease models., mGluR5 knockout mice exhibit obvious schizophrenia symptoms, including reduced spatial memory and reduced sensorimotor gating.

59Group II mGluR consists of mGluR2 and mGluR3. Activating mGluR2 and mGluR3 can control panic-like behaviors and ameliorates acute stress responses in the anxiety model. Mutant huntingtin in Huntington’s disease is toxic to neurons. In the mouse model, activating mGluR2 and mGluR3 could enhance limb coordination by attenuating the generation of huntingtin aggregate. mGluR2 and mGluR3 demonstrate protective effects on the nigrostriatal system, which restores functional deficits in Parkinson’s disease rat model., Overexpression of mGluR2 in the neocortical layers, cerebellum, striatum, hippocampus, and thalamus/hypothalamus could build up glutamate-mediated excitotoxicity and promote Huntington’s disease progression.–

60Group III mGluR includes mGluR4/6/7/8. mGluR4 activation ameliorates locomotion disorder in Parkinson’s disease rats. mGluR7/8 are associated with the anxiety-related phenotype., SNPs in mGluR7/8 are correlated to the susceptibility of schizophrenia.–

GPCR dimers

61GPCRs can function in homodimeric or heterodimeric forms., The receptor complex consists of one GPCR dimer with two orthosteric binding sites and a heterotrimeric G protein. GPCR dimer exhibits different biochemical properties compared to the individual receptor. Activation of either one of the receptors is sufficient to promote dimer formation. Dimeric GPCR has a different ligand binding affinity as compared to the monomer. Receptor dimerization affects receptor trafficking in agonist-induced GPCR endocytosis. Closely related GPCR subtypes are more efficient in forming heteromers. Here, we focused on discussing two physiologically existing GPCR heterodimers (A2AR-D2R and mGluR2-5-HT2A).

62Adenosine 2A receptor-dopamine D2 receptor (A2AR-D2R) heterodimer is located in the ventral striato-pallidal GABA neurons., A2AR-D2R heterodimer attracts attention in the field of Parkinson’s disease medication as ligands for A2AR can modulate dopamine signaling in Parkinson’s disease. Co-administration of dopamine precursor L-DOPA (L-3,4-dihydroxyphenylalanine) and dopamine receptor agonists could improve mobility in Parkinson’s disease. It has been shown that adenosine antagonists such as caffeine could enhance dopamine agonist action in Parkinson’s disease treatment. A2AR activation can suppress D2R-mediated Gi/o signaling. Stimulating A2AR with adenosine A2AR agonist in the nucleus accumbens produces behavioural effects similar to local dopamine depletion. Thus, the action of A2AR modulators should be considered in the drug design for Parkinson’s disease.

63Serotonin type A 5-HT2A receptor and type C metabotropic glutamate 2 (mGlu2) receptor regulates psychoactive behavior in schizophrenia., 5-HT2A receptor is a Gq-coupled receptor, while mGluR2 receptor signals through Gi. 5-HT2A receptor is upregulated in the frontal cortex of schizophrenic subjects compared with normal subjects. In contrast, the expression level of mGluR2 is decreased. Balance between Gq and Gi is a predictive indicator of antipsychotic drug properties. 5-HT2A receptor and mGluR2 can form stable complexes in physiological conditions which regulate Gq-Gi balance cooperatively. mGluR2 agonist reduces 5-HT2A receptor/Gq signaling in the frontal cortex of schizophrenic subjects. mGluR2 agonist can downregulate 5-HT2A receptor expression. On the contrary, it has been shown that the 5-HT2A receptor controls mGluR2 expression at the epigenetic level in the frontal cortex. Although the 5-HT2A receptor and mGluR2 regulate the activity of each other remains elusive, interrupting the functional crosstalk in the 5-HT2A receptor/ mGluR2 complex is a putative approach in schizophrenia treatment.

Therapeutic development

64The small molecules regulate GPCR activity by stabilizing receptors at unique conformational state (Fig. 5). To explore the GPCRs-based therapeutic strategies against neuropsychiatric disorders, we examined the clinically approved drugs (Fig. 5a) and compounds being tested in different stages of clinical trials (Fig. 5b) in the DrugBank database (https://go.drugbank.com/). In total, 92 drugs are being approved (Table 2). Forty-one candidates are undergoing clinical trials (Table 3). Selected receptors/drugs interaction are shown in Fig. 6.

Alzheimer’s disease

65Alzheimer’s disease (AD) is a progressive neurodegenerative disease. AD patients present with cognitive deficits, memory loss, and personality and behaviour changes. Currently, there is no curative treatment for AD. Reducing patients’ symptoms and delaying the disease’s progression is the primary objective of treatment. α1-adrenergic receptor, dopamine receptor, muscarinic acetylcholine receptor M3, histamine H1 receptor, and serotonin receptors are the primary therapeutic targets. Medication to control mental symptoms is another important objective, as patients manifest neuropsychiatric symptoms frequently.

66Developing new drugs for AD is challenging, with high failure rates and long development periods. Several trials attempt to explore the use of GPCR agonism in AD treatment. SUVN-502 is in the Phase II trial (NCT02580305) to evaluate its safety and efficacy in moderate AD treatment. SUVN-502 is an orally active 5-HT6 receptor antagonist exhibiting effects by modulating cholinergic and glutamatergic neurotransmission. ∆9-tetrahydrocannabinol (THC) analog Nabilone (agonist targeting CB1/2 receptor) is under phase III investigation (NCT02351882) for its benefit on agitation, hyperactive behavioural symptoms of AD., Caffeine, the antagonist of adenosine receptor antagonist, could modify brain dysfunctions in various neurodegenerative diseases including AD, Parkinson’s disease, Huntington’s disease. The efficacy of caffeine on cognitive decline in AD dementia is undergoing examination in phase III clinical trial (NCT04570085).

67Guanfacine is an α2a-adrenergic agonist. Guanfacine could increase brain noradrenaline levels. Dual actions of Guanfacine on noradrenergic transmission and thalamocortical glutamatergic transmission have been reported. Guanfacine is a drug for treating children’s attention deficit/hyperactivity disorder (ADHD). The efficacy for improving cognition in AD is evaluated in the phase III trial (NCT03116126). The α1-adrenergic receptor antagonist, Prazosin, is being tested for its effectiveness on agitation in adults with AD in a phase III trial (NCT03710642). Prazosin is a drug for hypertension, benign prostatic hyperplasia, and post-traumatic stress disorder (PTSD) associated nightmares. Prazosin can cross the blood-brain barrier and act on the active α1-adrenoreceptor in the brain.

68Brexpiprazole is classified as a novel class of antipsychotic with serotonin-dopamine modulating functions. It is an atypical antipsychotic that function as a partial agonist for serotonin and dopamine receptors. As a partial agonist, Brexpiprazole exerts smaller responses than the native ligands., The use of Brexpiprazole in AD agitation is now in phase III study (NCT03620981).

Parkinson’s disease

69Parkinson’s disease (PD) is the second most prevalent age-related disorder. Early stage with mild symptoms did not require medication. Dopamine-like agonists, also known as dopamine-replacement therapy, are the primary treatment for symptomatic PD. As degeneration of the substantia nigra leading to striatal dopamine reduction is a leading cause of PD, re-introducing dopamine can improve motor problems dramatically and slow down PD progression.,

70Levodopa is a dopamine precursor. It has long been used in controlling bradykinetic symptoms in PD. Levodopa can cross the blood-brain barrier and is known as a well-tolerated drug for dopamine-replacement therapy. However, Levodopa could lead to motor and psychiatric side effects. Amantadine could reduce dyskinesia (involuntary movements) in PD patients receiving Levodopa. Amantadine is an antiviral medicine with antiparkinsonian effects. Synergistic effects are observed when used in combination with Levodopa., Lisuride functions as a dopamine receptor agonist with 5-HT1A receptor agonist and 5-HT2B receptor antagonist for PD treatment. Piribedil is a dopamine agonist used with or without Levodopa in a phase III trial to treat idiopathic PD (NCT01519856). Bromocriptine is a dopamine D2 receptor agonist for early PD treatment. Bromocriptine works by activating post-synaptic dopamine receptors.

71Apomorphine is a morphine derivative. It functions as a D2 dopamine agonist for treating hypermobile “off” episodes of advanced PD, a stage in which PD symptoms get worse even with scheduled medication. It also prevents dyskinesia by functioning as a 5-HT1A receptor agonist. The A2A receptor in the basal ganglia is involved in the motor control of PD. At present, Istradefylline is the principal adenosine A2A receptor antagonist employed in adult PD patients presenting “off” episodes associated with Levodopa treatment.

72Pergolide is a long-acting dopamine receptor agonist approved in 1982 for treating PD. It functions on various GPCRs, including dopamine D2/3 receptor, α1/2-adrenergic receptor, and 5-HT receptors. It is used as adjunct therapy with Levodopa and carbidopa in the symptomatic treatment of PD. Ropinirole is a non-ergoline dopamine agonist, approved as monotherapy and as an adjunct to Levodopa in the treatment of PD.

73Benztropine is used to treat the molecular mechanism of anticholinergics PD. Benztropine inhibits dopamine uptake and exhibits varied binding affinities for muscarinic acetylcholine M1 and histamine H1 receptors. Biperiden, another anticholinergic drug launched in 1954, has an antagonistic effect on the muscarinic acetylcholine receptor.

74Pramipexole is a non-ergot-derived dopaminergic agonist for PD treatment. Pramipexole treatment enhances DA and 5-HT neurotransmission and increases tonic activation of post-synaptic D2 and 5-HT1A receptors in the forebrain. Apart from PD, Pramipexole can also be prescribed for psychiatric conditions such as treatment-resistant depression and bipolar disorder.

Multiple sclerosis

75Multiple sclerosis (MS) results from an immune attack by infiltrating inflammatory leukocytes in the central nervous system, causing hard, mottled pathologic changes and nerve conduction disorders., At present, medication aims to control GPCR-regulated immune cell function as one of the treatment regime for MS. In the database, 6 GPCR-related drugs are recorded. The drugs target multiple GPCRs, including adrenergic receptors, cannabinoid receptors, dopamine receptors, GABA receptors, opioid receptors, orphan GPCRs (GPR12/18/55), S1PR1/5, and chemokine receptors.

76Baclofen is a derivative of the neurotransmitter γ-aminobutyric acid (GABA). Baclofen can help relax the stiff muscle (muscle spasticity) experienced by MS patients. Cannabidiol (CBD), one of the active components in cannabis, could improve mobility in MS by reducing depression, fatigue, inflammation, pain, and spasticity (stiff muscle with feelings of pain or tightness) in MS patients. Modafinil is a partial agonist for brain α1b-adrenoceptor. Pharmacological blockade of α1b-adrenoceptor shows benefit in controlling fatigue syndromes in MS. Modafinil exhibits clinical efficacy in psychiatric conditions, including treatment-resistant depression and attention deficit/hyperactivity disorder.

77Ozanimod, Siponimod, and Fingolimod are S1PR agonists that selectively bind to the S1PR1 and S1PR5 subtypes, inhibiting lymphocyte egress from lymph nodes. Ozanimod demonstrates a favourable safety profile in trials. Fingolimod may cause undesirable effects because of its interaction with other S1PR subtypes. Compared to Fingolimod, Siponimod has fewer off-target effects.

78Ceralifimod is a selective S1PΡ1/5 agonist under investigation in phase II clinical trial NCT01226745 in patients with relapsing-remitting multiple sclerosis (a condition with relapses or exacerbations of old and new symptoms). Plozalizumab is another potential drug for MS treatment. It is a humanized anti-CCR2 monoclonal antibody targeting white blood cells. Plozalizumab may regulate inflammatory responses by targeting the CCL2‐CCR2 axis in MS.

Huntington’s disease

79Huntington’s disease (HD) is a hereditary neurodegenerative disease. Symptoms include movement disorders and cognitive and psychiatric manifestations. Blocking and antagonizing dopamine are effective for HD treatment. Tetrabenazine is a reversible vesicular monoamine transporter 2 (VMAT) inhibitor that inhibits the reuptake of neurotransmitters in presynaptic neurons. VMAT helps to repackage the unbound dopamine taken up by the pre-synaptic terminal. Although it is first designed for schizophrenia treatment, clinical trials demonstrate efficacy in treating hyperkinetic movement disorders. Tetrabenazine also functions as a D2 post-synaptic receptor blocker at high doses and is used to treat uncontrolled muscle movement in HD. Haloperidol is a first-generation antipsychotic for schizophrenia and psychotic disorders. As a dopamine receptor antagonist, Haloperidol is used off-label for managing chorea associated with HD. For cognitive impairment, no effective targeted therapy is available at the present stage. Tiapride is in phase III for the treatment of HD (NCT00632645). Preclinical pharmacologic and behavioral research suggests that Tiapride is a selective blocker of dopamine D2 and D3 receptors in limbic brain regions.

Schizophrenia

80Schizophrenia is characterized by cognitive deficits and positive and negative symptoms with complex inheritance patterns. Patients may have positive, negative, cognitive, and general psychopathological disorders. According to the positive and negative syndrome scale (a psychiatric rating system), positive symptoms include delusions, hallucinations, conceptual disorganization, hallucinatory, excitement, grandiosity, suspiciousness, and hostility; Negative symptoms include blunted affect, emotional withdrawal, poor rapport, passive social withdrawal, difficulty in abstract thinking or stereotyped thinking and lack of spontaneity and flow of conversation. Schizophrenia patients could also present general cognitive disorders. Examples include anxiety, guilt feeling, tension, depression, poor attention or impulse control, and active social avoidance.

81Schizophrenia treatment is challenging because existing antipsychotics are antidopaminergic drugs that improve only positive symptoms such as agitation and aggression but have limited efficacy for negative and cognitive symptoms. Globally marketed antipsychotic drugs include typical antipsychotic drugs (mostly specific dopamine D2 receptor antagonists) and atypical antipsychotic drugs (such as dopamine D2 and 5-HT2A dual antagonists and D2/D3 partial agonists).

82Aripiprazole, a blockbuster drug for controlling psychiatric symptoms, has high affinities for 5-HT1A, 5-HT2A, D2, and D3 receptors. It is a partial agonist of D2, D3, and 5-HT1A receptors and a 5-HT2A receptor antagonist. Aripiprazole is also a drug for bipolar disorders. Brexpiprazole, developed by Otsuka, is considered as the pharmacological successor to Aripiprazole. Brexpiprazole can also be used as an adjunct for major depressive disorder.–

83Cariprazine is a D3/D2 partial agonist with moderate affinity for the 5-HT2A receptor. FDA approved it in 2016 for treating adult schizophrenia and bipolar disorder.

84Lumateperone is an antipsychotic targeting multiple GPCRs. It is a post-synaptic dopamine D2 receptor antagonist, a presynaptic dopamine D2 receptor partial agonist, and a 5-HT2A receptor antagonist. Lumateperone can be used for positive & negative symptoms and cognitive dysfunction in schizophrenia. It can also be used in bipolar disorder treatment.

85Chlorpromazine blocks dopamine receptors, α-adrenergic receptors, and 5-HT receptors. It can quickly control the state of agitation and gradually eliminate hallucinations and delusions. Thus, it can apply as medication to control combativeness and aggressive behaviour in children.

86Risperidone can be used for various mental disorders, including schizophrenia and mood disorders. Risperidone has high affinities for 5-HT receptors and dopamine receptors and mildly inhibits α1-adrenergic receptors and histamine receptors.

87Olanzapine is developed based on clozapine with structural modification. It was approved to be marketed by FDA in 1996. Olanzapine not only inhibits dopamine receptors but also binds to serotonin receptors, and its affinity with serotonin receptors is far greater than its affinity with dopamine receptors.

88Haloperidol is a widely used antipsychotic for positive symptoms of schizophrenia, Tourette syndrome, and behavioural disorders/hyperactivity in children. Haloperidol can block dopamine, α-adrenergic, and serotonin receptors. It is highly selective for dopamine receptors.

89Spiperone is a potent dopamine D2 receptor antagonist bearing the butyrophenone scaffold. Although it displayed efficacy in treating drug-resistant schizophrenia, it is not yet approved by the FDA. Zotepine is an atypical antipsychotic drug for treating schizophrenia in Japan. It is a potent dopamine D1/D2 receptor and 5-HT2A receptor antagonist.

90Medication for schizophrenia is an active research area. Schizophrenia drugs generally target multiple GPCRs. For instance, Brilaroxazine, an investigational antipsychotic drug developed by Reviva, could stabilize the dopamine-serotonin system by partially activating D2, D3, D4, 5-HT1A, and 5-HT2A receptors. In addition, it antagonizes 5-HT6 and 5-HT7 receptors. A phase III clinical trial of Brilaroxazine for the safety and efficacy of the treatment of schizophrenia is now under recruitment (NCT05184335).

91Zicronapine is a tetracyclic azepine developed by Lundbeck with affinities for 5-HT2A/2 C and D1/2 receptors. Phase III study of Zicronapine has been completed (NCT01295372).

92Eltoprazine is a piperazine derivative that partially activates the 5-HT1A/2B receptor. It is tested in a phase II trial to investigate the treatment of schizophrenia and cognitive impairment (NCT01266174).

93LuAF35700 is an antagonist targeting dopamine receptors, serotonin receptors, and α-adrenergic receptors. The efficacy and safety of the LuAF35700 have been examined in phase III randomized, double-blind trial (NCT02717195).

94Roluperidone is a novel 5-HT2A and σ2 receptor antagonist developed by Minerva Neurosciences. Phase III studies have shown that Roperidone may treat negative symptoms in schizophrenia patients without causing post-synaptic dopaminergic blockade due to low or no affinity for dopamine and histamine receptors (NCT03397134).

Depression

95The underlying mechanism of depression is not clear. According to the record in the DrugBank database, a total of 31 antidepressants target GPCRs. Examples include tricyclic antidepressants, bioamine neurotransmitters (serotonin, norepinephrine, and dopamine) reuptake blockers, and 5-HT2A receptor inhibitors.

96Imipramine and Desipramine are examples of tricyclic drugs for major depressive disorders, anxiety, and ADHD. They have high affinities to 5-HT2C and 5-HT2A receptor subtypes. The pharmacological properties of Amitriptyline are similar to Imipramine. Amitriptyline can inhibit 5-HT reuptake with sedative, hypnotic and anticholinergic effects. A combination of Amitriptyline and Imipramine could block serotonin reuptake in the brain’s limbic (emotional) regions.

97Currently, monoaminergic alterations involving serotonin receptors are a significant cause of depression. Selective or non-selective 5-HT reuptake inhibitors are the first-line treatment for depression. Representative drugs include Fluoxetine, Paroxetine, and Citalopram.– Fluoxetine, a weak antagonist of 5-HT2C and 5-HT2A receptors, was approved for marketing in 1988 to treat major depressive disorder. Later, Paroxetine was approved in 1992. It is a highly selective reuptake inhibitor of 5-HT in neurons. Citalopram has a similar function in depression treatment. It is also a serotonin reuptake inhibitor. Nefazodone and Trazodone improve mood by antagonizing 5-HT2A/C receptors. They showed affinity to the 5-HT1A receptor., Pindolol can accelerate the effects of selective serotonin reuptake by antagonizing 5-HT1A and β-adrenergic receptors., Meanwhile, Mirtazapine and Mianserin have antagonistic properties on 5-HT2A/2C receptors. They exhibit inhibitory effects on presynaptic A2-adrenergic receptors. Both drugs improve sleep duration.,, Vortioxetine is a multi-mode antidepressant for major depressive disorder treatment in adults. Vortioxetine inhibits serotonin reuptake. It exerts different effects on different members of the 5-HT receptor. On one hand, Vortioxetine is an antagonist for 5-HT1D, 5-HT3, and 5-HT7 receptors. On the other hand, it is a partial agonist for the 5-HT1B receptor.– Bupropion and its primary metabolite hydroxybupropion function by blocking 5-HT3A receptor. Agomelatine is an atypical antidepressant acting as a melatonin receptor (MT1/2) agonist and a 5-HT2C/2B receptor antagonist.

98Inhibitors of dopamine (DA) transporters are another class of antidepressants. Nortriptyline can bind directly to the DA transporter to inhibit dopamine uptake. It can be used in treatment-resistant depression.– Brexpiprazole is a partial agonist on the 5-HT1A receptor and D2 receptor. Brexpiprazole can also be used in adult patients with schizophrenia.

99Ansofaxine is a reuptake inhibitor for 5-HT, norepinephrine, and dopamine which is under clinical development for major depressive disorder (NCT04853407). 5-methoxy-N, N-dimethyltryptamine (5-MEO-DMT) is a non-selective serotonin receptors agonist for depression (NCT04698603).

Anxiety disorders

100Anxiety disorders are the most common psychiatric disorders. Anxiety is accompanied by other psychiatric disorders, including major depressive disorders, substance use disorders, and personality disorders.

101Partial agonists of the 5-HT1A receptor and selective 5-HT reuptake inhibitors are frequently used in anxiety treatment., Buspirone, the partial agonist for the 5-HT1A receptor, is approved for treating anxiety due to neurosis. Paroxetine and Escitalopram, the 5-HT reuptake inhibitors, can relieve anxiety symptoms and prevent recurrence in patients. Trazodone is used to treat anxiety disorders with depressive symptoms and is suitable for patients with significant psychomotor agitation, anxiety, and insomnia.

102Hydroxyzine is the most studied antihistamine for anxiety and the only FDA-approved antihistamine for treating anxiety. It is commonly used for anxiety, panic attacks, and insomnia in inpatients and outpatients.,

103Drug targeting β-adrenoreceptor in the central nervous system can also relieve anxiety. Propranolol, the selective β1/2-adrenoceptor antagonist (β-blockers), is the first-line pharmacological treatment for anxiety disorders., Doxepin can be used for depression and anxiety. It is an antagonist of the histamine H1 and H2 receptors, 5-HT2A/2C receptors, and the muscarinic acetylcholine receptors (M1–M5).

104Naluzotan, the selective 5-HT1A receptor agonist, has been investigated for anxiety disorders and depression treatment (NCT00248183). Ansofaxine, a reuptake inhibitor of serotonin, norepinephrine, and dopamine, is a new-generation drug for anxiety management. The drug has completed phase III clinical trials in China to treat anxiety and depression (NCT04853407).

Bipolar disorder

105Bipolar disorder (BD) is characterized by periodic mood disorders. Medication is the primary treatment to improve the psychosocial function and quality of life of patients with BD. Pharmacological management of acute depressive/manic episodes and prevention of recurrence is also essential. Atypical antipsychotics for bipolar disorder exhibit high affinities for multiple serotonergic receptors, including 5-HT1A, 5-HT2A-C, 5-HT6, and 5-HT7 receptors.

106Quetiapine was approved by the FDA in 1997 for the symptomatic treatment of schizophrenia and is used as a first-line treatment to control depressive episodes of BD. It exerts therapeutic effects may by antagonizing 5-HT1A, 5-HT2A, D1, D2, and H1 receptors as well as α1/2- adrenergic receptors., Dexmedetomidine is an α2-adrenergic receptor agonist that can be used for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorders. Risperidone, an atypical antipsychotic drug, is now used as maintenance therapy for patients with bipolar I disorder.

107Tianeptine is a novel antidepressant that stimulates serotonin, increases levels of 5-hydroxyindoleacetic acid in brain tissue and plasma, and decreases serotonin-induced behavior., Clinical trials are underway for the adjuvant treatment for BD with Tientidine (NCT00879372). Lumateperone, an antagonist with high binding affinity to the 5-HT2A receptor and moderate affinity to the post-synaptic D2 receptor, is being evaluated for treating BD, depression, and other neuropsychiatric and neurological disorders (NCT03249376, NCT02600507).

Tourette’s syndrome

108Tourette’s syndrome (TS) is a neurodevelopmental disorder characterized by repetitive behaviours, including motor/phonic tics. TS is commonly coupled with obsessive-compulsive disorder (OCD) and ADHD. The underlying mechanism of TS remains poorly clarified.– Abnormalities in synaptic neurotransmission involved in the cortico-striatal-thalamocortical circuitry are implicated in TS pathogenesis., Dopaminergic signaling in cortico-striatal-thalamocortical pathways might be associated with TS progression.,, α-adrenergic agonists are the first choice in TS treatment. Examples include Clonidine and Guanfacine., Aripiprazole is a partial agonist of dopamine D2 and 5-HT1A receptors. It can stabilize dopamine receptor and improves TS symptoms. In contrast, Pimozide exerts a therapeutic effect by inhibiting the dopamine D2 receptor in the central nervous system.

Attention deficit hyperactivity disorder

109Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder affecting school-age children. It is a neurodevelopmental disorder with multifactorial etiological risk factors. ADHD is characterized by hyperactivity, impulsivity, and age-inappropriate symptoms of inattention. Irregularities in catecholamines circuits in the prefrontal cortex, such as dopamine and norepinephrine, are a leading cause of ADHD., Most ADHD drugs are designed to enhance catecholamine transmission in the prefrontal cortex.

110Methylphenidate can significantly reduce hyperactive behavior, increase attention concentration ability, and effectively improve the core symptoms of ADHD, so it is one of the most widely used first-line drugs approved by the FDA. Methylphenidate blocks dopamine D1 and D2 transporters, resulting in increased levels of synaptic dopamine, and also shows activity against serotonergic 5-HT1A receptors.,,

111Second-line drugs for ADHD include Atomoxetine, Guanfacine, and Clonidine.,, Atoroxetine is a non-stimulant medication that acts as a selective norepinephrine reuptake inhibitor in ADHD., Guanfacine is a phenylacetyl guanidine derivative, which is more selective than Clonidine in activating the α2-adrenergic receptor. Venlafaxine is a new type of selective serotonin and dopamine reuptake inhibitor. It is a dual-channel antidepressant. Venlafaxine inhibits the reuptake of serotonin by neuron endings at low doses and inhibits the reuptake function of neuron endings at a high dose to enhance attention. Amfetamine (AMF) acts on the cerebral cortex and reticular activation system. AMF stimulates adrenalin receptors and enhances neurotransmitter secretion, such as 5-HT and dopamine. Fluoxetine is a potent and selective serotonin reuptake inhibitor for ADHD treatment.,

112Edivoxetine is an adrenergic absorption inhibitor. It is now in phase III development for ADHD with hyperactivity (NCT00922636, NCT00965419). Centanafadine is a triple-reuptake inhibitor for dopamine, norepinephrine, and serotonin reuptake. It is currently in phase III clinical trials (NCT03605849, NCT03605680, NCT03605836). SGS-742 has been investigated for ADHD treatment. It acts as a GABA-B receptor antagonist and could enhance the release of glutamate, aspartate, glycine, and somatostatin.

Example of emerging GPCR targets

113Most of the GPCRs targeted by approved drugs for neuropsychiatric diseases belong to class A and C GPCRs. With the advance of biotechnology and increase in understanding of GPCR functions, new candidates are discovered in other GPCR families, including class A (orphan), class B1 (secretin), class B2 (adhesion), class C (calcium-sensing receptor), and class F.

Class A (orphan GPCR)

114Orphan GPCRs are receptors whose cognate ligands are not discovered or validated in cellular/ animal models. Deorphanization with reverse pharmacology is currently an active area in GPCR research.

GPR17

115GPR17 is activated by two different endogenous ligands: uracil nucleotides and cysteinyl-leukotrienes. Uracil nucleotides trigger astrocytic migration by upregulating membrane integrins. Cysteinyl-leukotrienes are lipid mediators secreted by inflammatory cells and nervous tissues. Cysteinyl‐leukotrienes can stimulate astrocyte proliferation via autocrine signaling. GPR17 is a sensor of local damage to the myelin sheath. GPR17 downregulation promotes the development of mature oligodendrocytes from myelin-producing oligodendrocyte precursors. GPR17 is involved in reconstructing and repairing demyelinating plaques formed by ongoing inflammatory processes. In a mouse model of multiple sclerosis, targeting GPR17 can delay the onset of autoimmune encephalomyelitis.

GPR26

116GPR26 is a brain-specific GPCR. GPR26 has high sequence homology with purinergic P2Y receptor and serotonin 5-HT5A receptor., GPR26 regulates emotion in animal models. GPR26 knockout mice exhibits anxiety- and depressive-like behaviors. Colocalization of GPR26 and neuronal nuclear inclusions is observed in brain tissues suggesting a potential link between GPR26 and neurodegenerative diseases.

GPR37 and GPR37L1

117GPR37 can be found in pre-myelinating/myelinating oligodendrocytes, dopaminergic neurons, and hippocampal neurons. GPR37 shares high sequence homology with peptide-activated GPCRs such as endothelin receptor B (ETB). In Parkinson’s disease, GPR37 acts as an adenosine A2A receptor inhibitor via receptor oligomerization; GPR37L1, in contrast, is found mainly in astrocytes and oligodendrocyte progenitor cells. GPR37L1 is involved in the adaptive myelination of oligodendrocytes which is critical for neural plasticity, learning, and memory in adults.

GPR39

118Zinc regulates behavior, cognition, and ability to learn. Dysregulation in zinc homeostasis is associated with progressive dementia and cognitive impairment. Zinc deficiency gives rise to various neuropsychiatric disorders, including epilepsy, seizures, and depression., Extracellular zinc can activate zinc-sensing receptor GPR39., Zinc stimulates GPR39-mediated signal transduction and induces calcium mobilization in HEK293 cells. Zinc-activated GPR39 increases expression of K+/Cl− cotransporter 2 (KCC2), the Cl- outward transporter in neurons. Further, GPR39 increases Na+/H+ exchanger activity in hippocampal neurons in a pH-dependent process.

GPR40

119GPR40 (also known as free fatty acid receptor 1) is the receptor for medium and long-chain unsaturated fatty acids. GPR40 activates the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome pathway by blocking the formation of apoptosis-associated speck-like protein containing a CARD (an inflammasome component). GPR40 promotes hypothalamic neurogenesis by enhancing cell proliferation and survival. GPR40 may associate with the development of epilepsy by altering N-methyl-d-aspartate receptor-mediated synaptic transmission. In Alzheimer’s disease model, activating the GPR40 receptor can reduce β-amyloid production and rescue cognitive deficits.,

GPR50

120GPR50 exhibits high sequence homology with melatonin MT1/2 receptors. However, melatonin (the endogenous ligand for MT1/2 receptors) cannot bind to GPR50 directly. GPR50 can be detected in the pituitary, hypothalamus, and hippocampus intermedia., GPR50 enhances neuronal differentiation via notch and WNT/β-catenin. GPR50 might be involved in psychiatric illness by interacting with neurite outgrowth inhibitor NOGO-A. GPR50 is an X-linked gene (Xq28). It is suggested to be a sex-specific risk factor in bipolar affective disorder, major depressive disorder, and schizophrenia. GPR50 can antagonize the MT1 receptor by forming a heterodimer. The inhibitory effects are mediated via the large C-terminal tail, which blocks the β-arrestin recruitment and G protein coupling. MT2 receptor could also form a heterodimer with GPR50, but the functional consequence remains to be defined.

GPR52

121GPR52, a striatal-enriched orphan GPCR. GPR52 stabilizes HTT by cAMP-dependent but PKA-independent mechanisms. GPR52 antagonist can ameliorate Huntington disease-like phenotypes by diminishing mHTT protein levels. GPR52 is a potential target of antipsychotic drugs. GPR52 is associated with cognitive function, emotion, and psychosis-related/antipsychotic-like behaviors.,, GPR52 has high sequence homology with histamine H2 receptor and 5-HT4 receptor. GPR52 agonist treatment suppresses methamphetamine-induced hyperactivity suggesting that GPR52 might be involved in neurochemical sensitization. Recent study reveals that GPR52 is a self-activating receptor. The extracellular loop 2 is immersed deeply into the typical ligand binding pocket of GPR52, which maintains the constitutive active state at physiological conditions.

Super-conserved receptors expressed in the brain

122GPR27, GPR85, and GPR173 are super-conserved receptors expressed in the brain (SREB). GRR27 deletion is associated with speech delay, contractures, hypertonia, and blepharophimosis. GPR85 may function as a negative regulator in hippocampal adult neurogenesis and alters cognitive functions, including learning and memory. It has been reported that GPR85 is a risk factor for schizophrenia. GPR173 may function by interacting with phoenixin (a recently discovered peptide controlling reproductive hormone secretion, visceral pain, and pruritus) in hypothalamic neurons, which regulates memory and anxiety., In neuronal M17 cells, phoenixin promotes neuronal mitochondrial activity and biogenesis by activating the CREB pathway. Further, binding of gonadotropin-releasing hormone 1–5 (GnRH 1–5) to GPR173 could inhibit neuronal migration.

GPR88

123GPR88 expresses exclusively in the neuron of the rat brain throughout the striatum. In GABAergic medium spiny neurons (MSNs), GPR88 contributes to tonic GABAergic inhibition and responses to GABA release. GPR88 might play a part in prepulse inhibition of startle, apomorphine-induced climbing, and amphetamine-stimulated locomotor activity. Co-expression of GPR88 and D1 dopamine receptors is found in the brain. In Parkinson’s disease (unilateral 6-hydroxydopamine-lesioned rats), GPR88 expression is associated with L-DOPA-mediated behavioural changes. Antidepressant treatments can modulate GPR88 expression in rat brains. Morphine can regulate GPR88 expression in the amygdala via the mu-opioid receptor. GPR88 is genetically associated with various neuropsychiatric disorders, including schizophrenia, bipolar disorder, speech delay, and chorea.,

Structural highlights

124Class B1 GPCRs have a conserved extracellular N-terminal domain (ECD) with a three-layered α-β-β/α fold structure (100 to 160 residues) responsible for the binding of peptide hormones (Fig. 7).– Peptide ligands stabilize receptors by interacting with both ECD and transmembrane core. N-terminus of the peptide interacts with the orthosteric pocket within the transmembrane domain., Class B1 GPCRs recognize peptide ligands with different C-terminus, ranging from disordered secondary structures to continuous α-helix., Like class A GPCRs, the cavity formed by the receptor cytoplasmic part allows anchoring of the α5 helix of G proteins., Among class B1 GPCRs, calcitonin and calcitonin gene-related peptide receptors, corticotropin-releasing factor receptors, and the glucagon receptor family are frequently reported to be involved in neurodegenerative diseases and psychiatric disorders.

Receptors for calcitonin and calcitonin gene-related peptides

125Calcitonin (CT) and calcitonin gene-related peptides (CGRPs) are ligands of the CT receptor. CGRPs also exert their biological functions through CL (calcitonin receptor-like) receptors.

126The activity of CT and CL receptors is modulated by receptor activity-modifying protein (RAMP1-3). CT receptor-RAMP complexes can also interact with amylin. Therefore they are also known as amylin receptors (AMY1-3). CT receptors are implicated in neuroinflammation in Alzheimer’s disease. Antagonists targeting amylin receptors might be beneficial for Alzheimer’s disease treatment.

Corticotropin-releasing factor receptor

127Corticotropin-releasing hormone (CRF) regulates the neuroendocrine stress response. CRH exerts its biological function through two receptors: CRFR1 and CRFR2. Human corticotropin-releasing factor receptor 1 (CRFR1) exhibits widespread distribution in the central nervous system. In contrast, human CRFR2 is predominately expressed in peripheral tissues. CRFR1 signaling shows sex divergence in Alzheimer’s disease. CRFR1 antagonist treatment delays Alzheimer’s disease symptoms, including cognitive impairment and accumulation of Aβ amyloid plaques, by regulating oxidative stress in transgenic mice. CRF/CRFR1 signaling plays a crucial role in stress-induced behaviour. It has been shown that noise exposure can increase CRF/CRFR1 expression in the hippocampus. CRFR1 could sensitize 5-HT2 receptor signaling to modulate anxiety behavior. In addition, CRFR1 antagonist modulates gamma-aminobutyric acid (GABA)-ergic activity in the brain and controls fear response in rat anxiety models. Single-nucleotide polymorphisms of CRFR1/2 are positively associated with major depressive disorder.–

Glucagon receptor family

128The glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1/2 (GLP-1/2) are gut peptide hormones. The hormones can pass through the blood-brain barrier. GIP and GIP receptors are expressed throughout the central nervous system., Protease-resistant analog of GIP is designed to treat type 2 diabetes mellitus by controlling weight and improving glycaemic control., Clinical trials indicate that GIP and GLP-1 analogs exhibit therapeutic effects for neurodegenerative diseases. GLP-1 enhances the supportive function of astrocytes to neurons. Activated GLP-2 receptor protects hippocampal cells from glutamate-induced cell death and increases the growth of astrocytes. GLP-1 mimetic reduces oxidative stress and inflammation and promotes neuron formation., GIP can alleviate amyloid beta-induced toxicity in Alzheimer’s disease and relieve symptoms of Parkinson’s disease.,

Structural highlights

129Class B2 GPCR, also known as adhesion GPCR, has a large extracellular domain (ECD). ECD is responsible for the adhesive function exhibiting high structural diversity (Fig. 8a, b). Adhesion GPCRs are essential for the early development of the nervous system and the brain. The receptor allows neural cells to communicate with the surrounding environment and migrate to destinate sites to carry out specific functions. In mouse Purkinje neurons, adhesion GPCR is required to generate intricate dendritic structures for synaptic connections. Adhesion GPCRs are further classified into ADGRL, ADGRE, ADGRA, ADGRC, ADGRD, ADGRF, ADGRB, ADGRG, and ADGRV subfamilies.

130Nearly all class B2 orthologs have the GPCR autoproteolysis inducing domain (GAIN). The GAIN domain is located at the juxtamembrane region. GAIN domain is crucial for the maturation and function of adhesion GPCR. GAIN possesses intrinsic autoproteolytic activity and cleaves at the integral cysteine-rich GPCR proteolysis site (GPS). Autoproteolysis give rise to two noncovalently associated fragments: N-terminal fragment (NTF) with most of the extracellular domain; and C-terminal fragment (CTF) consisting of a small proportion of the GAIN domain and most of the entire transmembrane domain (Fig. 8a).,,

131The activation mechanism of adhesion GPCR is the least understood among different GPCR classes. Most adhesion GPCRs are orphan GPCRs as their natural ligands remain poorly defined. Receptor activation may follow the tethered-peptide-agonist models. The stalk region bends approximately 180º downward into the core of the 7TM domain, which functions as tethered agonist to initiate G protein signaling (Fig. 8c)., Cleavage-independent mechanisms may exist for receptor activation. Ligand binding at the GAIN domain might induce conformational changes, which initiate transient G protein signaling. Upon activation, the intracellular milieu is in the open conformation facilitating G protein coupling. Adhesion GPCRs could employ non–G protein such as PDZ/SH3 domain-proteins and arrestins for signal transduction.

Examples of class B2 GPCR

132Adhesion G protein-coupled receptor B1 (ADGRB1 or brain-specific angiogenesis inhibitor 1, BAI1) regulates synaptic plasticity in learning and memory processes in the hippocampus. ADGRB1 is a post-synaptic receptor controlling excitatory synapse development., Forced ADGRB1 attenuates toxin-induced neuronal cell death. ADGRB1 is associated with dopaminergic neuronal loss in Parkinson’s disease.

133Adhesion G protein-coupled receptor B3 (ADGRB3) is enriched in post-synaptic density and cerebellar Purkinje cells.,, ADGRB3 modulates synaptic connection in the cerebellum. SNPs and gene amplification in ADGRB3 are associated with familial schizophrenia. Other psychiatric conditions, such as bipolar disorder, are suggested to be linked with ADGRB3.

134Adhesion G protein-coupled receptor L3 (ADGRL3) is genetically associated with attention deficit/hyperactivity disorder (ADHD) in adults. Knockout mice models show enhanced locomotive activity, improved levels of impulsivity, and working memory deficits. Maternal smoking during pregnancy is an environmental risk factor for ADHD. In fibroblast cells, nicotine exposure could stimulate ADGRL3 expression. The downstream ADGRL3 signaling events leading to ADHD remains poorly defined. ADGRL3 might alter monoaminergic signaling by modulating the expression of dopamine and serotonin transporters.

Calcium-sensing receptor

135Calcium-sensing (CaS) receptor participates in the regulation of Ca2+ homeostasis. In Alzheimer’s disease model, elevated expression of CaS receptor is observed in the hippocampal CA1 area and dentate gyrus, which is in accord with the β-amyloid plaques increase. CaS receptor impeding amyloid-β42 oligomers (Aβ42-os) proteolysis via direct interaction, leading to Aβ42-os aggregation and oversecretion. CaS receptor inhibitor sustains mental competence by promoting Aβ42 proteolysis. Inhibiting the CaS receptor improves memory and cognitive defects caused by β-amyloid in mice. CaS receptor might induce cognitive defects via eliciting cytosolic phospholipase A2 and prostaglandin E2 signaling pathway.

Structural highlights of Class F GPCR

136Class F GPCR contains a large extracellular and cysteine-rich (CRD) domain (Fig. 9). CRD is essential for the stability and activity of class F GPCRs. FZD gene family is highly conserved in mammals with conserved structural features. FZD is a receptor for the WNT family of lipoglycoprotein, which mediates signal transduction via canonical WNT-β-catenin pathway and β-catenin-independent noncanonical pathways. The secretory WNT binds to the cysteine-rich domain at the extracellular side. The Lys-Thr-X-X-X-Trp (KTXXXW) motif located at the C-terminal is essential for activating the canonical WNT/ β-catenin pathway., WNT signaling regulates neuronal polarization and axon specification polarity by activating atypical protein kinase C in rat hippocampal neurons. Further, WNT signaling governs collateral or terminal branching of the axon, dendrite outgrowth and guidance, dendritic spine formation, synapse formation/plasticity, and elimination. WNT/FZD signaling alterations are observed in several neurological disorders, including Alzheimer’s disease and Huntington’s disease., The transmembrane region is compact and hydrophilic., Similar to class A GPCR, outward bending of TM6 and an inward shift of TM5 at the cytoplasmic side is observed in the active class F GPCR.

137Class F receptors frizzled (FZD1-10) and smoothened (SMO) are closely associated with embryonic development and tissue homeostasis. Reported FZD ligands include frizzled-related proteins (SFRPs) and R-spondin., FZD1 is found in dopamine-synthesizing neurons, which form an astrocyte-DA autoprotective loop via WNT1/FZD1/β-catenin signaling. FZD1 enhances myelin preservation and neuronal survival; FZD3 is genetically related to substance-induced psychosis and schizophrenia;, Neuronal degeneration observed in amyotrophic lateral sclerosis is regulated by WNT5a/FZD4 signaling. WNT5a/FZD5 activity is associated with neuronal inflammatory signaling; Genetic FZD6 variants are associated with neural tube defects in the central nervous system; FZD9 deletion is noted in patients with Williams-Beuren syndrome, a rare genetic disorder with mild to moderate intellectual disability or learning difficulties FZD10 may play a role in brain vascular development; SMO is the receptor for hedgehog proteins involved in neuronal/ glial proliferation and tissue regeneration.

Concluding remarks

138GPCRs are cooperatively involved in the manifestations of neuropsychiatric disorders. Elucidating the intrinsic signaling preference of G proteins or arrestins helps to improve drug efficacy and side-effect profiles. GPCR can work in the dimeric form in disease development. Characterizing the allosteric interactions and the functional consequences of GPCR dimers might provide insights into the pathogenesis of neuropsychiatric disorders. Apart from acting directly in the nervous system, GPCRs might contribute to disease development via the immune system.

139Target identification is challenging as the clinical presentations are resulted from heterogeneous biological, genetic, and environmental factors. Nevertheless, the increasing understanding of GPCR functions opens a new possibility in drug discovery. Most of the drugs targeting GPCR lack subtype-selectivity. Local drug administration may require to avoid debilitating side effects. The development of psychiatric medications remains slow as the pharmaceutical industry pays more attention to antidepressants and antipsychotic drug development. Therefore, developing specific therapeutic modulators which could recognize subtypes with high specificity is crucial for effective drug development.

140Benefiting from the advances in crystallography and cryo-electron microscopy technology, the resolved GPCR structures increase our understanding of GPCR functions in pathological conditions. Detailed protein structures could reveal crucial ligand binding features in physiological conditions.,, Detailed receptor/ligand profile could facilitate lead compound identification and drug optimization. Hence, harnessing our knowledge of molecular mechanisms and structural information of GPCR will be advantageous for developing effective treatments against neuropsychiatric disorders.

References 825

1.
G protein-coupled receptors: structure- and function-based drug discovery · 2021
No notice
2.
Shoichet BK, Kobilka BK. Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol. Sci. 2012;33:268-272.
Not in our library10.1016/j.tips.2012.03.007
3.
Denis C, et al. Probing heterotrimeric G protein activation: applications to biased ligands. Curr. Pharm. Des. 2012;18:128-144.
Not in our library10.2174/138161212799040466
4.
Heemels MT. Neurodegenerative diseases. Nature. 2016;539:179.
Not in our library10.1038/539179a
5.
Kumar D, Md Ashraf G, Bilgrami AL, Imtaiyaz Hassan M. Emerging therapeutic developments in neurodegenerative diseases: a clinical investigation. Drug Discov. Today. 2022;27:103305.
Not in our library10.1016/j.drudis.2022.06.005
6.
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. J. Am. Med. Assoc. 2020;323:548-560.
Not in our library10.1001/jama.2019.22360
7.
Old Drugs as New Treatments for Neurodegenerative Diseases · 2018
No notice
8.
Organization, W. H. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (2020).
Not in our library
9.
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment · 2020
No notice
10.
Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease · 2021
Corrected
11.
McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur. J. Neurol. 2018;25:24-34.
Not in our library10.1111/ene.13413
12.
Brodie C, Blumberg PM, Jacobson KA. Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett. 1998;429:139-142.
Not in our library10.1016/s0014-5793(98)00556-0
13.
Neurodegenerative Diseases: An Overview of Environmental Risk Factors · 2005
No notice
14.
Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur. J. Neurol. 2019;26:27-40.
Not in our library10.1111/ene.13819
15.
Lyketsos CG. Lessons from neuropsychiatry. J. Neuropsychiatry Clin. Neurosci. 2006;18:445-449.
Not in our library10.1176/jnp.2006.18.4.445
16.
Chaudhury PK, Deka K, Chetia D. Disability associated with mental disorders. Indian J. Psychiatry. 2006;48:95-101.
Not in our library10.4103/0019-5545.31597
17.
Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality · 2020
No notice
18.
Ilyas A, Chesney E, Patel R. Improving life expectancy in people with serious mental illness: should we place more emphasis on primary prevention? Br. J. Psychiatry. 2017;211:194-197.
Not in our library10.1192/bjp.bp.117.203240
19.
Suicide Risk and Mental Disorders · 2018
No notice
20.
Understanding the psychiatric symptoms of COVID-19: a meta-analysis of studies assessing psychiatric symptoms in Chinese patients with and survivors of COVID-19 and SARS by using the Symptom Checklist-90-Revised · 2021
Not checked
21.
Hauser AS, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 2017;16:829-842.
Not in our library10.1038/nrd.2017.178
22.
Sriram K, Insel PA. G Protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol. Pharmacol. 2018;93:251-258.
Not in our library10.1124/mol.117.111062
23.
Greengard P. The neurobiology of slow synaptic transmission. Science. 2001;294:1024-1030.
Not in our library10.1126/science.294.5544.1024
24.
Wacker D, Stevens RC, Roth BL. How ligands illuminate GPCR molecular pharmacology. Cell. 2017;170:414-427.
Not in our library10.1016/j.cell.2017.07.009
25.
Wheatley M, et al. Lifting the lid on GPCRs: the role of extracellular loops. Br. J. Pharmacol. 2012;165:1688-1703.
Not in our library10.1111/j.1476-5381.2011.01629.x
26.
Kim HR, et al. Structural mechanism underlying primary and secondary coupling between GPCRs and the Gi/o family. Nat. Commun. 2020;11:3160.
Not in our library10.1038/s41467-020-16975-2
27.
Smith SO. Deconstructing the transmembrane core of class A G protein-coupled receptors. Trends Biochem. Sci. 2021;46:1017-1029.
Not in our library10.1016/j.tibs.2021.08.006
28.
Miyagi H, et al. The discovery of a new antibody for BRIL-fused GPCR structure determination. Sci. Rep. 2020;10:11669.
Not in our library10.1038/s41598-020-68355-x
29.
Mahoney JP, Sunahara RK. Mechanistic insights into GPCR-G protein interactions. Curr. Opin. Struct. Biol. 2016;41:247-254.
Not in our library10.1016/j.sbi.2016.11.005
30.
Traut TW. Physiological concentrations of purines and pyrimidines. Mol. Cell Biochem. 1994;140:1-22.
Not in our library10.1007/bf00928361
31.
Sprang SR. Activation of G proteins by GTP and the mechanism of Galpha-catalyzed GTP hydrolysis. Biopolymers. 2016;105:449-462.
Not in our library10.1002/bip.22836
32.
Forn J, Krueger BK, Greengard P. Adenosine 3’,5’-monophosphate content in rat caudate nucleus: demonstration of dopaminergic and adrenergic receptors. Science. 1974;186:1118-1120.
Not in our library10.1126/science.186.4169.1118
33.
Desale SE, Chidambaram H, Chinnathambi S. G-protein coupled receptor, PI3K and Rho signaling pathways regulate the cascades of Tau and amyloid-beta in Alzheimer’s disease. Mol. Biomed. 2021;2:17.
Not in our library10.1186/s43556-021-00036-1
34.
Rai SN, et al. The role of PI3K/Akt and ERK in neurodegenerative disorders. Neurotox. Res. 2019;35:775-795.
Not in our library10.1007/s12640-019-0003-y
35.
Singh S, Singh TG. Role of nuclear factor Kappa B (NF-kappaB) signalling in neurodegenerative diseases: an mechanistic approach. Curr. Neuropharmacol. 2020;18:918-935.
Not in our library10.2174/1570159x18666200207120949
36.
Sobolczyk M, Boczek T. Astrocytic calcium and cAMP in neurodegenerative diseases. Front. Cell Neurosci. 2022;16:889939.
Not in our library10.3389/fncel.2022.889939
37.
Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361:315-325.
Not in our library10.1038/361315a0
38.
Durkee CA, et al. Gi/o protein-coupled receptors inhibit neurons but activate astrocytes and stimulate gliotransmission. Glia. 2019;67:1076-1093.
Not in our library10.1002/glia.23589
39.
Berridge MJ. Inositol trisphosphate and calcium signalling mechanisms. Biochim. Biophys. Acta. 2009;1793:933-940.
Not in our library10.1016/j.bbamcr.2008.10.005
40.
Ponce A, et al. G-protein-gated inward rectifier K+ channel proteins (GIRK1) are present in the soma and dendrites as well as in nerve terminals of specific neurons in the brain. J. Neurosci. 1996;16:1990-2001.
Not in our library10.1523/jneurosci.16-06-01990.1996
41.
Luscher C, et al. G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron. 1997;19:687-695.
Not in our library10.1016/s0896-6273(00)80381-5
42.
Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J. Biol. Chem. 2010;285:12463-12468.
Not in our library10.1074/jbc.r109.080895
43.
Role of Oxidative Stress and Ca2+ Signaling in Psychiatric Disorders · 2021
Not checked
44.
Dutt P, Nguyen N, Toksoz D. Role of Lbc RhoGEF in Galpha12/13-induced signals to Rho GTPase. Cell. Signal. 2004;16:201-209.
Not in our library10.1016/s0898-6568(03)00132-3
45.
The RHO Family GTPases: Mechanisms of Regulation and Signaling · 2021
No notice
46.
Siehler S. Regulation of RhoGEF proteins by G12/13-coupled receptors. Br. J. Pharmacol. 2009;158:41-49.
Not in our library10.1111/j.1476-5381.2009.00121.x
47.
Koch JC, et al. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol. Ther. 2018;189:1-21.
Not in our library10.1016/j.pharmthera.2018.03.008
48.
Miano JM. Role of serum response factor in the pathogenesis of disease. Lab. Invest. 2010;90:1274-1284.
Not in our library10.1038/labinvest.2010.104
49.
Zou Y. Breaking symmetry - cell polarity signaling pathways in growth cone guidance and synapse formation. Curr. Opin. Neurobiol. 2020;63:77-86.
Not in our library10.1016/j.conb.2020.03.010
50.
Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration · 2014
No notice
51.
Rajagopal S, Shenoy SK. GPCR desensitization: acute and prolonged phases. Cell. Signal. 2018;41:9-16.
Not in our library10.1016/j.cellsig.2017.01.024
52.
Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308:512-517.
Not in our library10.1126/science.1109237
53.
Stadel JM, et al. Catecholamine-induced desensitization of turkey erythrocyte adenylate cyclase is associated with phosphorylation of the beta-adrenergic receptor. Proc. Natl Acad. Sci. USA. 1983;80:3173-3177.
Not in our library10.1073/pnas.80.11.3173
54.
Benovic JL, et al. Beta-adrenergic receptor kinase: primary structure delineates a multigene family. Science. 1989;246:235-240.
Not in our library10.1126/science.2552582
55.
Thomsen ARB, et al. GPCR-G protein-beta-arrestin super-complex mediates sustained G protein signaling. Cell. 2016;166:907-919.
Not in our library10.1016/j.cell.2016.07.004
56.
Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol. 2007;69:451-482.
Not in our library10.1146/annurev.physiol.69.022405.154712
57.
Pitcher JA, et al. The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. J. Biol. Chem. 1998;273:12316-12324.
Not in our library10.1074/jbc.273.20.12316
58.
Carman CV, et al. Selective regulation of Galpha(q/11) by an RGS domain in the G protein-coupled receptor kinase, GRK2. J. Biol. Chem. 1999;274:34483-34492.
Not in our library10.1074/jbc.274.48.34483
59.
Degos V, et al. G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration. Ann. Neurol. 2013;73:667-678.
Not in our library10.1002/ana.23868
60.
Zhao J, et al. GRK5 influences the phosphorylation of Tau via GSK3β and contributes to Alzheimer’s disease. J. Cell Physiol. 2019;234:10411-10420.
Not in our library10.1002/jcp.27709
61.
Pennington LK, et al. How is adaptive potential distributed within species ranges? Evolution. 2021;75:2152-2166.
Not in our library10.1111/evo.14292
62.
Bychkov ER, et al. Arrestins and two receptor kinases are upregulated in Parkinson’s disease with dementia. Neurobiol. Aging. 2008;29:379-396.
Not in our library10.1016/j.neurobiolaging.2006.10.012
63.
Arawaka S, et al. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson’s disease. J. Neurosci. 2006;26:9227-9238.
Not in our library10.1523/jneurosci.0341-06.2006
64.
Grange-Midroit M, et al. Regulation of GRK 2 and 6, beta-arrestin-2 and associated proteins in the prefrontal cortex of drug-free and antidepressant drug-treated subjects with major depression. Brain Res. Mol. Brain Res. 2003;111:31-41.
Not in our library10.1016/s0169-328x(02)00667-8
65.
Funk AJ, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia. Schizophr. Res. 2014;159:130-135.
Not in our library10.1016/j.schres.2014.07.040
66.
Kuhn H. Light-regulated binding of rhodopsin kinase and other proteins to cattle photoreceptor membranes. Biochemistry. 1978;17:4389-4395.
Not in our library10.1021/bi00614a006
67.
Haider RS, et al. Arrestin-1 engineering facilitates complex stabilization with native rhodopsin. Sci. Rep. 2019;9:439.
Not in our library10.1038/s41598-018-36881-4
68.
Zhou XE, et al. Identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors. Cell. 2017;170:457-469 e413.
Not in our library10.1016/j.cell.2017.07.002
69.
Shenoy SK, Lefkowitz R. J. beta-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 2011;32:521-533.
Not in our library10.1016/j.tips.2011.05.002
70.
Oakley RH, et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 2000;275:17201-17210.
Not in our library10.1074/jbc.m910348199
71.
Lally CC, Bauer B, Selent J, Sommer ME. C-edge loops of arrestin function as a membrane anchor. Nat. Commun. 2017;8:14258.
Not in our library10.1038/ncomms14258
72.
Pottie E, Dedecker P, Stove CP. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT(2A)R through simultaneous use of β-arrestin 2 and miniGα(q) bioassays. Biochem. Pharmacol. 2020;182:114251.
Not in our library10.1016/j.bcp.2020.114251
73.
Liu P, et al. Ligand-induced activation of ERK1/2 signaling by constitutively active G(s)-coupled 5-HT receptors. Acta Pharmacol. Sin. 2019;40:1157-1167.
Not in our library10.1038/s41401-018-0204-6
74.
Wang Y, et al. β-arrestin 2 mediates cardiac ischemia-reperfusion injury via inhibiting GPCR-independent cell survival signalling. Cardiovasc. Res. 2017;113:1615-1626.
Not in our library10.1093/cvr/cvx147
75.
Eichel K, Jullié D, von Zastrow M. β-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. Nat. Cell Biol. 2016;18:303-310.
Not in our library10.1038/ncb3307
76.
Luttrell LM, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999;283:655-661.
Not in our library10.1126/science.283.5402.655
77.
Tohgo A, et al. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J. Biol. Chem. 2003;278:6258-6267.
Not in our library10.1074/jbc.m212231200
78.
Xiao K, et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc. Natl Acad. Sci. USA. 2007;104:12011-12016.
Not in our library10.1073/pnas.0704849104
79.
DeFea KA. Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold? Cell. Signal. 2011;23:621-629.
Not in our library10.1016/j.cellsig.2010.10.004
80.
Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 2012;52:179-197.
Not in our library10.1146/annurev.pharmtox.010909.105800
81.
Campo GM, et al. Beta-arrestin-2 negatively modulates inflammation response in mouse chondrocytes induced by 4-mer hyaluronan oligosaccharide. Mol. Cell. Biochem. 2015;399:201-208.
Not in our library10.1007/s11010-014-2246-5
82.
Scarpa M, et al. Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proc. Natl Acad. Sci. USA. 2021;118:e2107389118.
Not in our library10.1073/pnas.2107389118
83.
Masri B, et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc. Natl Acad. Sci. USA. 2008;105:13656-13661.
Not in our library10.1073/pnas.0803522105
84.
Zhu J, et al. Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of beta-arrestin2 and NLRP3. Cell Death Differ. 2018;25:2037-2049.
Not in our library10.1038/s41418-018-0127-2
85.
Ko MJ, et al. beta-Arrestin-dependent ERK signaling reduces anxiety-like and conditioned fear-related behaviors in mice. Sci. Signal. 2021;14:eaba0245.
Not in our library10.1126/scisignal.aba0245
86.
Yan R. Physiological functions of the beta-site amyloid precursor protein cleaving enzyme 1 and 2. Front. Mol. Neurosci. 2017;10:97.
Not in our library10.3389/fnmol.2017.00097
87.
Zhao J, et al. GRK5 influences the phosphorylation of tau via GSK3beta and contributes to Alzheimer’s disease. J. Cell Physiol. 2019;234:10411-10420.
Not in our library10.1002/jcp.27709
88.
Forero DA, et al. A network of synaptic genes associated with schizophrenia and bipolar disorder. Schizophr. Res. 2016;172:68-74.
Not in our library10.1016/j.schres.2016.02.012
89.
cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia · 2018
No notice
90.
Ren X, et al. Alteration of cyclic-AMP response element binding protein in the postmortem brain of subjects with bipolar disorder and schizophrenia. J. Affect. Disord. 2014;152-154:326-333.
Not in our library10.1016/j.jad.2013.09.033
91.
Ao H, Ko SW, Zhuo M. CREB activity maintains the survival of cingulate cortical pyramidal neurons in the adult mouse brain. Mol. Pain. 2006;2:15.
Not in our library10.1186/1744-8069-2-15
92.
Lopez de Armentia M, et al. cAMP response element-binding protein-mediated gene expression increases the intrinsic excitability of CA1 pyramidal neurons. J. Neurosci. 2007;27:13909-13918.
Not in our library10.1523/jneurosci.3850-07.2007
93.
Vergara R, et al. Spontaneous voltage oscillations in striatal projection neurons in a rat corticostriatal slice. J. Physiol. 2003;553:169-182.
Not in our library10.1113/jphysiol.2003.050799
94.
Schmutz I, et al. Protein phosphatase 1 (PP1) is a post-translational regulator of the mammalian circadian clock. PLoS ONE. 2011;6:e21325.
Not in our library10.1371/journal.pone.0021325
95.
Mulkey RM, Herron CE, Malenka RC. An essential role for protein phosphatases in hippocampal long-term depression. Science. 1993;261:1051-1055.
Not in our library10.1126/science.8394601
96.
DARPP-32 Is a Robust Integrator of Dopamine and Glutamate Signals · 2006
No notice
97.
Flores-Hernandez J, et al. D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-32/PP1 signaling cascade. J. Neurophysiol. 2000;83:2996-3004.
Not in our library10.1152/jn.2000.83.5.2996
98.
GPCR activation mechanisms across classes and macro/microscales · 2021
No notice
99.
Latorraca NR, Venkatakrishnan AJ, Dror RO. GPCR dynamics: structures in motion. Chem. Rev. 2017;117:139-155.
Not in our library10.1021/acs.chemrev.6b00177
100.
Hilger D, Masureel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. Nat. Struct. Mol. Biol. 2018;25:4-12.
Not in our library10.1038/s41594-017-0011-7
101.
Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol. Ther. 1998;80:231-264.
Not in our library10.1016/s0163-7258(98)00030-8
102.
Manglik A, Kruse AC. Structural basis for G protein-coupled receptor activation. Biochemistry. 2017;56:5628-5634.
Not in our library10.1021/acs.biochem.7b00747
103.
Rovati GE, Capra V, Neubig RR. The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol. Pharmacol. 2007;71:959-964.
Not in our library10.1124/mol.106.029470
104.
Unal H, Karnik SS. Domain coupling in GPCRs: the engine for induced conformational changes. Trends Pharmacol. Sci. 2012;33:79-88.
Not in our library10.1016/j.tips.2011.09.007
105.
Common activation mechanism of class A GPCRs · 2019
No notice
106.
Filipek S. Molecular switches in GPCRs. Curr. Opin. Struct. Biol. 2019;55:114-120.
Not in our library10.1016/j.sbi.2019.03.017
107.
Hilger D. The role of structural dynamics in GPCR-mediated signaling. FEBS J. 2021;288:2461-2489.
Not in our library10.1111/febs.15841
108.
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: targeting the cholinergic system. Curr. Neuropharmacol. 2016;14:101-115.
Not in our library10.2174/1570159x13666150716165726
109.
Ishii M, Kurachi Y. Muscarinic acetylcholine receptors. Curr. Pharm. Des. 2006;12:3573-3581.
Not in our library10.2174/138161206778522056
110.
Caulfield MP, Birdsall NJ. International union of pharmacology. XVII. classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998;50:279-290.
Not in our library
111.
Whitehouse PJ, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981;10:122-126.
Not in our library10.1002/ana.410100203
112.
Janickova H, et al. Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1-42). Neuropharmacology. 2013;67:272-283.
Not in our library10.1016/j.neuropharm.2012.11.014
113.
Medeiros R, et al. Loss of muscarinic M1 receptor exacerbates Alzheimer’s disease-like pathology and cognitive decline. Am. J. Pathol. 2011;179:980-991.
Not in our library10.1016/j.ajpath.2011.04.041
114.
Morozova V, et al. Normal and pathological tau uptake mediated by M1/M3 muscarinic receptors promotes opposite neuronal changes. Front. Cell. Neurosci. 2019;13:403.
Not in our library10.3389/fncel.2019.00403
115.
Gomez-Ramos A, et al. Extracellular tau is toxic to neuronal cells. FEBS Lett. 2006;580:4842-4850.
Not in our library10.1016/j.febslet.2006.07.078
116.
Tanaka S, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 2003;141:155-164.
Not in our library10.1016/s0165-5728(03)00252-2
117.
Borda T, et al. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J. Immunol. 2002;168:3667-3674.
Not in our library10.4049/jimmunol.168.7.3667
118.
Scarr E. Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neurosci. Ther. 2012;18:369-379.
Not in our library10.1111/j.1755-5949.2011.00249.x
119.
Hopper S, Pavey GM, Gogos A, Dean B. Widespread changes in positive allosteric modulation of the muscarinic m1 receptor in some participants with schizophrenia. Int. J. Neuropsychopharmacol. 2019;22:640-650.
Not in our library10.1093/ijnp/pyz045
120.
Lai MK, et al. Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001;57:805-811.
Not in our library10.1212/wnl.57.5.805
121.
Zuchner T, Schliebs R, Perez-Polo JR. Down-regulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer’s disease-relevant genes and proteins. J. Neurochem. 2005;95:20-32.
Not in our library10.1111/j.1471-4159.2005.03335.x
122.
Jeon WJ, Dean B, Scarr E, Gibbons A. The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment? Curr. Neuropharmacol. 2015;13:739-749.
Not in our library10.2174/1570159x13666150612230045
123.
Gibbons AS, et al. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J. Affect. Disord. 2009;116:184-191.
Not in our library10.1016/j.jad.2008.11.015
124.
Jeon WJ, Gibbons AS, Dean B. The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2013;47:7-12.
Not in our library10.1016/j.pnpbp.2013.08.001
125.
Cheng Z, et al. A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. Transl. Psychiatry. 2019;9:309.
Not in our library10.1038/s41398-019-0639-7
126.
Wang Q, et al. The CHRM3 gene is implicated in abnormal thalamo-orbital frontal cortex functional connectivity in first-episode treatment-naive patients with schizophrenia. Psychol. Med. 2016;46:1523-1534.
Not in our library10.1017/s0033291716000167
127.
Chambers NE, et al. Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-Parkinsonian rat. Neuroscience. 2019;409:180-194.
Not in our library10.1016/j.neuroscience.2019.04.008
128.
Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 2008;117:232-243.
Not in our library10.1016/j.pharmthera.2007.09.009
129.
Dencker D, et al. Muscarinic acetylcholine receptor subtypes as potential drug targets for the treatment of schizophrenia, drug abuse and Parkinson’s disease. ACS Chem. Neurosci. 2012;3:80-89.
Not in our library10.1021/cn200110q
130.
Mayorga AJ, et al. Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. Eur. J. Pharmacol. 1999;364:7-11.
Not in our library10.1016/s0014-2999(98)00811-5
131.
Miller NR, et al. Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists. Bioorg. Med. Chem. Lett. 2010;20:2174-2177.
Not in our library10.1016/j.bmcl.2010.02.041
132.
Costa A, et al. Deletion of muscarinic acetylcholine receptor 3 in microglia impacts brain ischemic injury. Brain Behav. Immun. 2021;91:89-104.
Not in our library10.1016/j.bbi.2020.09.008
133.
Dean B, Scarr E. Possible involvement of muscarinic receptors in psychiatric disorders: a focus on schizophrenia and mood disorders. Curr. Mol. Med. 2015;15:253-264.
Not in our library10.2174/1566524015666150330144821
134.
Weiner DM, Levey AI, Brann MR. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc. Natl Acad. Sci. USA. 1990;87:7050-7054.
Not in our library10.1073/pnas.87.18.7050
135.
Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 2001;24:31-55.
Not in our library10.1146/annurev.neuro.24.1.31
136.
Perez-Pinzon MA, Lutz PL, Sick TJ, Rosenthal M. Adenosine, a “retaliatory” metabolite, promotes anoxia tolerance in turtle brain. J. Cereb. Blood Flow Metab. 1993;13:728-732.
Not in our library10.1038/jcbfm.1993.93
137.
Martin ED, et al. Adenosine released by astrocytes contributes to hypoxia-induced modulation of synaptic transmission. Glia. 2007;55:36-45.
Not in our library10.1002/glia.20431
138.
Fredholm BB, et al. Adenosine and brain function. Int. Rev. Neurobiol. 2005;63:191-270.
Not in our library10.1016/s0074-7742(05)63007-3
139.
Zheng J, Zhang X, Zhen X. Development of adenosine A2A receptor antagonists for the treatment of Parkinson’s disease: a recent update and challenge. ACS Chem. Neurosci. 2019;10:783-791.
Not in our library10.1021/acschemneuro.8b00313
140.
Popoli P, Pezzola A, de Carolis AS. Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. Eur. J. Pharmacol. 1994;257:21-25.
Not in our library10.1016/0014-2999(94)90689-0
141.
Cieslak, M., Komoszynski, M. & Wojtczak, A. Adenosine A(2A) receptors in Parkinson’s disease treatment. Purinergic Signal4, 305–312 (2008).
Not in our library10.1007/s11302-008-9100-8
142.
Smith AP. Caffeine, cognitive failures and health in a non-working community sample. Hum. Psychopharmacol. 2009;24:29-34.
Not in our library10.1002/hup.991
143.
Lucas M, et al. Coffee, caffeine, and risk of depression among women. Arch. Intern. Med. 2011;171:1571-1578.
Not in our library10.1001/archinternmed.2011.393
144.
Ferre S. An update on the mechanisms of the psychostimulant effects of caffeine. J. Neurochem. 2008;105:1067-1079.
Not in our library10.1111/j.1471-4159.2007.05196.x
145.
Yamada K, Kobayashi M, Kanda T. Involvement of adenosine A2A receptors in depression and anxiety. Int. Rev. Neurobiol. 2014;119:373-393.
Not in our library10.1016/b978-0-12-801022-8.00015-5
146.
Fredholm BB, Yang J, Wang Y. Low, but not high, dose caffeine is a readily available probe for adenosine actions. Mol. Aspects Med. 2017;55:20-25.
Not in our library10.1016/j.mam.2016.11.011
147.
The Safety of Ingested Caffeine: A Comprehensive Review · 2017
No notice
148.
Tewari D, et al. Role of nitric oxide in neurodegeneration: function, regulation, and inhibition. Curr. Neuropharmacol. 2021;19:114-126.
Not in our library10.2174/18756190mta2pmjapy
149.
Liy PM, Puzi NNA, Jose S, Vidyadaran S. Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells. Exp. Biol. Med. 2021;246:2399-2406.
Not in our library10.1177/1535370221997052
150.
Sun J, Steenbergen C, Murphy E. S-nitrosylation: NO-related redox signaling to protect against oxidative stress. Antioxid. Redox Signal. 2006;8:1693-1705.
Not in our library10.1089/ars.2006.8.1693
151.
Nakato R, et al. Regulation of the unfolded protein response via S-nitrosylation of sensors of endoplasmic reticulum stress. Sci. Rep. 2015;5:14812.
Not in our library10.1038/srep14812
152.
Batalha VL, et al. The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. Sci. Rep. 2016;6:31493.
Not in our library10.1038/srep31493
153.
Perez D. M. alpha1-adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Front. Pharmacol. 2020;11:581098.
Not in our library10.3389/fphar.2020.581098
154.
McCorry LK. Physiology of the autonomic nervous system. Am. J. Pharm. Educ. 2007;71:78.
Not in our library10.5688/aj710478
155.
O’Donnell J, et al. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res. 2012;37:2496-2512.
Not in our library10.1007/s11064-012-0818-x
156.
Jung YH, et al. Relationships between catecholamine levels and stress or intelligence. Neurochem. Res. 2019;44:1192-1200.
Not in our library10.1007/s11064-019-02762-z
157.
Feinstein DL, Kalinin S, Braun D. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. J. Neurochem. 2016;139:154-178.
Not in our library10.1111/jnc.13447
158.
Frohman EM, Vayuvegula B, Gupta S, van den Noort S. Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc. Natl Acad. Sci. USA. 1988;85:1292-1296.
Not in our library10.1073/pnas.85.4.1292
159.
Feinstein DL. Suppression of astroglial nitric oxide synthase expression by norepinephrine results from decreased NOS-2 promoter activity. J. Neurochem. 1998;70:1484-1496.
Not in our library10.1046/j.1471-4159.1998.70041484.x
160.
Ballestas ME, Benveniste EN. Elevation of cyclic AMP levels in astrocytes antagonizes cytokine-induced adhesion molecule expression. J. Neurochem. 1997;69:1438-1448.
Not in our library10.1046/j.1471-4159.1997.69041438.x
161.
Etienne-Manneville S, Chaverot N, Strosberg AD, Couraud PO. ICAM-1-coupled signaling pathways in astrocytes converge to cyclic AMP response element-binding protein phosphorylation and TNF-alpha secretion. J. Immunol. 1999;163:668-674.
Not in our library10.4049/jimmunol.163.2.668
162.
Evans AK, et al. Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 2020;146:105089.
Not in our library10.1016/j.nbd.2020.105089
163.
Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 2004;45:38-78.
Not in our library10.1016/j.brainresrev.2004.02.002
164.
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease · 2021
No notice
165.
Cottingham C, Wang Q. alpha2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy. Neurosci. Biobehav. Rev. 2012;36:2214-2225.
Not in our library10.1016/j.neubiorev.2012.07.011
166.
Garcia-Sevilla JA, et al. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J. Neurochem. 1999;72:282-291.
Not in our library10.1046/j.1471-4159.1999.0720282.x
167.
Wang B, et al. Effects of alpha2A adrenoceptors on norepinephrine secretion from the locus coeruleus during chronic stress-induced depression. Front. Neurosci. 2017;11:243.
Not in our library10.3389/fnins.2017.00243
168.
Zhang HT, et al. Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior. Neuropsychopharmacology. 2009;34:1067-1077.
Not in our library10.1038/npp.2008.184
169.
Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products · 2020
No notice
170.
Cannabinoid receptor type-1: breaking the dogmas [version 1; referees: 3 approved] · 2016
Not checked
171.
The CB2 receptor and its role as a regulator of inflammation · 2016
No notice
172.
Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol. Psychiatry. 2016;79:516-525.
Not in our library10.1016/j.biopsych.2015.07.028
173.
Sugiura T, et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 2000;275:605-612.
Not in our library10.1074/jbc.275.1.605
174.
Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 2006;147:S163-S171.
Not in our library10.1038/sj.bjp.0706406
175.
Amin MR, Ali DW. Pharmacology of medical cannabis. Adv. Exp. Med. Biol. 2019;1162:151-165.
Not in our library10.1007/978-3-030-21737-2_8
176.
Osei-Hyiaman D, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Investig. 2005;115:1298-1305.
Not in our library10.1172/jci200523057
177.
Cavuoto P, et al. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem. Biophys. Res. Commun. 2007;364:105-110.
Not in our library10.1016/j.bbrc.2007.09.099
178.
Pertwee RG. Endocannabinoids and their pharmacological actions. Handb. Exp. Pharmacol. 2015;231:1-37.
Not in our library10.1007/978-3-319-20825-1_1
179.
Soria-Gomez E, et al. Habenular CB1 receptors control the expression of aversive memories. Neuron. 2015;88:306-313.
Not in our library10.1016/j.neuron.2015.08.035
180.
Chen X, Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. Neuroscience. 2011;178:159-168.
Not in our library10.1016/j.neuroscience.2011.01.024
181.
Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr. Neurol. Neurosci. Rep. 2018;18:50.
Not in our library10.1007/s11910-018-0859-x
182.
Glass M, Faull RL, Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease. Neuroscience. 1993;56:523-527.
Not in our library10.1016/0306-4522(93)90352-g
183.
Richfield EK, Herkenham M. Selective vulnerability in Huntington’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 1994;36:577-584.
Not in our library10.1002/ana.410360406
184.
Fernandez-Ruiz J, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 2013;75:323-333.
Not in our library10.1111/j.1365-2125.2012.04341.x
185.
Bie B, Wu J, Foss JF, Naguib M. An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Curr. Opin. Anaesthesiol. 2018;31:407-414.
Not in our library10.1097/aco.0000000000000616
186.
Morcuende A, et al. Immunomodulatory role of CB2 receptors in emotional and cognitive disorders. Front. Psychiatry. 2022;13:866052.
Not in our library10.3389/fpsyt.2022.866052
187.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016;16:22-34.
Not in our library10.1038/nri.2015.5
188.
Garcia-Gutierrez MS, Perez-Ortiz JM, Gutierrez-Adan A, Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br. J. Pharmacol. 2010;160:1773-1784.
Not in our library10.1111/j.1476-5381.2010.00819.x
189.
Schmole AC, et al. Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer’s disease mouse model. Neurobiol. Aging. 2015;36:710-719.
Not in our library10.1016/j.neurobiolaging.2014.09.019
190.
Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 2003;139:775-786.
Not in our library10.1038/sj.bjp.0705304
191.
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation · 2005
No notice
192.
Arjmand S, et al. Bipolar disorder and the endocannabinoid system. Acta Neuropsychiatr. 2019;31:193-201.
Not in our library10.1017/neu.2019.21
193.
Allende G, et al. Advances in neurobiology and pharmacology of GPR12. Front. Pharmacol. 2020;11:628.
Not in our library10.3389/fphar.2020.00628
194.
Constitutive Activity among Orphan Class-A G Protein Coupled Receptors · 2015
No notice
195.
Ignatov A, et al. Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. J. Neurosci. 2003;23:907-914.
Not in our library10.1523/jneurosci.23-03-00907.2003
196.
Laun AS, Shrader SH, Brown KJ, Song ZH. GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol. Sin. 2019;40:300-308.
Not in our library10.1038/s41401-018-0031-9
197.
Lu X, Zhang N, Dong S, Hu Y. Involvement of GPR12 in the induction of neurite outgrowth in PC12 cells. Brain Res. Bull. 2012;87:30-36.
Not in our library10.1016/j.brainresbull.2011.09.020
198.
Zhao M, et al. Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. Transl. Psychiatry. 2022;12:173.
Not in our library10.1038/s41398-022-01942-w
199.
McHugh D. GPR18 in microglia: implications for the CNS and endocannabinoid system signalling. Br. J. Pharmacol. 2012;167:1575-1582.
Not in our library10.1111/j.1476-5381.2012.02019.x
200.
Ross GR, Lichtman A, Dewey WL, Akbarali HI. Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice. Pharmacology. 2012;90:55-65.
Not in our library10.1159/000339076
201.
Morales P, et al. Therapeutic exploitation of GPR18: beyond the cannabinoids? J. Med. Chem. 2020;63:14216-14227.
Not in our library10.1021/acs.jmedchem.0c00926
202.
Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J. Exp. Med. 2015;212:1203-1217.
Not in our library10.1084/jem.20150225
203.
Reyes-Resina I, et al. Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases. Biochem. Pharmacol. 2018;157:169-179.
Not in our library10.1016/j.bcp.2018.06.001
204.
Sawzdargo M, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 1999;64:193-198.
Not in our library10.1016/s0169-328x(98)00277-0
205.
Balenga NA, Henstridge CM, Kargl J, Waldhoer M. Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55. Adv. Pharmacol. 2011;62:251-277.
Not in our library10.1016/b978-0-12-385952-5.00004-x
206.
Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells · 2018
Not checked
207.
Celorrio M, et al. GPR55: a therapeutic target for Parkinson’s disease? Neuropharmacology. 2017;125:319-332.
Not in our library10.1016/j.neuropharm.2017.08.017
208.
Arias-Carrion O, Poppel E. Dopamine, learning, and reward-seeking behavior. Acta Neurobiol. Exp. 2007;67:481-488.
Not in our library10.55782/ane-2007-1664
209.
Missale C, et al. Dopamine receptors: from structure to function. Physiol. Rev. 1998;78:189-225.
Not in our library10.1152/physrev.1998.78.1.189
210.
Baik JH. Dopamine signaling in food addiction: role of dopamine D2 receptors. BMB Rep. 2013;46:519-526.
Not in our library10.5483/bmbrep.2013.46.11.207
211.
International Guidelines for the Treatment of Huntington's Disease · 2019
No notice
212.
Kish SJ, Shannak K, Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington’s disease striatum. Ann. Neurol. 1987;22:386-389.
Not in our library10.1002/ana.410220318
213.
Sedvall G, et al. Dopamine D1 receptor number-a sensitive PET marker for early brain degeneration in Huntington’s disease. Eur. Arch. Psychiatry Clin. Neurosci. 1994;243:249-255.
Not in our library10.1007/bf02191583
214.
Harris KL, Kuan WL, Mason SL, Barker RA. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD). J. Neurol. Neurosurg. Psychiatry. 2020;91:622-630.
Not in our library10.1136/jnnp-2019-322038
215.
Dopamine and Noradrenaline in the Brain; Overlapping or Dissociate Functions? · 2020
No notice
216.
Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis · 2019
No notice
217.
Hisahara S, Shimohama S. Dopamine receptors and Parkinson’s disease. Int. J. Med. Chem. 2011;2011:403039.
Not in our library10.1155/2011/403039
218.
Melnikov M, Pashenkov M, Boyko A. Dopaminergic receptor targeting in multiple sclerosis: is there therapeutic potential? Int. J. Mol. Sci. 2021;22:5313.
Not in our library10.3390/ijms22105313
219.
Fu J, et al. The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A. J. Neuroinflammation. 2022;19:98.
Not in our library10.1186/s12974-022-02446-6
220.
Th17-cells in depression: Implication in multiple sclerosis · 2022
Not checked
221.
Borovac JA. Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J. Biol. Med. 2016;89:37-47.
Not in our library
222.
Urs NM, et al. Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action. Proc. Natl Acad. Sci. USA. 2012;109:20732-20737.
Not in our library10.1073/pnas.1215489109
223.
Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011;63:182-217.
Not in our library10.1124/pr.110.002642
224.
Urs NM, Peterson SM, Caron MG. New concepts in dopamine D2 receptor biased signaling and implications for schizophrenia therapy. Biol. Psychiatry. 2017;81:78-85.
Not in our library10.1016/j.biopsych.2016.10.011
225.
Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol. Rev. 2008;88:1183-1241.
Not in our library10.1152/physrev.00043.2007
226.
Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol. Neurobiol. 2000;20:131-147.
Not in our library10.1023/a:1007074420772
227.
Histamine: a new immunomodulatory player in the neuron-glia crosstalk · 2014
Not checked
228.
Burfoot C. Chronic sport-induced hypohydration. Med. J. Aust. 1993;158:140.
Not in our library
229.
Mehta P, et al. Enigmatic histamine receptor H4 for potential treatment of multiple inflammatory, autoimmune, and related diseases. Life. 2020;10:50.
Not in our library10.3390/life10040050
230.
Nuutinen S, Panula P. Histamine in neurotransmission and brain diseases. Adv. Exp. Med. Biol. 2010;709:95-107.
Not in our library10.1007/978-1-4419-8056-4_10
231.
John J, Wu MF, Boehmer LN, Siegel JM. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron. 2004;42:619-634.
Not in our library10.1016/s0896-6273(04)00247-8
232.
Higuchi M, et al. Histamine H(1) receptors in patients with Alzheimer’s disease assessed by positron emission tomography. Neuroscience. 2000;99:721-729.
Not in our library10.1016/s0306-4522(00)00230-x
233.
Kano M, et al. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur. J. Neurosci. 2004;20:803-810.
Not in our library10.1111/j.1460-9568.2004.03540.x
234.
Iwabuchi K, et al. Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur. Neuropsychopharmacol. 2005;15:185-191.
Not in our library10.1016/j.euroneuro.2004.10.001
235.
Passani MB, Ballerini C. Histamine and neuroinflammation: insights from murine experimental autoimmune encephalomyelitis. Front. Syst. Neurosci. 2012;6:32.
Not in our library10.3389/fnsys.2012.00032
236.
Esbenshade TA, et al. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br. J. Pharmacol. 2008;154:1166-1181.
Not in our library10.1038/bjp.2008.147
237.
Zhou P, et al. Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model. Brain Behav. Immun. 2019;76:61-73.
Not in our library10.1016/j.bbi.2018.11.006
238.
Nahon JL, et al. The rat melanin-concentrating hormone messenger ribonucleic acid encodes multiple putative neuropeptides coexpressed in the dorsolateral hypothalamus. Endocrinology. 1989;125:2056-2065.
Not in our library10.1210/endo-125-4-2056
239.
Diniz GB, Bittencourt JC. The melanin-concentrating hormone as an integrative peptide driving motivated behaviors. Front. Syst. Neurosci. 2017;11:32.
Not in our library10.3389/fnsys.2017.00032
240.
Benedetto L, et al. Microinjection of melanin concentrating hormone into the lateral preoptic area promotes non-REM sleep in the rat. Peptides. 2013;39:11-15.
Not in our library10.1016/j.peptides.2012.10.005
241.
Macneil DJ. The role of melanin-concentrating hormone and its receptors in energy homeostasis. Front. Endocrinol. 2013;4:49.
Not in our library10.3389/fendo.2013.00049
242.
Roy M, et al. Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects. Neuropsychopharmacology. 2006;31:112-120.
Not in our library10.1038/sj.npp.1300805
243.
Smith DG, et al. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology. 2006;31:1135-1145.
Not in our library10.1038/sj.npp.1300913
244.
Aziz A, et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 2008;18:474-483.
Not in our library10.1111/j.1750-3639.2008.00135.x
245.
Vawter MP, et al. Melanin concentrating hormone signaling deficits in Schizophrenia: ssociation with memory and social impairments and abnormal sensorimotor gating. Int. J. Neuropsychopharmacol. 2020;23:53-65.
Not in our library10.1093/ijnp/pyz051
246.
Tan DX, et al. The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness. Biol. Rev. Camb. Philos. Soc. 2010;85:607-623.
Not in our library10.1111/j.1469-185x.2009.00118.x
247.
Gupta YK, Gupta M, Kohli K. Neuroprotective role of melatonin in oxidative stress vulnerable brain. Indian J. Physiol. Pharmacol. 2003;47:373-386.
Not in our library
248.
Tan DX, et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal. Res. 2007;42:28-42.
Not in our library10.1111/j.1600-079x.2006.00407.x
249.
Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J. Pineal. Res. 2005;38:145-152.
Not in our library10.1111/j.1600-079x.2004.00196.x
250.
Pandi-Perumal SR, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008;85:335-353.
Not in our library10.1016/j.pneurobio.2008.04.001
251.
Wu YH, et al. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol. Aging. 2007;28:1239-1247.
Not in our library10.1016/j.neurobiolaging.2006.06.002
252.
de Oliveira GAP, Silva JL. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson’s disease. Commun. Biol. 2019;2:374.
Not in our library10.1038/s42003-019-0598-9
253.
Su LY, et al. Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/alpha-synuclein aggregation. Autophagy. 2015;11:1745-1759.
Not in our library10.1080/15548627.2015.1082020
254.
Vakilzadeh G, et al. The effect of melatonin on behavioral, molecular, and histopathological changes in cuprizone model of demyelination. Mol. Neurobiol. 2016;53:4675-4684.
Not in our library10.1007/s12035-015-9404-y
255.
Rogerio F, et al. Superoxide dismutase isoforms 1 and 2 in lumbar spinal cord of neonatal rats after sciatic nerve transection and melatonin treatment. Brain Res. Dev. Brain Res. 2005;154:217-225.
Not in our library10.1016/j.devbrainres.2004.10.017
256.
The neuroprotective role of melatonin in neurological disorders · 2018
No notice
257.
Boiko DI, et al. Melatonergic receptors (Mt1/Mt2) as a potential additional target of novel drugs for depression. Neurochem. Res. 2022;47:2909-2924.
Not in our library10.1007/s11064-022-03646-5
258.
Liu J, et al. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu. Rev. Pharmacol. Toxicol. 2016;56:361-383.
Not in our library10.1146/annurev-pharmtox-010814-124742
259.
Wu YH, et al. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J. Affect. Disord. 2013;148:357-367.
Not in our library10.1016/j.jad.2012.12.025
260.
Weishaupt JH, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 2006;41:313-323.
Not in our library10.1111/j.1600-079x.2006.00377.x
261.
Hansen MV, et al. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst. Rev. 2015;2015:CD009861.
Not in our library10.1002/14651858.cd009861.pub2
262.
Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum. Psychopharmacol. 2008;23:571-585.
Not in our library10.1002/hup.964
263.
Perez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81:985-1002.
Not in our library10.1007/s40265-021-01528-8
264.
Perez-Jeldres T, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front. Pharmacol. 2019;10:212.
Not in our library10.3389/fphar.2019.00212
265.
Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential · 2016
Corrected
266.
Cohan S, et al. Sphingosine-1-phosphate: its pharmacological regulation and the treatment of multiple sclerosis: a review article. Biomedicines. 2020;8:227.
Not in our library10.3390/biomedicines8070227
267.
Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-phosphate receptor modulators for multiple sclerosis. CNS Drugs. 2021;35:385-402.
Not in our library10.1007/s40263-021-00798-w
268.
Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 2008;8:753-763.
Not in our library10.1038/nri2400
269.
Jaillard C, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 2005;25:1459-1469.
Not in our library10.1523/jneurosci.4645-04.2005
270.
Pradhan AA, Smith ML, Kieffer BL, Evans CJ. Ligand-directed signalling within the opioid receptor family. Br. J. Pharmacol. 2012;167:960-969.
Not in our library10.1111/j.1476-5381.2012.02075.x
271.
Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat. Rev. Neurosci. 2018;19:499-514.
Not in our library10.1038/s41583-018-0028-x
272.
Weninger SC, et al. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc. Natl Acad. Sci. USA. 1999;96:8283-8288.
Not in our library10.1073/pnas.96.14.8283
273.
Borodovitsyna O, Flamini MD, Chandler DJ. Acute stress persistently alters locus coeruleus function and anxiety-like behavior in adolescent rats. Neuroscience. 2018;373:7-19.
Not in our library10.1016/j.neuroscience.2018.01.020
274.
Wong ML, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl Acad. Sci. USA. 2000;97:325-330.
Not in our library10.1073/pnas.97.1.325
275.
Jelen LA, Stone JM, Young AH, Mehta MA. The opioid system in depression. Neurosci. Biobehav. Rev. 2022;140:104800.
Not in our library10.1016/j.neubiorev.2022.104800
276.
Moustafa SR, et al. The endogenous opioid system in schizophrenia and treatment resistant schizophrenia: increased plasma endomorphin 2, and kappa and mu opioid receptors are associated with interleukin-6. Diagnostics. 2020;10:633.
Not in our library10.3390/diagnostics10090633
277.
Tan J, Evin G. Beta-site APP-cleaving enzyme 1 trafficking and Alzheimer’s disease pathogenesis. J. Neurochem. 2012;120:869-880.
Not in our library10.1111/j.1471-4159.2011.07623.x
278.
Opposite Roles of δ- and μ-Opioid Receptors in BACE1 Regulation and Alzheimer’s Injury · 2020
Not checked
279.
Yamada M, et al. The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson’s disease brain. Brain Res. Mol. Brain Res. 1997;44:12-20.
Not in our library10.1016/s0169-328x(96)00139-8
280.
Maneuf YP, et al. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson’s disease. Brain Res. 1995;683:102-108.
Not in our library10.1016/0006-8993(95)00358-w
281.
Ikeda K, et al. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson’s disease. Eur. J. Pharmacol. 2009;620:42-48.
Not in our library10.1016/j.ejphar.2009.08.013
282.
Marazziti D. Understanding the role of serotonin in psychiatric diseases. F1000Res. 2017;6:180.
Not in our library10.12688/f1000research.10094.1
283.
The serotonergic system and cognitive function · 2016
Not checked
284.
Nichols DE, Nichols CD. Serotonin receptors. Chem. Rev. 2008;108:1614-1641.
Not in our library10.1021/cr078224o
285.
Piszczek L, et al. Modulation of anxiety by cortical serotonin 1A receptors. Front. Behav. Neurosci. 2015;9:48.
Not in our library10.3389/fnbeh.2015.00048
286.
Belmer A, Patkar OL, Lanoue V, Bartlett SE. 5-HT1A receptor-dependent modulation of emotional and neurogenic deficits elicited by prolonged consumption of alcohol. Sci. Rep. 2018;8:2099.
Not in our library10.1038/s41598-018-20504-z
287.
Braem S, et al. The role of anterior cingulate cortex in the affective evaluation of conflict. J. Cogn. Neurosci. 2017;29:137-149.
Not in our library10.1162/jocn_a_01023
288.
Veldman ER, Svedberg MM, Svenningsson P, Lundberg J. Distribution and levels of 5-HT1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia—an autoradiography study. Eur. Neuropsychopharmacol. 2017;27:504-514.
Not in our library10.1016/j.euroneuro.2017.02.011
289.
Norton N, Owen MJ. HTR2A: association and expression studies in neuropsychiatric genetics. Ann. Med. 2005;37:121-129.
Not in our library10.1080/07853890510037347
290.
Papasergi-Scott MM, et al. Structures of metabotropic GABAB receptor. Nature. 2020;584:310-314.
Not in our library10.1038/s41586-020-2469-4
291.
Park J, et al. Structure of human GABAB receptor in an inactive state. Nature. 2020;584:304-309.
Not in our library10.1038/s41586-020-2452-0
292.
Shaye H, et al. Structural basis of the activation of a metabotropic GABA receptor. Nature. 2020;584:298-303.
Not in our library10.1038/s41586-020-2408-4
293.
Du J, et al. Structures of human mGlu2 and mGlu7 homo- and heterodimers. Nature. 2021;594:589-593.
Not in our library10.1038/s41586-021-03641-w
294.
Gao Y, et al. Asymmetric activation of the calcium-sensing receptor homodimer. Nature. 2021;595:455-459.
Not in our library10.1038/s41586-021-03691-0
295.
Kim Y, et al. Structural basis for activation of the heterodimeric GABAB receptor. J. Mol. Biol. 2020;432:5966-5984.
Not in our library10.1016/j.jmb.2020.09.023
296.
Shen C, et al. Structural basis of GABAB receptor-Gi protein coupling. Nature. 2021;594:594-598.
Not in our library10.1038/s41586-021-03507-1
297.
Lin S, et al. Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4. Nature. 2021;594:583-588.
Not in our library10.1038/s41586-021-03495-2
298.
Seven AB, et al. G-protein activation by a metabotropic glutamate receptor. Nature. 2021;595:450-454.
Not in our library10.1038/s41586-021-03680-3
299.
Patel H, Dobson RJB, Newhouse SJ. A meta-analysis of Alzheimer’s disease brain transcriptomic data. J. Alzheimers Dis. 2019;68:1635-1656.
Not in our library10.3233/jad-181085
300.
Niu HM, et al. Comprehensive functional annotation of susceptibility SNPs prioritized 10 genes for schizophrenia. Transl. Psychiatry. 2019;9:56.
Not in our library10.1038/s41398-019-0398-5
301.
Philpott AL, et al. A GABBR2 gene variant modifies pathophysiology in Huntington’s disease. Neurosci. Lett. 2016;620:8-13.
Not in our library10.1016/j.neulet.2016.03.038
302.
Tyagi RK, et al. Possible role of GABA-B receptor modulation in MPTP induced Parkinson’s disease in rats. Exp. Toxicol. Pathol. 2015;67:211-217.
Not in our library10.1016/j.etp.2014.12.001
303.
Hovelso N, et al. Therapeutic potential of metabotropic glutamate receptor modulators. Curr. Neuropharmacol. 2012;10:12-48.
Not in our library10.2174/157015912799362805
304.
Role of Metabotropic Glutamate Receptors in Neurological Disorders · 2019
No notice
305.
Mikulecka A, Mares P. Effects of mGluR5 and mGluR1 antagonists on anxiety-like behavior and learning in developing rats. Behav. Brain Res. 2009;204:133-139.
Not in our library10.1016/j.bbr.2009.05.032
306.
Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31:577-585.
Not in our library10.2165/00002018-200831070-00003
307.
Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int. J. Biol. Sci. 2013;9:948-959.
Not in our library10.7150/ijbs.6426
308.
Hamilton A, et al. Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer’s disease. Mol. Brain. 2014;7:40.
Not in our library10.1186/1756-6606-7-40
309.
Hamilton A, Zamponi GW, Ferguson SS. Glutamate receptors function as scaffolds for the regulation of beta-amyloid and cellular prion protein signaling complexes. Mol. Brain. 2015;8:18.
Not in our library10.1186/s13041-015-0107-0
310.
Haas LT, et al. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer’s disease. Brain. 2016;139:526-546.
Not in our library10.1093/brain/awv356
311.
Abd-Elrahman KS, Ferguson SSG. Noncanonical metabotropic glutamate receptor 5 signaling in Alzheimer’s disease. Annu. Rev. Pharmacol. Toxicol. 2022;62:235-254.
Not in our library10.1146/annurev-pharmtox-021821-091747
312.
Doria JG, et al. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington’s disease. Br. J. Pharmacol. 2013;169:909-921.
Not in our library10.1111/bph.12164
313.
Doria JG, et al. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington’s disease. Neurobiol. Dis. 2015;73:163-173.
Not in our library10.1016/j.nbd.2014.08.021
314.
Matosin N, Newell KA. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 2013;37:256-268.
Not in our library10.1016/j.neubiorev.2012.12.005
315.
Schoepp DD, et al. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress. 2003;6:189-197.
Not in our library10.1080/1025389031000146773
316.
Li SH, Colson TL, Abd-Elrahman KS, Ferguson SSG. Metabotropic glutamate receptor 2/3 activation improves motor performance and reduces pathology in heterozygous zQ175 Huntington disease mice. J. Pharmacol. Exp. Ther. 2021;379:74-84.
Not in our library10.1124/jpet.121.000735
317.
Chan H, et al. Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent model of Parkinson’s disease. Parkinsons Dis. 2010;2010:190450.
Not in our library10.4061/2010/190450
318.
Murray TK, et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson’s disease. Pharmacol. Biochem. Behav. 2002;73:455-466.
Not in our library10.1016/s0091-3057(02)00842-0
319.
Arnett PA, et al. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology. 1999;13:546-556.
Not in our library10.1037/0894-4105.13.4.546
320.
Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease. J. Neurosci. 1991;11:1649-1659.
Not in our library10.1523/jneurosci.11-06-01649.1991
321.
Bruno V, et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology. 2000;39:2223-2230.
Not in our library10.1016/s0028-3908(00)00079-4
322.
Schiefer J, et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington’s disease. Brain Res. 2004;1019:246-254.
Not in our library10.1016/j.brainres.2004.06.005
323.
Le Poul E, et al. A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease. J. Pharmacol. Exp. Ther. 2012;343:167-177.
Not in our library10.1124/jpet.112.196063
324.
Cryan JF, et al. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci. 2003;17:2409-2417.
Not in our library10.1046/j.1460-9568.2003.02667.x
325.
Robbins MJ, et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res. 2007;1152:215-227.
Not in our library10.1016/j.brainres.2007.03.028
326.
Shibata H, et al. Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res. 2009;167:88-96.
Not in our library10.1016/j.psychres.2007.12.002
327.
Ohtsuki T, et al. A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr Res. 2008;101:9-16.
Not in our library10.1016/j.schres.2008.01.027
328.
Niu W, et al. Association study of GRM7 polymorphisms and schizophrenia in the Chinese Han population. Neurosci. Lett. 2015;604:109-112.
Not in our library10.1016/j.neulet.2015.07.047
329.
Takaki H, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am. J. Med. Genet. 2004;B128B:6-14.
Not in our library10.1002/ajmg.b.20108
330.
Gomes I, et al. G protein-coupled receptor heteromers. Annu. Rev. Pharmacol. Toxicol. 2016;56:403-425.
Not in our library10.1146/annurev-pharmtox-011613-135952
331.
Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 2004;5:30-34.
Not in our library10.1038/sj.embor.7400052
332.
Ferre S, et al. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer. Neuropharmacology. 2016;104:154-160.
Not in our library10.1016/j.neuropharm.2015.05.028
333.
Hillion J, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 2002;277:18091-18097.
Not in our library10.1074/jbc.m107731200
334.
Ramsay D, et al. Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem. J. 2002;365:429-440.
Not in our library10.1042/bj20020251
335.
Ferre S, et al. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Des. 2008;14:1468-1474.
Not in our library10.2174/138161208784480108
336.
Borroto-Escuela DO, et al. Disruption of A2AR-D2R heteroreceptor complexes after A2AR transmembrane 5 peptide administration enhances cocaine self-administration in rats. Mol. Neurobiol. 2018;55:7038-7048.
Not in our library10.1007/s12035-018-0887-1
337.
Fuxe K, Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 1974;52:48-54.
Not in our library
338.
Font L, et al. Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats. Psychopharmacology. 2008;199:515-526.
Not in our library10.1007/s00213-008-1174-z
339.
Muguruza C, et al. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur. Neuropsychopharmacol. 2013;23:852-864.
Not in our library10.1016/j.euroneuro.2012.10.006
340.
Moreno JL, et al. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J. Biol. Chem. 2012;287:44301-44319.
Not in our library10.1074/jbc.m112.413161
341.
Moreno JL, et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci. Signal. 2016;9:ra5.
Not in our library10.1126/scisignal.aab0467
342.
Ibi D. Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects. Pharmacol. Biochem. Behav. 2022;221:173474.
Not in our library10.1016/j.pbb.2022.173474
343.
Fribourg M, et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell. 2011;147:1011-1023.
Not in our library10.1016/j.cell.2011.09.055
344.
Moreno JL, et al. Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice. Neurosci. Lett. 2013;536:69-73.
Not in our library10.1016/j.neulet.2012.12.053
345.
Poulie CBM, Liu N, Jensen AA, Bunch L. Design, synthesis, and pharmacological characterization of heterobivalent ligands for the putative 5-HT2A/mGlu2 receptor complex. J. Med. Chem. 2020;63:9928-9949.
Not in our library10.1021/acs.jmedchem.0c01058
346.
Nirogi, R. et al. Discovery and development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (SUVN-502): a novel, potent, selective and orally active serotonin 6 (5-HT(6)) receptor antagonist for potential treatment of Alzheimer’s disease. J. Med. Chem.60, 1843–1859 (2017).
Not in our library10.1021/acs.jmedchem.6b01662
347.
Nirogi R, et al. SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization. Behav. Pharmacol. 2019;30:16-35.
Not in our library10.1097/fbp.0000000000000414
348.
Koenig AM, Arnold SE, Streim JE. Agitation and Irritability in Alzheimer’s disease: evidenced-based treatments and the black-box warning. Curr. Psychiatry Rep. 2016;18:3.
Not in our library10.1007/s11920-015-0640-7
349.
Ruthirakuhan M, et al. Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation. J. Geriatr. Psychiatry Neurol. 2020;33:175-184.
Not in our library10.1177/0891988719874118
350.
Londzin P, et al. Potential of caffeine in Alzheimer’s disease-a review of experimental studies. Nutrients. 2021;13:537.
Not in our library10.3390/nu13020537
351.
Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann. Pharmacother. 2014;48:209-225.
Not in our library10.1177/1060028013510699
352.
Fukuyama K, Nakano T, Shiroyama T, Okada M. Chronic administrations of guanfacine on mesocortical catecholaminergic and thalamocortical glutamatergic transmissions. Int. J. Mol. Sci. 2021;22:4122.
Not in our library10.3390/ijms22084122
353.
Kikuchi T, et al. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacol. Rep. 2021;41:134-143.
Not in our library10.1002/npr2.12180
354.
Caraci F, et al. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin. F1000Res. 2020;9:F1000.
Not in our library10.12688/f1000research.22662.1
355.
Aurora RN, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American academy of sleep medicine clinical practice guideline. Sleep. 2012;35:1039-1062.
Not in our library10.5665/sleep.1986
356.
Salat D, Tolosa E. Levodopa in the treatment of Parkinson’s disease: current status and new developments. J. Parkinsons Dis. 2013;3:255-269.
Not in our library10.3233/jpd-130186
357.
Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst. Rev. 2003;2003:CD003468.
Not in our library10.1002/14651858.cd003468
358.
Marmol S, Feldman M, Singer C, Margolesky J. Amantadine revisited: a contender for initial treatment in Parkinson’s disease? CNS Drugs. 2021;35:1141-1152.
Not in our library10.1007/s40263-021-00862-5
359.
Dragasevic-Miskovic N, Petrovic I, Stankovic I, Kostic VS. Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opin. Pharmacother. 2019;20:219-230.
Not in our library10.1080/14656566.2018.1543407
360.
Machado-Alba JE, Calvo-Torres LF, Gaviria-Mendoza A, Castrillon-Spitia JD. [Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015]. Biomedica. 2018;38:417-426.
Not in our library10.7705/biomedica.v38i4.3781
361.
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics · 2017
No notice
362.
Perez-Lloret S, Rascol O. Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs. 2016;30:703-717.
Not in our library10.1007/s40263-016-0360-5
363.
Lieberman AN, Goldstein M. Bromocriptine in Parkinson disease. Pharmacol. Rev. 1985;37:217-227.
Not in our library
364.
Kvernmo T, Houben J, Sylte I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr. Top Med. Chem. 2008;8:1049-1067.
Not in our library10.2174/156802608785161457
365.
Dungo R, Deeks ED. Istradefylline: first global approval. Drugs. 2013;73:875-882.
Not in our library10.1007/s40265-013-0066-7
366.
Pezzoli G, Canesi M, Pesenti A, Mariani CB. Pergolide mesylate in Parkinson’s disease treatment. J. Neural. Transm. Suppl. 1995;45:203-212.
Not in our library
367.
Nashatizadeh MM, Lyons KE, Pahwa R. A review of ropinirole prolonged release in Parkinson’s disease. Clin. Interv. Aging. 2009;4:179-186.
Not in our library10.2147/cia.s3358
368.
LiverTox: Clinical and Research Information on Drug-induced Liver Injuryhttps://pubmed.ncbi.nlm.nih.gov/31643176/ (National Institute of Diabetes and Digestive and Kidney Diseases, 2012).
Not in our library
369.
Kulkarni SS, Kopajtic TA, Katz JL, Newman AH. Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg. Med. Chem. 2006;14:3625-3634.
Not in our library10.1016/j.bmc.2006.01.017
370.
Chernoloz O, El Mansari M, Blier P. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J. Psychiatry Neurosci. 2012;37:113-121.
Not in our library10.1503/jpn.110038
371.
Moirand R, Galvao F, Donde C. Pramipexole and selegiline combination therapy in a case of treatment-resistant depression. J. Clin. Psychopharmacol. 2019;39:684-685.
Not in our library10.1097/jcp.0000000000001139
372.
Alavi MS, Karimi G, Roohbakhsh A. The role of orphan G protein-coupled receptors in the pathophysiology of multiple sclerosis: a review. Life Sci. 2019;224:33-40.
Not in our library10.1016/j.lfs.2019.03.045
373.
McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. J. Am. Med. Assoc. 2021;325:765-779.
Not in our library10.1001/jama.2020.26858
374.
Rudroff T, Sosnoff J. Cannabidiol to improve mobility in people with multiple sclerosis. Front. Neurol. 2018;9:183.
Not in our library10.3389/fneur.2018.00183
375.
Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33:1477-1502.
Not in our library10.1038/sj.npp.1301534
376.
Callegari I, Derfuss T, Galli E. Update on treatment in multiple sclerosis. La Presse Médicale. 2021;50:104068.
Not in our library10.1016/j.lpm.2021.104068
377.
Comi G, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18:1009-1020.
Not in our library10.1016/s1474-4422(19)30239-x
378.
Gilbert J, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am. J. Cardiol. 2011;107:906-911.
Not in our library10.1016/j.amjcard.2010.11.005
379.
Paleacu D. Tetrabenazine in the treatment of Huntington’s disease. Neuropsychiatr. Dis. Treat. 2007;3:545-551.
Not in our library
380.
Dold M, et al. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst. Rev. 2015;1:CD009831.
Not in our library10.1002/14651858.cd009831.pub2
381.
Videnovic A. Treatment of Huntington disease. Curr. Treat. Options Neurol. 2013;15:424-438.
Not in our library10.1007/s11940-013-0219-8
382.
Lissek S, et al. Opposing effects of dopamine antagonism in a motor sequence task-tiapride increases cortical excitability and impairs motor learning. Front. Behav. Neurosci. 2014;8:201.
Not in our library10.3389/fnbeh.2014.00201
383.
Tashiro M, et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H-1-receptor occupancy using C-11-doxepin positron emission tomography. J. Clin. Pharmacol. 2004;44:890-900.
Not in our library10.1177/0091270004267590
384.
Shankar G, Nate C. Positive and negative syndrome scale as a long-term outcome measurement tool in patients receiving clozapine ODT- a pilot study. Pharm. Pract. 2007;5:42-45.
Not in our library10.4321/s1886-36552007000100007
385.
Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr. Top Med. Chem. 2016;16:3385-3403.
Not in our library10.2174/1568026616666160608084834
386.
de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29:773-799.
Not in our library10.1007/s40263-015-0278-3
387.
Fleischhacker WW. Aripiprazole. Expert. Opin. Pharmacother. 2005;6:2091-2101.
Not in our library10.1517/14656566.6.12.2091
388.
Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract. 2015;69:978-997.
Not in our library10.1111/ijcp.12714
389.
Maeda K, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014;350:589-604.
Not in our library10.1124/jpet.114.213793
390.
Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J. Pharmacol. Exp. Ther. 2014;351:585-595.
Not in our library10.1124/jpet.114.218578
391.
Mahmood D, et al. New paradigms of old psychedelics in schizophrenia. Pharmaceuticals. 2022;15:640.
Not in our library10.3390/ph15050640
392.
Kumar B, Kuhad A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today. 2018;54:713-719.
Not in our library10.1358/dot.2018.54.12.2899443
393.
Edinoff A, et al. Lumateperone for the treatment of Schizophrenia. Psychopharmacol. Bull. 2020;50:32-59.
Not in our library10.64719/pb.4372
394.
Ahmed R, et al. Evaluation of the use of chlorpromazine for agitation in pediatric patients. Ment. Health Clin. 2021;11:40-44.
Not in our library10.9740/mhc.2021.03.040
395.
Moller HJ. Risperidone: a review. Expert Opin. Pharmacother. 2005;6:803-818.
Not in our library10.1517/14656566.6.5.803
396.
Rahman, S. & Marwaha, R. Haloperidol (StatPearls Publishing, 2022).
Not in our library
397.
Davis, C. in xPharm: The Comprehensive Pharmacology Reference (eds Enna, S. J. & Bylund, D. B.) 1–3 (Elsevier, 2007).
Not in our library
398.
Green B. Zotepine: a clinical review. Expert. Opin. Drug. Metab. Toxicol. 2009;5:181-186.
Not in our library10.1517/17425250802670482
399.
Capuzzi E, et al. Experimental serotonergic agents for the treatment of schizophrenia. J. Exp. Pharmacol. 2021;13:49-67.
Not in our library10.2147/jep.s259317
400.
Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27:879-911.
Not in our library10.1007/s40263-013-0105-7
401.
Tiihonen J, Hakola P, Paanila J, Turtiainen M. Eltoprazine for aggression in schizophrenia and mental retardation. Lancet. 1993;341:307.
Not in our library10.1016/0140-6736(93)92660-l
402.
Davidson M, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr. Bull. 2022;48:609-619.
Not in our library10.1093/schbul/sbac013
403.
Zhao J, et al. A simple, rapid and reliable method to determine imipramine and desipramine in mouse serum using ultra-high-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. J. Chromatogr. Sci. 2016;54:561-568.
Not in our library10.1093/chromsci/bmv187
404.
Jesulola E, Micalos P, Baguley IJ. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet? Behav. Brain Res. 2018;341:79-90.
Not in our library10.1016/j.bbr.2017.12.025
405.
Dawson LA, Nguyen HQ. The role of 5-HT1A and 5-HT1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000;39:1044-1052.
Not in our library10.1016/s0028-3908(99)00192-6
406.
Fernandez-Perez S, Pache DM, Sewell RD. Co-administration of fluoxetine and WAY100635 improves short-term memory function. Eur. J. Pharmacol. 2005;522:78-83.
Not in our library10.1016/j.ejphar.2005.08.039
407.
Werling LL, Keller A, Frank JG, Nuwayhid SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp. Neurol. 2007;207:248-257.
Not in our library10.1016/j.expneurol.2007.06.013
408.
Sato H, et al. Histamine H-1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers. Psychopharmacology. 2013;230:227-234.
Not in our library10.1007/s00213-013-3146-1
409.
Bareggi SR, Mundo E, Dell’Osso B, Altamura AC. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin. Drug. Metab. Toxicol. 2007;3:741-753.
Not in our library10.1517/17425255.3.5.741
410.
Avila A, et al. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J. Clin. Psychopharmacol. 2003;23:509-513.
Not in our library10.1097/01.jcp.0000088908.24613.db
411.
Shin DS, et al. A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method. Toxicol. Appl. Pharmacol. 2014;274:361-371.
Not in our library10.1016/j.taap.2013.12.012
412.
Joseph SS, et al. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 2003;368:496-503.
Not in our library10.1007/s00210-003-0835-z
413.
Olianas MC, Dedoni S, Onali P. The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors. Br. J. Pharmacol. 2012;167:1329-1341.
Not in our library10.1111/j.1476-5381.2012.02078.x
414.
Pawlyk AC, et al. Effects of the 5-HT2A antagonist mirtazapine in rat models of thermoregulation. Brain Res. 2006;1123:135-144.
Not in our library10.1016/j.brainres.2006.09.050
415.
Bang-Andersen B, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 2011;54:3206-3221.
Not in our library10.1021/jm101459g
416.
Mørk A, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol. Biochem. Behav. 2013;105:41-50.
Not in our library10.1016/j.pbb.2013.01.019
417.
D’Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. Pharmacy Ther. 2015;40:36-40.
Not in our library
418.
Pandhare A, et al. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors. Neuropharmacology. 2017;113:89-99.
Not in our library10.1016/j.neuropharm.2016.09.021
419.
Smeraldi E, Delmonte D. Agomelatine in depression. Expert Opin. Drug Saf. 2013;12:873-880.
Not in our library10.1517/14740338.2013.828690
420.
Bravo L, Llorca-Torralba M, Berrocoso E, Micó JA. Monoamines as drug targets in chronic pain: focusing on neuropathic pain. Front. Neurosci. 2019;13:1268.
Not in our library10.3389/fnins.2019.01268
421.
Nojimoto FD, et al. The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010;59:49-57.
Not in our library10.1016/j.neuropharm.2010.03.015
422.
Nierenberg AA, et al. Nortriptyline for treatment-resistant depression. J. Clin. Psychiatry. 2003;64:35-39.
Not in our library10.4088/jcp.v64n0108
423.
Mi W, et al. Efficacy, safety, and tolerability of ansofaxine (LY03005) extended-release tablet for major depressive disorder: a randomized, double-blind, placebo-controlled, dose-finding, phase 2 clinical trial. Int. J. Neuropsychopharmacol. 2022;25:252-260.
Not in our library10.1093/ijnp/pyab074
424.
Craske MG, Stein MB. Anxiety. Lancet. 2016;388:3048-3059.
Not in our library10.1016/s0140-6736(16)30381-6
425.
Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin. Neurosci. 2017;19:93-107.
Not in our library10.31887/dcns.2017.19.2/bbandelow
426.
Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. 5-HT(1A) receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology. 2014;231:623-636.
Not in our library10.1007/s00213-013-3389-x
427.
de Boer SF, Lesourd M, Mocaer E, Koolhaas JM. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: a comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. J. Pharmacol. Exp. Ther. 1999;288:1125-1133.
Not in our library
428.
van Zeeland YR, et al. Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. J. Vet. Pharmacol. Ther. 2013;36:51-58.
Not in our library10.1111/j.1365-2885.2012.01391.x
429.
Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgrad. Med. 2017;129:140-148.
Not in our library10.1080/00325481.2017.1249265
430.
Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst. Rev. 2010;8:Cd006815.
Not in our library10.1002/14651858.cd006815.pub2
431.
Noyes R. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr. Clin. North Am. 1985;8:119-132.
Not in our library10.1016/s0193-953x(18)30713-5
432.
Propranolol: A 50-year historical perspective · 2019
Not checked
433.
Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br. J. Pharmacol. 2005;144:317-322.
Not in our library10.1038/sj.bjp.0706048
434.
Almasi, A. & Meza, C. E. StatPearls (StatPearls Publishing LLC., 2022).
Not in our library
435.
Rickels K, et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2008;28:235-239.
Not in our library10.1097/jcp.0b013e31816774de
436.
Jain M. Quetiapine associated central serous chorioretinopathy: implicit role of serotonin and dopamine pathways. Indian J. Ophthalmol. 2019;67:292-294.
Not in our library10.4103/ijo.ijo_929_18
437.
Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des. Devel. Ther. 2014;8:827-838.
Not in our library10.2147/dddt.s63779
438.
Millan MJ, et al. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 2000;295:1192-1205.
Not in our library
439.
Fenton C, Scott LJ. Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19:429-444.
Not in our library10.2165/00023210-200519050-00005
440.
Dziedzicka-Wasylewska M, et al. Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2) /D(3) receptors. Behav. Pharmacol. 2002;13:127-138.
Not in our library10.1097/00008877-200203000-00004
441.
Samuels BA, et al. The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor. Neuropsychopharmacology. 2017;42:2052-2063.
Not in our library10.1038/npp.2017.60
442.
Networks in the Field of Tourette Syndrome · 2021
Not checked
443.
Ünal D, Akdemir D. [Neurobiology of Tourette Syndrome]. Turk psikiyatri dergisi = Turkish journal of psychiatry. 2016;27:275-285.
Not in our library
444.
O’Rourke JA, Scharf JM, Yu D, Pauls DL. The genetics of Tourette syndrome: a review. J. Psychosom. Res. 2009;67:533-545.
Not in our library10.1016/j.jpsychores.2009.06.006
445.
Rose O, et al. Tourette syndrome research highlights from 2018. F1000Res. 2019;8:988.
Not in our library10.12688/f1000research.19542.1
446.
Felling RJ, Singer HS. Neurobiology of Tourette syndrome: current status and need for further investigation. J. Neurosci. 2011;31:12387-12395.
Not in our library10.1523/jneurosci.0150-11.2011
447.
Singer HS, Morris C, Grados M. Glutamatergic modulatory therapy for Tourette syndrome. Med. Hypotheses. 2010;74:862-867.
Not in our library10.1016/j.mehy.2009.11.028
448.
Paschou P. The genetic basis of gilles de la Tourette syndrome. Neurosci. Biobehav. Rev. 2013;37:1026-1039.
Not in our library10.1016/j.neubiorev.2013.01.016
449.
Huertas-Fernández I, et al. GDNF gene is associated with tourette syndrome in a family study. Mov. Disord. 2015;30:1115-1120.
Not in our library10.1002/mds.26279
450.
Hallett M. Tourette syndrome: update. Brain Dev. 2015;37:651-655.
Not in our library10.1016/j.braindev.2014.11.005
451.
Stahl SM. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J. Clin. Psychiatry. 2010;71:223-224.
Not in our library10.4088/jcp.09bs05899pur
452.
Cox JH, Cavanna AE. Aripiprazole for the treatment of Tourette syndrome. Expert Rev. Neurother. 2021;21:381-391.
Not in our library10.1080/14737175.2021.1893693
453.
Silva MR, Bernardi MM, Cruz-Casallas PE, Felicio LF. Pimozide injections into the Nucleus accumbens disrupt maternal behaviour in lactating rats. Pharmacol. Toxicol. 2003;93:42-47.
Not in our library10.1034/j.1600-0773.2003.930106.x
454.
A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD) · 2019
No notice
455.
Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol. Psychiatry. 2011;69:e145-e157.
Not in our library10.1016/j.biopsych.2011.02.036
456.
Wu CS, Shang CY, Lin HY, Gau SS. Differential treatment effects of methylphenidate and atomoxetine on executive functions in children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2021;31:187-196.
Not in our library10.1089/cap.2020.0146
457.
Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol. Biochem. Behav. 2011;99:211-216.
Not in our library10.1016/j.pbb.2011.01.020
458.
Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci. Biobehav. Rev. 2018;87:255-270.
Not in our library10.1016/j.neubiorev.2018.02.001
459.
Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ. The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Pharmazie. 2009;64:123-125.
Not in our library
460.
Creighton CJ, et al. Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect. Bioorg. Med. Chem. Lett. 2004;14:4083-4085.
Not in our library10.1016/j.bmcl.2004.05.018
461.
Fu D, et al. The mechanism, clinical efficacy, safety, and dosage regimen of atomoxetine for ADHD therapy in children: a narrative review. Front. Psychiatry. 2021;12:780921.
Not in our library10.3389/fpsyt.2021.780921
462.
Reese EA, et al. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J. Pharmacol. Exp. Ther. 2007;321:178-186.
Not in our library10.1124/jpet.106.115402
463.
Chanrion B, et al. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol. Pharmacol. 2008;73:748-757.
Not in our library10.1124/mol.107.041574
464.
Cryan JF, Lucki I. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J. Pharmacol. Exp. Ther. 2000;295:1120-1126.
Not in our library
465.
Ciana P, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006;25:4615-4627.
Not in our library10.1038/sj.emboj.7601341
466.
Bagchi S, et al. The P2Y2 nucleotide receptor interacts with alphav integrins to activate Go and induce cell migration. J. Biol. Chem. 2005;280:39050-39057.
Not in our library10.1074/jbc.m504819200
467.
Ghosh A, Chen F, Thakur A, Hong H. Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders. CNS Neurosci. Ther. 2016;22:943-951.
Not in our library10.1111/cns.12596
468.
Ciccarelli R, et al. Cysteinyl-leukotrienes are released from astrocytes and increase astrocyte proliferation and glial fibrillary acidic protein via cys-LT1 receptors and mitogen-activated protein kinase pathway. Eur. J. Neurosci. 2004;20:1514-1524.
Not in our library10.1111/j.1460-9568.2004.03613.x
469.
Coppolino GT, et al. Differential local tissue permissiveness influences the final fate of GPR17-expressing oligodendrocyte precursors in two distinct models of demyelination. Glia. 2018;66:1118-1130.
Not in our library10.1002/glia.23305
470.
Dziedzic A, Miller E, Saluk-Bijak J, Bijak M. The GPR17 receptor-a promising goal for therapy and a potential marker of the neurodegenerative process in multiple sclerosis. Int. J. Mol. Sci. 2020;21:1852.
Not in our library10.3390/ijms21051852
471.
Parravicini C, et al. Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis. PLoS ONE. 2020;15:e0231483.
Not in our library10.1371/journal.pone.0231483
472.
Lee DK, et al. Cloning and characterization of additional members of the G protein-coupled receptor family. Biochim. Biophys. Acta. 2000;1490:311-323.
Not in our library10.1016/s0167-4781(99)00241-9
473.
Mori F, et al. G protein-coupled receptor 26 immunoreactivity in intranuclear inclusions associated with polyglutamine and intranuclear inclusion body diseases. Neuropathology. 2016;36:50-55.
Not in our library10.1111/neup.12237
474.
Zhang LL, et al. GPR26-deficient mice display increased anxiety- and depression-like behaviors accompanied by reduced phosphorylated cyclic AMP responsive element-binding protein level in central amygdala. Neuroscience. 2011;196:203-214.
Not in our library10.1016/j.neuroscience.2011.08.069
475.
Mouhi S, Martin B, Owino S. Emerging roles for the orphan GPCRs, GPR37 and GPR37 L1, in stroke pathophysiology. Int. J. Mol. Sci. 2022;23:4028.
Not in our library10.3390/ijms23074028
476.
Morato X, et al. The Parkinson’s disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo. Sci. Rep. 2017;7:9452.
Not in our library10.1038/s41598-017-10147-x
477.
An J, et al. G protein-coupled receptor GPR37-like 1 regulates adult oligodendrocyte generation. Dev. Neurobiol. 2021;81:975-984.
Not in our library10.1002/dneu.22854
478.
Howland JG, Wang YT. Synaptic plasticity in learning and memory: stress effects in the hippocampus. Prog. Brain Res. 2008;169:145-158.
Not in our library10.1016/s0079-6123(07)00008-8
479.
Zinc Signal in Brain Diseases · 2017
No notice
480.
Davis CM, et al. GPR39 localization in the aging human brain and correlation of expression and polymorphism with vascular cognitive impairment. Alzheimers Dement. 2021;7:e12214.
Not in our library10.1002/trc2.12214
481.
Rychlik M, Mlyniec K. Zinc-mediated neurotransmission in Alzheimer’s disease: a potential role of the GPR39 in dementia. Curr. Neuropharmacol. 2020;18:2-13.
Not in our library10.2174/1570159x17666190704153807
482.
Khan MZ. A possible significant role of zinc and GPR39 zinc sensing receptor in Alzheimer disease and epilepsy. Biomed. Pharmacother. 2016;79:263-272.
Not in our library10.1016/j.biopha.2016.02.026
483.
Hershfinkel M, Moran A, Grossman N, Sekler I. A zinc-sensing receptor triggers the release of intracellular Ca2+ and regulates ion transport. Proc. Natl Acad. Sci. USA. 2001;98:11749-11754.
Not in our library10.1073/pnas.201193398
484.
Chorin E, et al. Upregulation of KCC2 activity by zinc-mediated neurotransmission via the mZnR/GPR39 receptor. J. Neurosci. 2011;31:12916-12926.
Not in our library10.1523/jneurosci.2205-11.2011
485.
Ganay T, et al. Regulation of neuronal pH by the metabotropic Zn(2+)-sensing Gq-coupled receptor, mZnR/GPR39. J. Neurochem. 2015;135:897-907.
Not in our library10.1111/jnc.13367
486.
Park J, et al. GPR40 agonist inhibits NLRP3 inflammasome activation via modulation of nuclear factor-kappaB and sarco/endoplasmic reticulum Ca(2+)-ATPase. Life Sci. 2021;287:120127.
Not in our library10.1016/j.lfs.2021.120127
487.
Engel DF, et al. Activation of GPR40 induces hypothalamic neurogenesis through p38- and BDNF-dependent mechanisms. Sci. Rep. 2020;10:11047.
Not in our library10.1038/s41598-020-68110-2
488.
Yang Y, et al. GPR40 modulates epileptic seizure and NMDA receptor function. Sci. Adv. 2018;4:eaau2357.
Not in our library10.1126/sciadv.aau2357
489.
Liu C, et al. GPR40 receptor agonist TAK-875 improves cognitive deficits and reduces beta-amyloid production in APPswe/PS1dE9 mice. Psychopharmacology. 2021;238:2133-2146.
Not in our library10.1007/s00213-021-05837-4
490.
Chen JJ, Gong YH, He L. Role of GPR40 in pathogenesis and treatment of Alzheimer’s disease and type 2 diabetic dementia. J. Drug. Target. 2019;27:347-354.
Not in our library10.1080/1061186x.2018.1491979
491.
Khan MZ, He L, Zhuang X. The emerging role of GPR50 receptor in brain. Biomed. Pharmacother. 2016;78:121-128.
Not in our library10.1016/j.biopha.2016.01.003
492.
Hamouda HO, et al. Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes. J. Pineal. Res. 2007;43:10-15.
Not in our library10.1111/j.1600-079x.2007.00437.x
493.
Ma YX, et al. G protein coupled receptor 50 promotes self-renewal and neuronal differentiation of embryonic neural progenitor cells through regulation of notch and wnt/beta-catenin signalings. Biochem. Biophys. Res. Commun. 2015;458:836-842.
Not in our library10.1016/j.bbrc.2015.02.040
494.
Grunewald E, Kinnell HL, Porteous DJ, Thomson PA. GPR50 interacts with neuronal NOGO-A and affects neurite outgrowth. Mol. Cell Neurosci. 2009;42:363-371.
Not in our library10.1016/j.mcn.2009.08.007
495.
Thomson PA, et al. Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol. Psychiatry. 2005;10:470-478.
Not in our library10.1038/sj.mp.4001593
496.
Levoye A, et al. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 2006;25:3012-3023.
Not in our library10.1038/sj.emboj.7601193
497.
Yao Y, et al. A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity. eLife. 2015;4:e05449.
Not in our library10.7554/elife.05449
498.
Komatsu H. Discovery of the first druggable GPR52 antagonist to treat Huntington’s disease. J. Med. Chem. 2021;64:938-940.
Not in our library10.1021/acs.jmedchem.0c02235
499.
Komatsu H, et al. Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders. PLoS ONE. 2014;9:e90134.
Not in our library10.1371/journal.pone.0090134
500.
Komatsu H. Novel therapeutic GPCRs for psychiatric disorders. Int. J. Mol. Sci. 2015;16:14109-14121.
Not in our library10.3390/ijms160614109
501.
Setoh M, et al. Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52. J. Med. Chem. 2014;57:5226-5237.
Not in our library10.1021/jm5002919
502.
Watkins LR, Orlandi C. Orphan G protein coupled receptors in affective disorders. Genes. 2020;11:694.
Not in our library10.3390/genes11060694
503.
Lin X, et al. Structural basis of ligand recognition and self-activation of orphan GPR52. Nature. 2020;579:152-157.
Not in our library10.1038/s41586-020-2019-0
504.
Pariani MJ, Spencer A, Graham JM, Rimoin DL. A 785kb deletion of 3p14.1p13, including the FOXP1 gene, associated with speech delay, contractures, hypertonia and blepharophimosis. Eur. J. Med. Genet. 2009;52:123-127.
Not in our library10.1016/j.ejmg.2009.03.012
505.
Chen Q, et al. SREB2/GPR85, a schizophrenia risk factor, negatively regulates hippocampal adult neurogenesis and neurogenesis-dependent learning and memory. Eur. J. Neurosci. 2012;36:2597-2608.
Not in our library10.1111/j.1460-9568.2012.08180.x
506.
Yuan T, et al. Phoenixin: a newly discovered peptide with multi-functions. Protein Pept. Lett. 2017;24:472-475.
Not in our library10.2174/0929866524666170207154417
507.
McIlwraith EK, Belsham DD. Phoenixin: uncovering its receptor, signaling and functions. Acta Pharmacol. Sin. 2018;39:774-778.
Not in our library10.1038/aps.2018.13
508.
Yang Y, et al. Phoenixin 20 promotes neuronal mitochondrial biogenesis via CREB-PGC-1alpha pathway. J. Mol. Histol. 2020;51:173-181.
Not in our library10.1007/s10735-020-09867-8
509.
Larco DO, et al. GnRH-(1-5) Inhibits TGF-beta signaling to regulate the migration of immortalized gonadotropin-releasing hormone neurons. Front. Endocrinol. 2018;9:45.
Not in our library10.3389/fendo.2018.00045
510.
Massart R, et al. Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. Eur. J. Neurosci. 2009;30:397-414.
Not in our library10.1111/j.1460-9568.2009.06842.x
511.
Lovinger DM. New twist on orphan receptor GPR88 function. Nat. Neurosci. 2012;15:1469-1470.
Not in our library10.1038/nn.3244
512.
Logue SF, et al. The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? Mol. Cell Neurosci. 2009;42:438-447.
Not in our library10.1016/j.mcn.2009.09.007
513.
Marley A, Choy RW, von Zastrow M. GPR88 reveals a discrete function of primary cilia as selective insulators of GPCR cross-talk. PLoS ONE. 2013;8:e70857.
Not in our library10.1371/journal.pone.0070857
514.
Conti B, et al. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol. Psychiatry. 2007;12:167-189.
Not in our library10.1038/sj.mp.4001897
515.
Befort K, et al. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Eur. J. Neurosci. 2008;27:2973-2984.
Not in our library10.1111/j.1460-9568.2008.06273.x
516.
Alkufri F, Shaag A, Abu-Libdeh B, Elpeleg O. Deleterious mutation in GPR88 is associated with chorea, speech delay, and learning disabilities. Neurol. Genet. 2016;2:e64.
Not in our library10.1212/nxg.0000000000000064
517.
Del Zompo M, et al. Association study in three different populations between the GPR88 gene and major psychoses. Mol. Genet. Genomic Med. 2014;2:152-159.
Not in our library10.1002/mgg3.54
518.
de Graaf C, et al. Extending the structural view of class B GPCRs. Trends Biochem. Sci. 2017;42:946-960.
Not in our library10.1016/j.tibs.2017.10.003
519.
Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci. 2009;34:303-310.
Not in our library10.1016/j.tibs.2009.02.004
520.
Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 2008;7:339-357.
Not in our library10.1038/nrd2518
521.
Pal K, Melcher K, Xu HE. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors. Acta Pharmacol. Sin. 2012;33:300-311.
Not in our library10.1038/aps.2011.170
522.
The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors · 2015
No notice
523.
Hoare SR. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov. Today. 2005;10:417-427.
Not in our library10.1016/s1359-6446(05)03370-2
524.
Liang YL, et al. Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature. 2018;561:492-497.
Not in our library10.1038/s41586-018-0535-y
525.
Liang YL, et al. Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature. 2017;546:118-123.
Not in our library10.1038/nature22327
526.
Ma S, et al. Molecular basis for hormone recognition and activation of corticotropin-releasing factor receptors. Mol. Cell. 2020;77:669-680 e664.
Not in our library10.1016/j.molcel.2020.01.013
527.
Krumm B, Roth BL. A structural understanding of Class B GPCR selectivity and activation revealed. Structure. 2020;28:277-279.
Not in our library10.1016/j.str.2020.02.004
528.
Edvinsson L, Grell AS, Warfvinge K. Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J. Mol. Neurosci. 2020;70:930-944.
Not in our library10.1007/s12031-020-01493-z
529.
Benemei S, Nicoletti P, Capone JA, Geppetti P. Pain pharmacology in migraine: focus on CGRP and CGRP receptors. Neurol. Sci. 2007;28:S89-S93.
Not in our library10.1007/s10072-007-0757-5
530.
Singh Y, et al. Calcitonin gene-related peptide (CGRP): a novel target for Alzheimer’s disease. CNS Neurosci. Ther. 2017;23:457-461.
Not in our library10.1111/cns.12696
531.
Fu W, et al. Role of microglial amylin receptors in mediating beta amyloid (Abeta)-induced inflammation. J. Neuroinflammation. 2017;14:199.
Not in our library10.1186/s12974-017-0972-9
532.
Dedic N, Chen A, Deussing JM. The CRF family of neuropeptides and their receptors– mediators of the central stress response. Curr. Mol. Pharmacol. 2018;11:4-31.
Not in our library10.2174/1874467210666170302104053
533.
Sex differences in chronic stress responses and Alzheimer's disease · 2018
Not checked
534.
Corticotropin-releasing factor receptor-1 modulates biomarkers of DNA oxidation in Alzheimer's disease mice. · 2017
Not checked
535.
Gai Z, et al. Effects of chronic noise on the corticotropin-releasing factor system in the rat hippocampus: relevance to Alzheimer’s disease-like tau hyperphosphorylation. Environ. Health Prev. Med. 2017;22:79.
Not in our library10.1186/s12199-017-0686-8
536.
Magalhaes AC, et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat. Neurosci. 2010;13:622-629.
Not in our library10.1038/nn.2529
537.
Skorzewska A, et al. Corticotropin releasing factor receptor 1 antagonist differentially inhibits freezing behavior and changes gamma-aminobutyric acidergic activity in the amygdala in low- and high-anxiety rats. J. Physiol. Pharmacol. 2017;68:35-46.
Not in our library
538.
Ishitobi Y, et al. Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population. Am. J. Med Genet. B Neuropsychiatr. Genet. 2012;159B:429-436.
Not in our library10.1002/ajmg.b.32046
539.
Liu Z, et al. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci. Lett. 2006;404:358-362.
Not in our library10.1016/j.neulet.2006.06.016
540.
Xiao Z, et al. Interaction between CRHR1 and BDNF genes increases the risk of recurrent major depressive disorder in Chinese population. PLoS ONE. 2011;6:e28733.
Not in our library10.1371/journal.pone.0028733
541.
Verma MK, Goel R, Krishnadas N, Nemmani KVS. Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders. Expert Opin. Ther. Targets. 2018;22:615-628.
Not in our library10.1080/14728222.2018.1487952
542.
Zhang ZQ, Holscher C. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models. Peptides. 2020;125:170184.
Not in our library10.1016/j.peptides.2019.170184
543.
Paratore S, et al. Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival. Cent. Nerv. Syst. Agents Med. Chem. 2011;11:210-222.
Not in our library10.2174/187152411798047771
544.
Kim DS, et al. A new treatment strategy for Parkinson’s disease through the gut-brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant. 2017;26:1560-1571.
Not in our library10.1177/0963689717721234
545.
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists · 2020
No notice
546.
Irwin N, et al. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J. Med. Chem. 2006;49:1047-1054.
Not in our library10.1021/jm0509997
547.
Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer’s disease. Recent Pat. CNS Drug Discov. 2010;5:109-117.
Not in our library10.2174/157488910791213130
548.
Zheng J, et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer’s disease. Mol. Metab. 2021;47:101180.
Not in our library10.1016/j.molmet.2021.101180
549.
Amato A, Mule F. Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration. Neural Regen. Res. 2019;14:1901-1902.
Not in our library10.4103/1673-5374.259612
550.
Duarte AI, et al. Liraglutide protects against brain amyloid-beta1-42 accumulation in female mice with early Alzheimer’s disease-like pathology by partially rescuing oxidative/nitrosative stress and inflammation. Int. J. Mol. Sci. 2020;21:1746.
Not in our library10.3390/ijms21051746
551.
Hansen HH, et al. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. J. Alzheimers Dis. 2015;46:877-888.
Not in our library10.3233/jad-143090
552.
Hamann J, et al. International union of basic and clinical pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharmacol. Rev. 2015;67:338-367.
Not in our library10.1124/pr.114.009647
553.
Ganesh RA, Venkataraman K, Sirdeshmukh R. GPR56: An adhesion GPCR involved in brain development, neurological disorders and cancer. Brain Res. 2020;1747:147055.
Not in our library10.1016/j.brainres.2020.147055
554.
Langenhan T, Piao X, Monk KR. Adhesion G protein-coupled receptors in nervous system development and disease. Nat. Rev. Neurosci. 2016;17:550-561.
Not in our library10.1038/nrn.2016.86
555.
Lala T, Hall RA. Adhesion G protein-coupled receptors: structure, signaling, physiology, and pathophysiology. Physiol. Rev. 2022;102:1587-1624.
Not in our library10.1152/physrev.00027.2021
556.
Promel S, Langenhan T, Arac D. Matching structure with function: the GAIN domain of adhesion-GPCR and PKD1-like proteins. Trends Pharmacol. Sci. 2013;34:470-478.
Not in our library10.1016/j.tips.2013.06.002
557.
Liebscher, I. et al. A guide to adhesion GPCR research. FEBS J. 289, 7610–7630 (2021).
Not in our library10.1111/febs.16258
558.
Barros-Alvarez X, et al. The tethered peptide activation mechanism of adhesion GPCRs. Nature. 2022;604:757-762.
Not in our library10.1038/s41586-022-04575-7
559.
Ping YQ, et al. Structures of the glucocorticoid-bound adhesion receptor GPR97-Go complex. Nature. 2021;589:620-626.
Not in our library10.1038/s41586-020-03083-w
560.
Structural basis of tethered agonism of the adhesion GPCRs ADGRD1 and ADGRF1 · 2022
No notice
561.
Folts CJ, Giera S, Li T, Piao X. Adhesion G protein-coupled receptors as drug targets for neurological diseases. Trends Pharmacol. Sci. 2019;40:278-293.
Not in our library10.1016/j.tips.2019.02.003
562.
Magalhaes AC, Dunn H, Ferguson SS. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br. J. Pharmacol. 2012;165:1717-1736.
Not in our library10.1111/j.1476-5381.2011.01552.x
563.
Zhu D, et al. BAI1 regulates spatial learning and synaptic plasticity in the hippocampus. J. Clin. Investig. 2015;125:1497-1508.
Not in our library10.1172/jci74603
564.
Stephenson JR, et al. Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. J. Biol. Chem. 2013;288:22248-22256.
Not in our library10.1074/jbc.m113.489757
565.
Tu YK, Duman JG, Tolias KF. The adhesion-GPCR BAI1 promotes excitatory synaptogenesis by coordinating bidirectional trans-synaptic signaling. J. Neurosci. 2018;38:8388-8406.
Not in our library10.1523/jneurosci.3461-17.2018
566.
Choi JS, Bae WY, Nam S, Jeong JW. New targets for Parkinson’s disease: adhesion G protein-coupled receptor B1 is downregulated by AMP-activated protein kinase activation. OMICS. 2018;22:493-501.
Not in our library10.1089/omi.2018.0047
567.
Scuderi C, et al. Biallelic intragenic duplication in ADGRB3 (BAI3) gene associated with intellectual disability, cerebellar atrophy, and behavioral disorder. Eur. J. Hum. Genet. 2019;27:594-602.
Not in our library10.1038/s41431-018-0321-1
568.
Duman JG, Tu YK, Tolias KF. Emerging roles of BAI adhesion-GPCRs in synapse development and plasticity. Neural Plast. 2016;2016:8301737.
Not in our library10.1155/2016/8301737
569.
DeRosse P, et al. The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. Schizophr. Bull. 2008;34:1047-1053.
Not in our library10.1093/schbul/sbn076
570.
A Survey of Genomic Studies Supports Association of Circadian Clock Genes with Bipolar Disorder Spectrum Illnesses and Lithium Response · 2012
No notice
571.
McNeill RV, et al. Expression of the adult ADHD-associated gene ADGRL3 is dysregulated by risk variants and environmental risk factors. World J. Biol. Psychiatry. 2021;22:335-349.
Not in our library10.1080/15622975.2020.1809014
572.
Mortimer N, et al. Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene Adgrl3: evidence for dopamine transporter dysregulation. Neuropharmacology. 2019;156:107557.
Not in our library10.1016/j.neuropharm.2019.02.039
573.
Effects of low birth weight, maternal smoking in pregnancy and social class on the phenotypic manifestation of Attention Deficit Hyperactivity Disorder and associated antisocial behaviour: investigation in a clinical sample · 2007
Not checked
574.
Mathiasen S, et al. G12/13 is activated by acute tethered agonist exposure in the adhesion GPCR ADGRL3. Nat. Chem. Biol. 2020;16:1343-1350.
Not in our library10.1038/s41589-020-0617-7
575.
Wallis D, et al. Initial characterization of mice null for Lphn3, a gene implicated in ADHD and addiction. Brain Res. 2012;1463:85-92.
Not in our library10.1016/j.brainres.2012.04.053
576.
Gardenal E, et al. Increased calcium-sensing receptor immunoreactivity in the hippocampus of a triple transgenic mouse model of Alzheimer’s disease. Front. Neurosci. 2017;11:81.
Not in our library10.3389/fnins.2017.00081
577.
CALCIUM-SENSING RECEPTORS OF HUMAN NEURAL CELLS PLAY CRUCIAL ROLES IN ALZHEIMER’S DISEASE · 2016
Not checked
578.
Feng C, et al. Calcium-sensing receptor mediates beta-amyloid-induced synaptic formation impairment and cognitive deficits via regulation of cytosolic phospholipase A2/prostaglandin E2 metabolic pathway. Front. Aging Neurosci. 2020;12:144.
Not in our library10.3389/fnagi.2020.00144
579.
Schulte G. International union of basic and clinical pharmacology. LXXX. The class Frizzled receptors. Pharmacol. Rev. 2010;62:632-667.
Not in our library10.1124/pr.110.002931
580.
Xu L, et al. Cryo-EM structure of constitutively active human Frizzled 7 in complex with heterotrimeric Gs. Cell Res. 2021;31:1311-1314.
Not in our library10.1038/s41422-021-00525-6
581.
Umbhauer M, et al. The C-terminal cytoplasmic Lys-thr-X-X-X-Trp motif in frizzled receptors mediates Wnt/beta-catenin signalling. EMBO J. 2000;19:4944-4954.
Not in our library10.1093/emboj/19.18.4944
582.
Schulte G, Kozielewicz P. Structural insight into Class F receptors—what have we learnt regarding agonist-induced activation? Basic Clin. Pharmacol. Toxicol. 2020;126:17-24.
Not in our library10.1111/bcpt.13235
583.
Zhang X, et al. Dishevelled promotes axon differentiation by regulating atypical protein kinase C. Nat. Cell Biol. 2007;9:743-754.
Not in our library10.1038/ncb1603
584.
He CW, Liao CP, Pan CL. Wnt signalling in the development of axon, dendrites and synapses. Open Biol. 2018;8:180116.
Not in our library10.1098/rsob.180116
585.
Zeng CM, Chen Z, Fu L. Frizzled receptors as potential therapeutic targets in human cancers. Int. J. Mol. Sci. 2018;19:1543.
Not in our library10.3390/ijms19051543
586.
Palomer E, et al. Epigenetic repression of Wnt receptors in AD: a role for Sirtuin2-induced H4K16ac deacetylation of Frizzled1 and Frizzled7 promoters. Mol. Psychiatry. 2022;27:3024-3033.
Not in our library10.1038/s41380-022-01492-z
587.
Yang S, et al. Crystal structure of the Frizzled 4 receptor in a ligand-free state. Nature. 2018;560:666-670.
Not in our library10.1038/s41586-018-0447-x
588.
Turku A, et al. Residue 6.43 defines receptor function in class F GPCRs. Nat. Commun. 2021;12:3919.
Not in our library10.1038/s41467-021-24004-z
589.
Bhat RA, Stauffer B, Komm BS, Bodine PV. Structure-function analysis of secreted frizzled-related protein-1 for its Wnt antagonist function. J. Cell Biochem. 2007;102:1519-1528.
Not in our library10.1002/jcb.21372
590.
de Lau WB, Snel B, Clevers HC. The R-spondin protein family. Genome Biol. 2012;13:242.
Not in our library10.1186/gb-2012-13-3-242
591.
A Wnt1 regulated Frizzled-1/β-Cateninsignaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection · 2011
No notice
592.
Gonzalez P, et al. Frizzled 1 and Wnt1 as new potential therapeutic targets in the traumatically injured spinal cord. Cell Mol. Life Sci. 2020;77:4631-4662.
Not in our library10.1007/s00018-019-03427-4
593.
Jeong SH, et al. Investigation of genetic association between human Frizzled homolog 3 gene (FZD3) and schizophrenia: results in a Korean population and evidence from meta-analysis. Psychiatry Res. 2006;143:1-11.
Not in our library10.1016/j.psychres.2005.07.026
594.
Kishimoto M, et al. The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population. Behav. Brain Funct. 2008;4:37.
Not in our library10.1186/1744-9081-4-37
595.
Jiang X, et al. The mechanism of the WNT5A and FZD4 receptor mediated WNT/beta-catenin pathway in the degeneration of ALS spinal cord motor neurons. Biochem. Biophys. Res. Commun. 2022;609:23-30.
Not in our library10.1016/j.bbrc.2022.03.126
596.
Calandria JM, et al. cRel and Wnt5a/Frizzled 5 receptor-mediated inflammatory regulation reveal novel neuroprotectin D1 targets for neuroprotection. Cell Mol. Neurobiol. 2023;43:1077-1096.
Not in our library10.1007/s10571-022-01231-6
597.
De Marco P, et al. FZD6 is a novel gene for human neural tube defects. Hum. Mutat. 2012;33:384-390.
Not in our library10.1002/humu.21643
598.
Zhou J, et al. Atypical deletion of Williams-Beuren syndrome reveals the mechanism of neurodevelopmental disorders. BMC Med. Genomics. 2022;15:79.
Not in our library10.1186/s12920-022-01227-7
599.
Hot B, et al. FZD10-Galpha13 signalling axis points to a role of FZD10 in CNS angiogenesis. Cell. Signal. 2017;32:93-103.
Not in our library10.1016/j.cellsig.2017.01.023
600.
Traiffort E, Angot E, Ruat M. Sonic Hedgehog signaling in the mammalian brain. J. Neurochem. 2010;113:576-590.
Not in our library10.1111/j.1471-4159.2010.06642.x
601.
Kruse AC, et al. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat. Rev. Drug Discov. 2014;13:549-560.
Not in our library10.1038/nrd4295
602.
Liu H, et al. Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. Proc. Natl Acad. Sci. USA. 2018;115:12046-12050.
Not in our library10.1073/pnas.1813988115
603.
Krystal JH, State MW. Psychiatric disorders: diagnosis to therapy. Cell. 2014;157:201-214.
Not in our library10.1016/j.cell.2014.02.042
604.
Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr. Res. 2011;128:66-75.
Not in our library10.1016/j.schres.2011.02.021
605.
Hayslett RL, Tizabi Y. Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette’s syndrome. Pharmacol. Biochem. Behav. 2005;81:879-886.
Not in our library10.1016/j.pbb.2005.06.010
606.
Nisijima K, et al. Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry. 2004;37:57-62.
Not in our library10.1055/s-2004-815526
607.
Mancini M, et al. Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. Neuropharmacology. 2016;101:341-350.
Not in our library10.1016/j.neuropharm.2015.10.015
608.
Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
Not in our library10.1016/s0024-3205(00)00911-5
609.
Bymaster FP, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87-96.
Not in our library10.1016/0893-133x(94)00129-n
610.
Krogsgaard-Larsen N, Jensen AA, Kehler J. Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands. Booing. Med. Chem. Lett. 2010;20:5431-5433.
Not in our library10.1016/j.bmcl.2010.07.105
611.
Rowley M, Bristow LJ, Hutson PH. Current and novel approaches to the drug treatment of schizophrenia. J. Med. Chem. 2001;44:477-501.
Not in our library10.1021/jm0002432
612.
Hertel P. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006;60:543-552.
Not in our library10.1002/syn.20322
613.
Hrib, N. J. et al. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. J. Med. Chem.39, 4044–4057 (1996).
Not in our library10.1021/jm960268u
614.
Hutchison KE, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31:1310-1317.
Not in our library10.1038/sj.npp.1300917
615.
Campiani G, et al. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. J. Med. Chem. 2005;48:1705-1708.
Not in our library10.1021/jm049629t
616.
Kongsamut S, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur. J. Pharmacol. 1996;317:417-423.
Not in our library10.1016/s0014-2999(96)00840-0
617.
Pettersson, F. et al. Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J. Med. Chem.53, 2510–2520 (2010).
Not in our library10.1021/jm901689v
618.
Gao M, Shi Z, Wang M, Zheng QH. [11C]olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand. Bioorg. Med. Chem. Lett. 2013;23:1953-1956.
Not in our library10.1016/j.bmcl.2013.02.045
619.
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry. 2008;13:27-35.
Not in our library10.1038/sj.mp.4002066
620.
Sunahara RK, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991;350:614-619.
Not in our library10.1038/350614a0
621.
Pearlstein R, Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J. Med. Chem. 2003;46:2017-2022.
Not in our library10.1021/jm0205651
622.
Cahir M, King DJ. Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur. Neuropsychopharmacol. 2005;15:231-234.
Not in our library10.1016/j.euroneuro.2004.10.002
623.
Kroeze WK, et al. HI-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519-526.
Not in our library10.1038/sj.npp.1300027
624.
Sultan MA, Courtney DB. Adjunctive trazodone and depression outcome in adolescents treated with serotonin re-uptake inhibitors. J. Canad. Acad. Child Adolesc. Psychiatry. 2017;26:233-240.
Not in our library
625.
Balsara JJ, et al. Effects of the antidepressant trazodone, a 5-HT2A/2C receptor antagonist, on dopamine-dependent behaviors in rats. Psychopharmacology. 2005;179:597-605.
Not in our library10.1007/s00213-004-2095-0
626.
LeWitt PA. Subcutaneously administered apomorphine—pharmacokinetics and metabolism. Neurology. 2004;62:S8-S11.
Not in our library10.1212/wnl.62.6_suppl_4.s8
627.
Succu S, et al. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: involvement of central oxytocin. Neuropharmacology. 2007;52:1034-1043.
Not in our library10.1016/j.neuropharm.2006.10.019
628.
Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 2006;5:821-834.
Not in our library10.1038/nrd2132
629.
Chen X, Ji ZL, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res. 2002;30:412-415.
Not in our library10.1093/nar/30.1.412
630.
Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat. Rev. Drug Discov. 2006;5:993-996.
Not in our library10.1038/nrd2199
631.
de Leeuw van Weenen JE, et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem. Pharmacol. 2010;79:1827-1836.
Not in our library10.1016/j.bcp.2010.01.029
632.
Cussac D, et al. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur. J. Pharmacol. 2008;594:32-38.
Not in our library10.1016/j.ejphar.2008.07.040
633.
Knight JA, et al. Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol. Pharmacol. 2009;75:374-380.
Not in our library10.1124/mol.108.052084
634.
Davis MP. Recent advances in the treatment of pain. F1000 Med. Rep. 2010;2:63.
Not in our library10.3410/m2-63
635.
Du L, Li M. Modeling the interactions between alpha(1)-adrenergic receptors and their antagonists. Curr. Comput. Aided Drug Des. 2010;6:165-178.
Not in our library10.2174/157340910791760082
636.
Mukai M, et al. Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J. Clin. Pharmacol. 2018;58:193-201.
Not in our library10.1002/jcph.1003
637.
Dupre KB, Eskow KL, Negron G, Bishop C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 2007;1158:135-143.
Not in our library10.1016/j.brainres.2007.05.005
638.
Kovoor A, et al. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J. Neurosci. 2005;25:2157-2165.
Not in our library10.1523/jneurosci.2840-04.2005
639.
Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin. Pharmacokinet. 2002;41:261-309.
Not in our library10.2165/00003088-200241040-00003
640.
Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin. Investig. Drugs. 2008;17:1115-1125.
Not in our library10.1517/13543784.17.7.1115
641.
Perachon S, Schwartz JC, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur. J. Pharmacol. 1999;366:293-300.
Not in our library10.1016/s0014-2999(98)00896-6
642.
Gornemann T, et al. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors. J. Pharmacol. Exp. Ther. 2008;324:1136-1145.
Not in our library10.1124/jpet.107.133165
643.
Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease-it was meant 2B. Pharmacol. Ther. 2011;132:146-157.
Not in our library10.1016/j.pharmthera.2011.03.008
644.
Gilliland SL, Alper RH. Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPgammaS binding assays. Naunyn Schmiedebergs Arch. Pharmacol. 2000;361:498-504.
Not in our library10.1007/s002100000224
645.
Lam YWF. Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000;20:17S-25S.
Not in our library10.1592/phco.20.2.17s.34627
646.
Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology. 2009;34:651-661.
Not in our library10.1038/npp.2008.114
647.
Piercey MF. Pharmacology of pramipexole, a dopamine D-3-preferring agonist useful in treating Parkinson’s disease. Clin. Neuropharmacol. 1998;21:141-151.
Not in our library
648.
Wood MD, et al. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol. Disord. Drug Targets. 2006;5:445-452.
Not in our library10.2174/187152706777950693
649.
Moallem N, Ray LA. Quetiapine improves response inhibition in alcohol dependent patients: a placebo-controlled pilot study. Pharmacol. Biochem. Behav. 2012;100:490-493.
Not in our library10.1016/j.pbb.2011.10.012
650.
Uys MM, Shahid M, Harvey BH. Therapeutic potential of selectively targeting the alpha(2C)-adrenoceptor in cognition, depression, and schizophrenia-new developments and future perspective. Front. Psychiatry. 2017;8:144.
Not in our library10.3389/fpsyt.2017.00144
651.
Vehof J, et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology. 2011;216:257-265.
Not in our library10.1007/s00213-011-2211-x
652.
Shill HA, Stacy M. Update on ropinirole in the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat. 2009;5:33-36.
Not in our library
653.
Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch. Pharmacol. 2009;379:73-86.
Not in our library10.1007/s00210-008-0341-4
654.
The gamma-aminobutyric acid type B (GABA<sub>B</sub>) receptor agonist baclofen inhibits morphine sensitization by decreasing the dopamine level in rat nucleus accumbens · 2012
Not checked
655.
de Beaurepaire R. A review of the potential mechanisms of action of baclofen in alcohol use disorder. Front. Psychiatry. 2018;9:506.
Not in our library10.3389/fpsyt.2018.00506
656.
Yang KH, et al. The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J. Pharmacol. Exp. Ther. 2010;333:547-554.
Not in our library10.1124/jpet.109.162594
657.
Bih CI, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699-730.
Not in our library10.1007/s13311-015-0377-3
658.
Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 2015;172:4790-4805.
Not in our library10.1111/bph.13250
659.
Chen CR, et al. Modafinil exerts a dose-dependent antiepileptic effect mediated by adrenergic alpha(1) and histaminergic H-1 receptors in mice. Neuropharmacology. 2007;53:534-541.
Not in our library10.1016/j.neuropharm.2007.06.017
660.
Cohen JA, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18:1021-1033.
Not in our library10.1016/s1474-4422(19)30238-8
661.
O’Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J. Neuroinflammation. 2016;13:31.
Not in our library10.1186/s12974-016-0494-x
662.
Zu Heringdorf DM, Ihlefeld K, Pfeilschifter J. Pharmacology of the sphingosine-1-phosphate signalling system. Handb. Exp. Pharmacol. 2013;215:239-253.
Not in our library10.1007/978-3-7091-1368-4_13
663.
David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin. Pharmacokinet. 2012;51:15-28.
Not in our library10.2165/11596550-000000000-00000
664.
Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry. 2002;47:27-38.
Not in our library10.1177/070674370204700106
665.
Bisson WH, et al. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc. Natl Acad. Sci. USA. 2007;104:11927-11932.
Not in our library10.1073/pnas.0609752104
666.
Tuppurainen H, et al. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin. Neurosci. 2009;63:529-537.
Not in our library10.1111/j.1440-1819.2009.01982.x
667.
Kulagowski JJ, et al. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J. Med. Chem. 1996;39:1941-1942.
Not in our library10.1021/jm9600712
668.
Leopoldo, M. et al. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. J. Med. Chem.45, 5727–5735 (2002).
Not in our library10.1021/jm020952a
669.
Zhang X, et al. trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D(2)/D(4) receptor antagonists as potential antipsychotic agents. J. Med. Chem. 2000;43:3923-3932.
Not in our library10.1021/jm990562x
670.
Pandey DK, et al. A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol. Biochem. Behav. 2010;94:363-373.
Not in our library10.1016/j.pbb.2009.09.018
671.
Nojimoto FD, et al. The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha(1B)-adrenoceptors. Neuropharmacology. 2010;59:49-57.
Not in our library10.1016/j.neuropharm.2010.03.015
672.
Cottingham C, Percival S, Birky T, Wang Q. Tricyclic antidepressants exhibit variable pharmacological profiles at the alpha(2A) adrenergic receptor. Biochem. Biophys. Res. Commun. 2014;451:461-466.
Not in our library10.1016/j.bbrc.2014.08.024
673.
Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M. Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur. J. Pharmacol. 2004;485:193-196.
Not in our library10.1016/j.ejphar.2003.11.047
674.
Benbouzid M, et al. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol. Psychiatry. 2008;63:633-636.
Not in our library10.1016/j.biopsych.2007.06.016
675.
Onali P, Dedoni S, Olianas MC. Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J. Pharmacol. Exp. Ther. 2010;332:255-265.
Not in our library10.1124/jpet.109.159939
676.
Connelly WM, et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br. J. Pharmacol. 2009;157:55-63.
Not in our library10.1111/j.1476-5381.2009.00227.x
677.
Nguyen T, et al. Discovery of a novel member of the histamine receptor family. Mol. Pharmacol. 2001;59:427-433.
Not in our library10.1124/mol.59.3.427
678.
Di Matteo V, De Blasi A, Di Giulio C, Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends. Pharmacol. Sci. 2001;22:229-232.
Not in our library10.1016/s0165-6147(00)01688-6
679.
Liu J, Reid AR, Sawynok J. Spinal serotonin 5-HT7 and adenosine A1 receptors, as well as peripheral adenosine A1 receptors, are involved in antinociception by systemically administered amitriptyline. Eur. J. Pharmacol. 2013;698:213-219.
Not in our library10.1016/j.ejphar.2012.10.042
680.
Lucchelli A, et al. The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 2000;362:284-289.
Not in our library10.1007/s002100000295
681.
Pithadia AB, Jain SM. 5-Hydroxytryptamine receptor subtypes and their modulators with therapeutic potentials. J. Clin. Med. Res. 2009;1:72-80.
Not in our library10.4021/jocmr2009.05.1237
682.
Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin. Investig. Drugs. 2007;16:771-775.
Not in our library10.1517/13543784.16.6.771
683.
Cosi C, et al. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005;1043:32-41.
Not in our library10.1016/j.brainres.2005.02.072
684.
Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 2009;23:65-73.
Not in our library10.1177/0269881107082944
685.
Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21:123-127.
Not in our library10.1017/s1092852916000043
686.
McCormack PL. Cariprazine: first global approval. Drugs. 2015;75:2035-2043.
Not in our library10.1007/s40265-015-0494-7
687.
Davies MA, et al. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacology. 2005;178:451-460.
Not in our library10.1007/s00213-004-2017-1
688.
Wu SN, et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol. Sin. 2006;27:966-970.
Not in our library10.1111/j.1745-7254.2006.00355.x
689.
Vasudevan SR, Moore JB, Schymura Y, Churchill GC. Shape-based reprofiling of FDA-approved drugs for the H(1) histamine receptor. J. Med. Chem. 2012;55:7054-7060.
Not in our library10.1021/jm300671m
690.
von Coburg Y, et al. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg. Med. Chem. Lett. 2009;19:538-542.
Not in our library10.1016/j.bmcl.2008.09.012
691.
Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the 5 cloned human muscarinic cholinergic receptors expressed in chinese-hamster ovary cells. J. Pharmacol. Exp. Ther. 1992;260:576-580.
Not in our library
692.
Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 1994;114:559-565.
Not in our library10.1007/bf02244985
693.
Wander TJ, Nelson A, Okazaki H, Richelson E. Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur. J. Pharmacol. 1987;143:279-282.
Not in our library10.1016/0014-2999(87)90544-9
694.
Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005;48:6523-6543.
Not in our library10.1021/jm058225d
695.
Fernandez J, et al. Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J. Med. Chem. 2005;48:1709-1712.
Not in our library10.1021/jm049632c
696.
Navailles S, De Deurwaerdere P, Spampinato U. Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol. Psychiatry. 2006;59:568-575.
Not in our library10.1016/j.biopsych.2005.07.035
697.
Glennon RA, et al. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J. Med. Chem. 2000;43:1011-1018.
Not in our library10.1021/jm990550b
698.
Taverne T, et al. Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics. J. Med. Chem. 1998;41:2010-2018.
Not in our library10.1021/jm970298c
699.
Vanover, K. E. et al. Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist. J. Pharmacol. Exp. Ther.310, 943–951 (2004).
Not in our library10.1124/jpet.104.066688
700.
Schotte A, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57-73.
Not in our library10.1007/bf02245606
701.
Hagino Y, Watanabe M. Effects of clozapine on the efflux of serotonin and dopamine in the rat brain: the role of 5-HT1A receptors. Can. J. Physiol. Pharmacol. 2002;80:1158-1166.
Not in our library10.1139/y02-150
702.
Zhao AL, et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int. J. Neurosci. 2005;115:1539-1547.
Not in our library10.1080/00207450590957863
703.
Heiser P, et al. Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004;28:297-302.
Not in our library10.1016/j.pnpbp.2003.10.008
704.
Haubmann C, Hubner H, Gmeiner P. 2,2-Dicyanovinyl as a nonaromatic aryl bioisostere: synthesis, binding experiments and SAR studies of highly selective dopamine D4 receptor ligands. Bioorg. Med. Chem. Lett. 1999;9:1969-1972.
Not in our library10.1016/s0960-894x(99)00302-9
705.
Takano A, et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006;30:75-81.
Not in our library10.1016/j.pnpbp.2005.06.011
706.
Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J. Med. Chem. 2003;46:2795-2812.
Not in our library10.1021/jm030030n
707.
Menon DV, et al. Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. J. Am. Coll. Cardiol. 2007;50:626-633.
Not in our library10.1016/j.jacc.2007.03.060
708.
Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904-914.
Not in our library10.1016/s0893-133x(01)00285-8
709.
Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev. Clin. Pharmacol. 2013;6:61-91.
Not in our library10.1586/ecp.12.70
710.
Roth BL, Lopez E, Patel S, Kroeze WK. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist. 2000;6:252-262.
Not in our library10.1177/107385840000600408
711.
Liao Y, et al. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation. J. Med. Chem. 1999;42:2235-2244.
Not in our library10.1021/jm991005d
712.
Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 2000;295:226-232.
Not in our library
713.
Hjerde E, Dahl SG, Sylte I. Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. Eur. J. Med. Chem. 2005;40:185-194.
Not in our library10.1016/j.ejmech.2004.10.010
714.
Phillips ST, et al. Binding of 5H-dibenzo [a,d] cycloheptene and dibenz [b,f] oxepin analogs of clozapine to dopamine and serotonin receptors. J. Med. Chem. 1995;38:708-714.
Not in our library10.1021/jm00004a016
715.
Li Z, Ichikawa J, Meltzer HY. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology. 2003;167:315-323.
Not in our library10.1007/s00213-003-1418-x
716.
Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry. 1998;3:123-134.
Not in our library10.1038/sj.mp.4000336
717.
Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert. Opin. Pharmacother. 2012;13:1911-1922.
Not in our library10.1517/14656566.2012.712114
718.
George M, et al. Newer antipsychotics and upcoming molecules for schizophrenia. Eur. J. Clin. Pharmacol. 2013;69:1497-1509.
Not in our library10.1007/s00228-013-1498-4
719.
Green B, Pettit T, Faith L, Seaton K. Focus on levomepromazine. Curr. Med. Res. Opin. 2004;20:1877-1881.
Not in our library10.1185/030079904x12708
720.
Teitler M, et al. Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology. 2010;212:687-697.
Not in our library10.1007/s00213-010-2001-x
721.
Leysen JE, Janssen PMF, Megens AAHP, Schotte A. Risperidone—a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacological activity. J. Clin. Psychiat. 1994;55:5-12.
Not in our library
722.
Cicek E, Cicek IE, Uguz F. Bilateral pretibial edema associated with paliperidone palmitate long-acting injectable: a case report. Clin. Psychopharmacol. Neurosci. 2017;15:184-186.
Not in our library10.9758/cpn.2017.15.2.184
723.
Narita M, et al. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur. J. Pharmacol. 2008;600:105-109.
Not in our library10.1016/j.ejphar.2008.10.030
724.
Strange PG. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 2008;29:314-321.
Not in our library10.1016/j.tips.2008.03.009
725.
Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009;6:78-85.
Not in our library10.1016/j.nurt.2008.10.020
726.
Leung JY, et al. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol. Ther. 2012;135:113-122.
Not in our library10.1016/j.pharmthera.2012.04.003
727.
Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs. R&D. 2015;15:163-174.
Not in our library10.1007/s40268-015-0092-x
728.
Cincotta SL, Rodefer JS. Emerging role of sertindole in the management of schizophrenia. Neuropsychiatr. Dis. Treat. 2010;6:429-441.
Not in our library10.2147/ndt.s7602
729.
Mork A, Witten LM, Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology. 2009;206:39-49.
Not in our library10.1007/s00213-009-1578-4
730.
Lindstrom E, Levander S. Sertindole: efficacy and safety in schizophrenia. Expert. Opin. Pharmacother. 2006;7:1825-1834.
Not in our library10.1517/14656566.7.13.1825
731.
Cavallotti C, Nuti F, Bruzzone P, Mancone M. Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin. Exp. Pharmacol. Physiol. 2002;29:412-418.
Not in our library10.1046/j.1440-1681.2002.03677.x
732.
Lipina TV, Vishnivetskaia GB. [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. 2009;59:482-487.
Not in our library
733.
Ciszowski K, Szpak D, Wilimowska J. [Toxicity of sulpiride]. Przegl. Lek. 2010;67:606-609.
Not in our library
734.
Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses. 2010;4:56-73.
Not in our library10.3371/csrp.4.1.5
735.
Bymaster FP, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003;27:1125-1143.
Not in our library10.1016/j.pnpbp.2003.09.008
736.
Ablordeppey, S. Y. et al. Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg. Med. Chem.16, 7291–7301 (2008).
Not in our library10.1016/j.bmc.2008.06.030
737.
Rollema H, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry. 2000;48:229-237.
Not in our library10.1016/s0006-3223(00)00850-7
738.
Graham JM, et al. 1-Aminoindanes as novel motif with potential atypical antipsychotic properties. Bioorg. Med. Chem. Lett. 2008;18:489-493.
Not in our library10.1016/j.bmcl.2007.11.106
739.
Khalifa AE. Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol. Biochem. Behav. 2003;75:755-762.
Not in our library10.1016/s0091-3057(03)00153-9
740.
Lublin H, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur. Neuropsychopharmacol. 1991;1:541-548.
Not in our library10.1016/0924-977x(91)90008-i
741.
Horacek J, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389-409.
Not in our library10.2165/00023210-200620050-00004
742.
Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry. 2002;159:180-190.
Not in our library10.1176/appi.ajp.159.2.180
743.
Rosenzweig P, et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum. Psychopharmacol. 2002;17:1-13.
Not in our library10.1002/hup.320
744.
Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int. J. Neurosci. 2004;114:593-611.
Not in our library10.1080/00207450490430552
745.
Abbas AI, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205:119-128.
Not in our library10.1007/s00213-009-1521-8
746.
Rehni AK, Singh TG, Chand P. Amisulpride-induced seizurogenic effect: a potential role of opioid receptor-linked transduction systems. Basic Clin. Pharmacol. Toxicol. 2011;108:310-317.
Not in our library10.1111/j.1742-7843.2010.00655.x
747.
Weizman T, et al. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur. J. Pharmacol. 2003;478:155-159.
Not in our library10.1016/j.ejphar.2003.08.049
748.
Xiberas X, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J. Clin. Psychopharmacol. 2001;21:207-214.
Not in our library10.1097/00004714-200104000-00013
749.
Burstein ES, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 2005;315:1278-1287.
Not in our library10.1124/jpet.105.092155
750.
Lim HD, et al. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J. Pharmacol. Exp. Ther. 2005;314:1310-1321.
Not in our library10.1124/jpet.105.087965
751.
Glusa E, Pertz HH. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br. J. Pharmacol. 2000;130:692-698.
Not in our library10.1038/sj.bjp.0703341
752.
Nasu R, et al. Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm. Drug Dispos. 2000;21:129-138.
Not in our library10.1002/1099-081x(200005)21:4<129::aid-bdd224>3.0.co;2-f
753.
Miller GM, et al. Primate trace amine receptor 1 modulation by the dopamine transporter. J. Pharmacol. Exp. Ther. 2005;313:983-994.
Not in our library10.1124/jpet.105.084459
754.
Xie Z, Miller GM. Trace amine-associated receptor 1 as a monoaminergic modulator in brain. Biochem. Pharmacol. 2009;78:1095-1104.
Not in our library10.1016/j.bcp.2009.05.031
755.
Xie Z, Miller GM. Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J. Pharmacol. Exp. Ther. 2007;321:128-136.
Not in our library10.1124/jpet.106.117382
756.
Vallender EJ, Xie Z, Westmoreland SV, Miller GM. Functional evolution of the trace amine associated receptors in mammals and the loss of TAAR1 in dogs. BMC Evol. Biol. 2010;10:51.
Not in our library10.1186/1471-2148-10-51
757.
Siemian JN, Zhang Y, Li JX. Trace amine-associated receptor 1 agonists RO5263397 and RO5166017 attenuate quinpirole-induced yawning but not hypothermia in rats. Behav. Pharmacol. 2017;28:590-593.
Not in our library10.1097/fbp.0000000000000330
758.
Revel FG, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl Acad. Sci. USA. 2011;108:8485-8490.
Not in our library10.1073/pnas.1103029108
759.
Luptak M, et al. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J. Psychiatry. 2021;11:277-296.
Not in our library10.5498/wjp.v11.i7.277
760.
Wolinsky TD, et al. The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007;6:628-639.
Not in our library10.1111/j.1601-183x.2006.00292.x
761.
Boido A, Boido CC, Sparatore F. Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes. II Farmaco. 2001;56:263-275.
Not in our library10.1016/s0014-827x(01)01033-3
762.
Malt EA, et al. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J. Affect. Disord. 2003;75:77-82.
Not in our library10.1016/s0165-0327(02)00025-3
763.
Osei-Owusu P, Scrogin KE. Buspirone raises blood pressure through activation of sympathetic nervous system and by direct activation of alpha1-adrenergic receptors after severe hemorrhage. J. Pharmacol. Exp. Ther. 2004;309:1132-1140.
Not in our library10.1124/jpet.103.064626
764.
Howland RH. Buspirone: Back to the Future. J. Psychosoc. Nurs. Ment. Health Serv. 2015;53:21-24.
Not in our library10.3928/02793695-20151022-01
765.
Pache DM, Fernandez-Perez S, Sewell RD. Buspirone differentially modifies short-term memory function in a combined delayed matching/non-matching to position task. Eur. J. Pharmacol. 2003;477:205-211.
Not in our library10.1016/j.ejphar.2003.08.029
766.
Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin. Drug Metab. Toxicol. 2014;10:121-128.
Not in our library10.1517/17425255.2014.863873
767.
Bartlett D. Drug-induced serotonin syndrome. Crit. Care Nurse. 2017;37:49-54.
Not in our library10.4037/ccn2017169
768.
Fisar Z. Drugs related to monoamine oxidase activity. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2016;69:112-124.
Not in our library10.1016/j.pnpbp.2016.02.012
769.
Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. 2005;20:131-137.
Not in our library10.1097/00004850-200505000-00002
770.
Baldwin DS, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2005;19:567-596.
Not in our library10.1177/0269881105059253
771.
Nevels RM, Gontkovsky ST, Williams BE. Paroxetine-the antidepressant from hell? probably not, but caution required. Psychopharmacol. Bull. 2016;46:77-104.
Not in our library10.64719/pb.4345
772.
Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis · 2019
Not checked
773.
Altamura AC, et al. Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin. Drug Metab. Toxicol. 2013;9:423-440.
Not in our library10.1517/17425255.2013.759209
774.
Spahr L, et al. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am. J. Gastroenterol. 2007;102:744-753.
Not in our library10.1111/j.1572-0241.2006.01028.x
775.
Sugimoto Y, Inoue K, Yamada J. The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J. Pharmacol. Sci. 2003;93:74-79.
Not in our library10.1254/jphs.93.74
776.
Hentall ID, Kurle PJ, White TR. Correlations between serotonin level and single-cell firing ln the rat’s nucleus raphe magnus. Neuroscience. 2000;95:1081-1088.
Not in our library10.1016/s0306-4522(99)00516-3
777.
Burgi S, Baltensperger K, Honegger UE. Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action. J. Biol. Chem. 2003;278:1044-1052.
Not in our library10.1074/jbc.m209972200
778.
Samnick S, et al. Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylpropylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats. Nucl. Med. Biol. 2004;31:511-522.
Not in our library10.1016/j.nucmedbio.2003.12.007
779.
Osadchii OE, Woodiwiss AJ, Deftereos D, Norton GR. Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats. Pflugers Arch. 2007;455:251-260.
Not in our library10.1007/s00424-007-0293-4
780.
Prenner L, et al. Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry. 2007;46:5106-5113.
Not in our library10.1021/bi6025819
781.
Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol. 2007;151:737-748.
Not in our library10.1038/sj.bjp.0707253
782.
Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13:1027-1038.
Not in our library10.1017/s1092852900017089
783.
Singh H, Becker PM. Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin. Investig. Drugs. 2007;16:1295-1305.
Not in our library10.1517/13543784.16.8.1295
784.
Wellman PJ, Miller DK, Ho DH. Noradrenergic modulation of ephedrine-induced hypophagia. Synapse. 2003;48:18-24.
Not in our library10.1002/syn.10182
785.
Berman HM, et al. The protein data bank. Nucleic Acids Res. 2000;28:235-242.
Not in our library10.1093/nar/28.1.235
786.
Ma G, et al. Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes. J. Pharmacol. Exp. Ther. 2007;322:214-221.
Not in our library10.1124/jpet.107.120709
787.
Reimold M, et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology. 2007;190:241-249.
Not in our library10.1007/s00213-006-0611-0
788.
Mahapatra J, et al. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. Cochrane Database Syst. Rev. 2014;2014:CD001470.
Not in our library10.1002/14651858.cd001470.pub2
789.
Li X, Murray WV, Jolliffe L, Pulito V. Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg. Med. Chem. Lett. 2000;10:1093-1096.
Not in our library10.1016/s0960-894x(00)00169-4
790.
Peddi S, Roth BL, Glennon RA, Westkaemper RB. Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(‘)-pyrrolidine (SpAMDA). Bioorg. Med. Chem. Lett. 2004;14:2279-2283.
Not in our library10.1016/j.bmcl.2004.02.014
791.
Zanoveli JM, Nogueira RL, Zangrossi H. Chronic imipramine treatment sensitizes 5-HT1A and 5-HT 2 A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav. Pharmacol. 2005;16:543-552.
Not in our library10.1097/01.fbp.0000179280.05654.5a
792.
Csaba G, Kovacs P, Pallinger E. Prolonged effect of the tricyclic antidepressant, mianserin on the serotonin and histamine content of young rats’ white blood cells and mast cells. A case of late-imprinting. Pharmacol. Res. 2003;48:457-460.
Not in our library10.1016/s1043-6618(03)00217-2
793.
Grinshpoon A, Valevski A, Moskowitz M, Weizman A. Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur. Psychiatry. 2000;15:388-390.
Not in our library10.1016/s0924-9338(00)00507-1
794.
Dekeyne A, Iob L, Millan MJ. Discriminative stimulus properties of the selective and highly potent alpha(2)-adrenoceptor agonist, S18616, in rats. Behav. Pharmacol. 2003;14:S41-S41.
Not in our library
795.
Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005;60:441-460.
Not in our library10.2515/therapie:2005065
796.
Lee HY, et al. Association of the adrenergic alpha 2a receptor-1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Res. 2009;1262:1-6.
Not in our library10.1016/j.brainres.2009.01.013
797.
Waldinger MD, Berendsen HH, Schweitzer DH. Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 2000;36:165-168.
Not in our library10.1016/s0378-5122(00)00152-3
798.
Peckham AM, De La Cruz A, Dufresne RL. Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression? Ment. Health Clin. 2018;8:175-183.
Not in our library10.9740/mhc.2018.07.175
799.
Salvi V, Mencacci C, Barone-Adesi F. H1-histamine receptor affinity predicts weight gain with antidepressants. Eur. Neuropsychopharmacol. 2016;26:1673-1677.
Not in our library10.1016/j.euroneuro.2016.08.012
800.
Talvik M, et al. A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology. 2004;175:148-153.
Not in our library10.1007/s00213-004-1802-1
801.
Dolzan V, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am. J. Med. Genet. B. 2007;144B:809-815.
Not in our library10.1002/ajmg.b.30544
802.
Hoffmann C, et al. Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn. Schmiedebergs Arch. Pharmacol. 2004;369:151-159.
Not in our library10.1007/s00210-003-0860-y
803.
Rubenstein LA, Zauhar RJ, Lanzara RG. Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation. J. Mol. Graph. Model. 2006;25:396-409.
Not in our library10.1016/j.jmgm.2006.02.008
804.
Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M. The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur. J. Pharmacol. 2004;497:161-171.
Not in our library10.1016/j.ejphar.2004.06.051
805.
Xie Z, et al. Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J. Pharmacol. Exp. Ther. 2007;321:116-127.
Not in our library10.1124/jpet.106.116863
806.
Liu JF, Li JX. TAAR1 in addiction: looking beyond the tip of the iceberg. Front. Pharmacol. 2018;9:279.
Not in our library10.3389/fphar.2018.00279
807.
Pei Y, Asif-Malik A, Canales JJ. Trace amines and the trace amine-associated receptor 1: pharmacology, neurochemistry, and clinical implications. Front. Neurosci. 2016;10:148.
Not in our library10.3389/fnins.2016.00148
808.
Ferry G, et al. Old and new inhibitors of quinone reductase 2. Chem. Biol. Interact. 2010;186:103-109.
Not in our library10.1016/j.cbi.2010.04.006
809.
Davies SJ, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J. Psychopharmacol. 2018;32:509-523.
Not in our library10.1177/0269881117744996
810.
Millan MJ, Girardon S, Monneyron S, Dekeyne A. Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000;39:586-598.
Not in our library10.1016/s0028-3908(99)00180-x
811.
Martinez D, et al. Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology. 2004;29:1190-1202.
Not in our library10.1038/sj.npp.1300420
812.
Lehmann A. GABAB receptors as drug targets to treat gastroesophageal reflux disease. Pharmacol. Ther. 2009;122:239-245.
Not in our library10.1016/j.pharmthera.2009.02.008
813.
Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14:859-873.
Not in our library10.1007/s13311-017-0565-4
814.
Scatton B, et al. The preclinical pharmacologic profile of tiapride. Eur. Psychiatry. 2001;16:29s-34s.
Not in our library10.1016/s0924-9338(00)00526-5
815.
Dawson LA, et al. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology. 2008;33:1642-1652.
Not in our library10.1038/sj.npp.1301549
816.
Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24:65-84.
Not in our library10.2165/11202620-000000000-00000
817.
Litman RE, et al. The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study. J. Clin. Psychopharmacol. 2014;34:199-204.
Not in our library10.1097/jcp.0000000000000071
818.
Morales, P., Hurst, D. P. & Reggio, P. H. in Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis Sativa, Vol 103 Progress in the Chemistry of Organic Natural Products-Series (eds Kinghorn, A. D. et al.) 103–131 (Springer, 2017).
Not in our library
819.
Langlois X, et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. Eur. Neuropsychopharmacol. 2010;20:S502-S502.
Not in our library10.1016/s0924-977x(10)70747-1
820.
Dedic N, et al. SEP-363856, a novel psychotropic agent with a unique, non-D(2) receptor mechanism of action. J. Pharmacol. Exp. Ther. 2019;371:1-14.
Not in our library10.1124/jpet.119.260281
821.
Nyandege A, Kolanos R, Roth BL, Glennon RA. Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg. Med. Chem. Lett. 2007;17:1691-1694.
Not in our library10.1016/j.bmcl.2006.12.089
822.
Su TP, Hayashi T, Vaupel DB. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci. Signal. 2009;2:pe12.
Not in our library10.1126/scisignal.261pe12
823.
Rusch D, et al. Subunit-dependent modulation of the 5-hydroxytryptamine type 3 receptor open-close equilibrium by n-alcohols. J. Pharmacol. Exp. Ther. 2007;321:1069-1074.
Not in our library10.1124/jpet.106.118752
824.
Riga MS, et al. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors. Neuropharmacology. 2016;101:370-378.
Not in our library10.1016/j.neuropharm.2015.10.016
825.
Di Fabio R, et al. Discovery and biological characterization of (2R,4S)-1’-acetyl-N-(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4’-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate. J. Med. Chem. 2011;54:1071-1079.
Not in our library10.1021/jm1013264

Cited by papers we hold 3

Pathology of pain and its implications for therapeutic interventions · 2024
No notice
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases · 2024
No notice
JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions · 2023
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.